Erholung von Hemosol in Sicht !?! - 500 Beiträge pro Seite
eröffnet am 03.07.00 17:05:29 von
neuester Beitrag 27.05.03 23:09:23 von
neuester Beitrag 27.05.03 23:09:23 von
Beiträge: 134
ID: 173.731
ID: 173.731
Aufrufe heute: 0
Gesamt: 11.266
Gesamt: 11.266
Aktive User: 0
Top-Diskussionen
Titel | letzter Beitrag | Aufrufe |
---|---|---|
gestern 21:55 | 647 | |
15.05.11, 11:34 | 340 | |
gestern 23:58 | 317 | |
gestern 23:09 | 231 | |
heute 00:01 | 227 | |
vor 1 Stunde | 226 | |
09.07.21, 17:39 | 220 | |
20.04.24, 12:11 | 219 |
Meistdiskutierte Wertpapiere
Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
---|---|---|---|---|---|---|---|
1. | 1. | 18.075,00 | +0,33 | 240 | |||
2. | 2. | 1,3800 | -1,43 | 98 | |||
3. | 3. | 0,1890 | -2,58 | 81 | |||
4. | 4. | 170,18 | +4,97 | 78 | |||
5. | 5. | 9,3325 | -3,69 | 75 | |||
6. | 6. | 7,0010 | +4,17 | 52 | |||
7. | 7. | 22,240 | -3,22 | 41 | |||
8. | 8. | 0,0160 | -24,17 | 38 |
Hallo Leute,
der Bericht vom 12.06.00 wird wohl in die Geschichte der dümmsten Nachrichten eingehen.
Ich habe vor kurzen meine Meinung zu der derzeitigen Situation dargestellt.
1. Hemosol hat das gehalten was es versprochen hat
2. Hemosol muß nun für den Markt zugänglich gemacht werden (d.h. Marktzulassung mitte Julie!?!)
3. Hemosol muß ausreichend Produziert werden (Abhängig von Nachfrage(risikofaktoren bei menschlichem Blut werden zunehmend verringerd) u. Angebot ( Produktionsstätten müssen fertig gestellt werden)
4. Es muß jetz viel PR-Arbeit geleistet werden.
Dann sehen wir Hemosol als wirtschaftliches und inovatives Wachstumswunder!!!!!!!
Letzt endlich muß man auch Mr. Kennedy ein Lob ausprechen, dass er dies nach jahrelanger Durststrecke (3-Jahre das Minus rapiede gesteigert) Investoren davon überzeugen konnte, was hinter seiner Vision steckt und ich denke auch diese Herren Investoren haben sich ausgiebig erkundigt.
Dies sind die wirtschaftlichen stärken von Hemosol und das Sie bis Dato, die ersten im Wettbewerb sind, die so weit gekommen sind. Jetzt fehlt nur noch, dass die Börse auch davon Wind bekommt.
Die Verkaufslawine nach dem 12.06.00 kann durch mehrerer indikatoren begründet sein
1. Interpretationsschwierigkeit der Nachricht
2. Kursdrücken um bessere Einstigskurse zu gewährleisten
3. Wettbewerber die Kurse drücken um Zeitvorteil zu erreichen und die positiven Ergebnisse von Hemosol nicht zu hoch kommen lassen
4. Feindliche Übernahme
Das sind nur einige Argumente, die mir so Addhoc einfallen aber es sind sicherlich einige Punkte die für eine Kursrally sorgen können.
Zusammengefaßt giebt es zwei Hauptgründe warum Hemosol wieder steigen wird:
1. Durch eingene Kraft wie im ersten Block beschrieben
2. Durch weitere Marktteilnehmer wie im zweiten Block beschrieben.
Ich würde mich freuen, wenn wir Diskussionen auf Basis des heutigen Stands weiter führen könnten und bitte gleichzeitig um Kritik (positiv/negativ) zu meinen Aufstellung.
Viel Spass bei einem neuen Thread
CoolMax
p.s.
Neu Nachricht ist auch vorhanden vom 01.07.00
Shares of the biopharmaceutical company fell for the fourth day in a row, despite positive news Tuesday about
Hemosol`s Hemolink blood substitute product. Dundee Securities analyst Claude Camire told Dow Jones news service
that investors are probably asking themselves many questions after Hemolink`s previous couple of news updates. On
June 12, Hemosol said Hemolink, an oxygen carrier derived from hemoglobin, was used safely in cardiac surgery, but
that high rates of transfusion avoidance were also found in the control group, which wasn`t expected. In two days, the
stock price dropped about 35 per cent. After taking two weeks to study the data further, Hemosol said it found a
"statistically significant" transfusion reduction of 27 per cent, compared with the control group. The confusion created by
the two pieces of news has cast a shadow over the company`s fundamentals, Mr. Camire said.
der Bericht vom 12.06.00 wird wohl in die Geschichte der dümmsten Nachrichten eingehen.
Ich habe vor kurzen meine Meinung zu der derzeitigen Situation dargestellt.
1. Hemosol hat das gehalten was es versprochen hat
2. Hemosol muß nun für den Markt zugänglich gemacht werden (d.h. Marktzulassung mitte Julie!?!)
3. Hemosol muß ausreichend Produziert werden (Abhängig von Nachfrage(risikofaktoren bei menschlichem Blut werden zunehmend verringerd) u. Angebot ( Produktionsstätten müssen fertig gestellt werden)
4. Es muß jetz viel PR-Arbeit geleistet werden.
Dann sehen wir Hemosol als wirtschaftliches und inovatives Wachstumswunder!!!!!!!
Letzt endlich muß man auch Mr. Kennedy ein Lob ausprechen, dass er dies nach jahrelanger Durststrecke (3-Jahre das Minus rapiede gesteigert) Investoren davon überzeugen konnte, was hinter seiner Vision steckt und ich denke auch diese Herren Investoren haben sich ausgiebig erkundigt.
Dies sind die wirtschaftlichen stärken von Hemosol und das Sie bis Dato, die ersten im Wettbewerb sind, die so weit gekommen sind. Jetzt fehlt nur noch, dass die Börse auch davon Wind bekommt.
Die Verkaufslawine nach dem 12.06.00 kann durch mehrerer indikatoren begründet sein
1. Interpretationsschwierigkeit der Nachricht
2. Kursdrücken um bessere Einstigskurse zu gewährleisten
3. Wettbewerber die Kurse drücken um Zeitvorteil zu erreichen und die positiven Ergebnisse von Hemosol nicht zu hoch kommen lassen
4. Feindliche Übernahme
Das sind nur einige Argumente, die mir so Addhoc einfallen aber es sind sicherlich einige Punkte die für eine Kursrally sorgen können.
Zusammengefaßt giebt es zwei Hauptgründe warum Hemosol wieder steigen wird:
1. Durch eingene Kraft wie im ersten Block beschrieben
2. Durch weitere Marktteilnehmer wie im zweiten Block beschrieben.
Ich würde mich freuen, wenn wir Diskussionen auf Basis des heutigen Stands weiter führen könnten und bitte gleichzeitig um Kritik (positiv/negativ) zu meinen Aufstellung.
Viel Spass bei einem neuen Thread
CoolMax
p.s.
Neu Nachricht ist auch vorhanden vom 01.07.00
Shares of the biopharmaceutical company fell for the fourth day in a row, despite positive news Tuesday about
Hemosol`s Hemolink blood substitute product. Dundee Securities analyst Claude Camire told Dow Jones news service
that investors are probably asking themselves many questions after Hemolink`s previous couple of news updates. On
June 12, Hemosol said Hemolink, an oxygen carrier derived from hemoglobin, was used safely in cardiac surgery, but
that high rates of transfusion avoidance were also found in the control group, which wasn`t expected. In two days, the
stock price dropped about 35 per cent. After taking two weeks to study the data further, Hemosol said it found a
"statistically significant" transfusion reduction of 27 per cent, compared with the control group. The confusion created by
the two pieces of news has cast a shadow over the company`s fundamentals, Mr. Camire said.
coolmax,
deine darstellungen der derzeitigen situation sind analytisch sehr gut.
wie der analyst mr. carmire in deinem englisch geschriebenen abschnitt richtig beschreibt, handelt es sich im moment nur um die mentale verarbeitung der zwei letzten nachrichten von hemosol.
der kurs wird steigen, wenn v.a. viele neue anleger mit der zeit erkennen, daß es sich bei der nachricht vom 12.6.00, um eine sehr ehrliche vorabmeldung handelt, in der lediglich ein zwischeneindruck dargestellt wurde, ohne das wissen signifikanter auswertungsdaten. es handelte sich also lediglich um einen subjektiven, nicht wissenschaftlich fundierten, beitrag.
die letzte nachricht von hemosol war die eigentliche heiß erwartete darstellung der wissenschaftlichen auswertung, also diesmal objektiv und mit darlegung eines eindeutig signifikanten faktors, der für wissenschaftliche studien der medizin eindeutig gut ist.
deine darstellungen der derzeitigen situation sind analytisch sehr gut.
wie der analyst mr. carmire in deinem englisch geschriebenen abschnitt richtig beschreibt, handelt es sich im moment nur um die mentale verarbeitung der zwei letzten nachrichten von hemosol.
der kurs wird steigen, wenn v.a. viele neue anleger mit der zeit erkennen, daß es sich bei der nachricht vom 12.6.00, um eine sehr ehrliche vorabmeldung handelt, in der lediglich ein zwischeneindruck dargestellt wurde, ohne das wissen signifikanter auswertungsdaten. es handelte sich also lediglich um einen subjektiven, nicht wissenschaftlich fundierten, beitrag.
die letzte nachricht von hemosol war die eigentliche heiß erwartete darstellung der wissenschaftlichen auswertung, also diesmal objektiv und mit darlegung eines eindeutig signifikanten faktors, der für wissenschaftliche studien der medizin eindeutig gut ist.
Hi Lexter LeMaitre,
freut mich, dass Du dich zu meiner Aufstellung geäusert hast und auch weitgehenst meiner Ansicht bist.
Ich schätze, dass ein Großteil des Vertrauens der Anleger durch die bekanntgabe der Vermarktung erfolgen wird. Dies wird sicherlicher für eine Kursrichtung ausschlaggebend sein.
Die indikatoren zur Zulassung am Markt stehen nach den nachgereichten NEWS sehr gut.
bis bald
CoolMax
p.s. wie auch die durch den Kurs vermuten läßt, bei sehr geringen handel in Canada + ca. 3% ist das Interesse nachwievor groß
freut mich, dass Du dich zu meiner Aufstellung geäusert hast und auch weitgehenst meiner Ansicht bist.
Ich schätze, dass ein Großteil des Vertrauens der Anleger durch die bekanntgabe der Vermarktung erfolgen wird. Dies wird sicherlicher für eine Kursrichtung ausschlaggebend sein.
Die indikatoren zur Zulassung am Markt stehen nach den nachgereichten NEWS sehr gut.
bis bald
CoolMax
p.s. wie auch die durch den Kurs vermuten läßt, bei sehr geringen handel in Canada + ca. 3% ist das Interesse nachwievor groß
Hi CoolMax,
Da ich Deine Sicht der Dinge bei Hemosol sehr treffend fand, war ich mal so frei, Deinen Beitrag ins Consors-BioTechBoard zu kopieren.
Ich denke, wer jetzt Nervenstärke beweist, wird an Hemosol noch viel Freude haben.
Gruß
Nucleus
Da ich Deine Sicht der Dinge bei Hemosol sehr treffend fand, war ich mal so frei, Deinen Beitrag ins Consors-BioTechBoard zu kopieren.
Ich denke, wer jetzt Nervenstärke beweist, wird an Hemosol noch viel Freude haben.
Gruß
Nucleus
In Frankfurt Kurs 8.90E !4855 Stück
@fleige2000
Hier sind einige sehr nervös.
Muß zugeben auch mich erwischts etwas.
Nur wass mich wiederum etwas beruhigt ist, dass: Eröffnungskurs Canad ca. C$ 14.40 geringer Handel dann 12.90 C$ VERKAUF von 1.000 St. und jetz wieder mit größeren Stückzahlen 13.50 C$
(leider sind mir nicht alle Daten zum Handel bekannt).
Über Newswire.ca kann man den Tageschart schön verfolgen aber nur das aufgelaufene Volumen zum Tageschart
Luft anhalten. bleibe dennoch drin.
übrigens seit 7.20 EUR/St.
Gruß
CoolMax
Hier sind einige sehr nervös.
Muß zugeben auch mich erwischts etwas.
Nur wass mich wiederum etwas beruhigt ist, dass: Eröffnungskurs Canad ca. C$ 14.40 geringer Handel dann 12.90 C$ VERKAUF von 1.000 St. und jetz wieder mit größeren Stückzahlen 13.50 C$
(leider sind mir nicht alle Daten zum Handel bekannt).
Über Newswire.ca kann man den Tageschart schön verfolgen aber nur das aufgelaufene Volumen zum Tageschart
Luft anhalten. bleibe dennoch drin.
übrigens seit 7.20 EUR/St.
Gruß
CoolMax
Hi CoolMax,
ja, bei solche Tagesverlusten fällt es wohl sogar Dir schwer COOL zu bleiben. ;-)
Ich habe zwei Drittel bei knapp unter 5€ gekauft und dann bei 10,60€ nochmal nachgelegt.
Selbst ich als Berufsoptimist bin jetzt etwas am Zweifeln, aber so langsam kommt der Kurs an meine Schmerzgrenze, hat Du irgendwo etwas negatives gelesen, was den Verfall heute begründet?
Danke und Gruß
Nucleus
ja, bei solche Tagesverlusten fällt es wohl sogar Dir schwer COOL zu bleiben. ;-)
Ich habe zwei Drittel bei knapp unter 5€ gekauft und dann bei 10,60€ nochmal nachgelegt.
Selbst ich als Berufsoptimist bin jetzt etwas am Zweifeln, aber so langsam kommt der Kurs an meine Schmerzgrenze, hat Du irgendwo etwas negatives gelesen, was den Verfall heute begründet?
Danke und Gruß
Nucleus
also leute,
auch wenn das nach dem heutigen kursverlauf etwas schräg klingt, hemosol ist für mich ein super investment, denn andere firmen müssen erst noch ihre studien durchlaufen, hemosol hat dieses bereits hinter sich...und zwar mit einschlagendem erfolg!!!
dieser kursverfall ist mit absoluter sicherheit nur ein zwischenzeitliches ereignis, denn die studie war erfolgreich, die kommende usa-studie wird noch besser, da man hier die erkenntnisse aus den bisherigen studien einfließen läßt, wobei es aber im eigentlichen nicht mehr um die erforschung von verträglichkeit und wirksamkeit von hemolink,in den usa, geht, sondern nur noch lediglich um die erfüllung einer prozedur, die bedingung für die zulassung von hemolink in den usa ist.
spätestens dann, wenn canada hemolink zuläßt, wird der kurs steigen, dies sollte schon demnächst(in den nächsten monaten) geschehen, denn wie hemosol im letzten bericht schrieb, wollen sie noch im juli, also jetzt, die zulassung für den canadischen markt beantragen, weil die ergebnisse der p3studie überzeugend erfolgreich waren.
ängstliche aktionäre lassen den kurs gerade absacken, weil sie nicht verstehen, was sie mit hemosol wertvolles in den händen halten oder weil eventuell irgendwo irgendein analyst negatives zu hemosol gasagt haben könnte, weil dieser analyst nämlich selber bei fallenden kursen sich mit günstigen hemosolaktien eindecken möchte, weil er in wahrheit das gute potential von hemosol erkannt hat.
solche kuszahlen, wie wir sie jetzt sehen, sollten einen überlegt handelnden aktionär eher zum nachkaufen anregen, denn es handelt sich nur um eine verunsicherung aufgrund einer zugegeben unglücklich formulierten aussage von hemosol vor der auswertung ihrer p3studie. was für uns aber in diesem geschäft, langfristig orientiert, interessieren MUSS, ist die lage der fakten, somit die dargelegten erfolgreichen ergebnisse der p3studie!
auch wenn das nach dem heutigen kursverlauf etwas schräg klingt, hemosol ist für mich ein super investment, denn andere firmen müssen erst noch ihre studien durchlaufen, hemosol hat dieses bereits hinter sich...und zwar mit einschlagendem erfolg!!!
dieser kursverfall ist mit absoluter sicherheit nur ein zwischenzeitliches ereignis, denn die studie war erfolgreich, die kommende usa-studie wird noch besser, da man hier die erkenntnisse aus den bisherigen studien einfließen läßt, wobei es aber im eigentlichen nicht mehr um die erforschung von verträglichkeit und wirksamkeit von hemolink,in den usa, geht, sondern nur noch lediglich um die erfüllung einer prozedur, die bedingung für die zulassung von hemolink in den usa ist.
spätestens dann, wenn canada hemolink zuläßt, wird der kurs steigen, dies sollte schon demnächst(in den nächsten monaten) geschehen, denn wie hemosol im letzten bericht schrieb, wollen sie noch im juli, also jetzt, die zulassung für den canadischen markt beantragen, weil die ergebnisse der p3studie überzeugend erfolgreich waren.
ängstliche aktionäre lassen den kurs gerade absacken, weil sie nicht verstehen, was sie mit hemosol wertvolles in den händen halten oder weil eventuell irgendwo irgendein analyst negatives zu hemosol gasagt haben könnte, weil dieser analyst nämlich selber bei fallenden kursen sich mit günstigen hemosolaktien eindecken möchte, weil er in wahrheit das gute potential von hemosol erkannt hat.
solche kuszahlen, wie wir sie jetzt sehen, sollten einen überlegt handelnden aktionär eher zum nachkaufen anregen, denn es handelt sich nur um eine verunsicherung aufgrund einer zugegeben unglücklich formulierten aussage von hemosol vor der auswertung ihrer p3studie. was für uns aber in diesem geschäft, langfristig orientiert, interessieren MUSS, ist die lage der fakten, somit die dargelegten erfolgreichen ergebnisse der p3studie!
Hi Nucleus,
leider kann ich Dir nichts fundiertes sagen, da es keine NEWS gegeben hat.
Ich kann Dir höchstens eine CAN/US Adresse geben, bei der auch wie bei WO gut diskutiert wird.
http://www.stockhouse.com/bullboards/forum.asp?Symbol=HML&ta…
Hier sind auch einige ratlos und mit möglichen theorien befaßt.
Denke es wird in kürze wieder eine neue Nachricht geben.
Habe aber dennoch eine interessante INFO auf der oben genannten Adresse gefunden. Hier werden die Verkaufs und Kauf zahlen der letzten wochen gesamt und auf die einzelnen Broker aufgezeigt
This is the last months activity for Nesbitt, it doesn`t seem to support any major sell off although there is clearly a trend. It is only 551M net shares sold. Having said that,
I don`t have any doubt that what is being suggested here does in fact happen.
Sorry for the length, but the first list is Nesbitt and the 2nd list is by all brokers.
Broker Position Summary
Broker Code: 9
Exchange: T
Symbol: HML
Date Range: 06/07/00 - 07/06/00
Date Bought Av/Sh Sold Av/Sh Day Net Position $Net $Position
06/07/00 10758 24.26 9802 24.37 956 956 -22111 -22111
06/08/00 10415 24.52 6450 24.53 3965 4921 -97167 -119278
06/09/00 1160 25.06 18245 25.13 -17085 -12164 429359 310081
06/12/00 88447 19.12 126274 18.85 -37827 -49991 689167 999248
06/13/00 56593 16.19 62619 16.33 -6026 -56017 106069 1105317
06/14/00 46264 17.77 102428 17.86 -56164 -112181 1007315 2112632
06/15/00 15155 17.44 49800 17.33 -34645 -146826 598745 2711377
06/16/00 27180 16.91 10975 17.03 16205 -130621 -272768 2438609
06/19/00 9840 16.05 25520 16.09 -15680 -146301 252786 2691395
06/20/00 10540 16.30 21720 16.25 -11180 -157481 181231 2872626
06/21/00 4800 16.23 34173 16.20 -29373 -186854 475811 3348437
06/22/00 4632 16.10 41300 16.12 -36668 -223522 591401 3939838
06/23/00 5728 16.23 39250 16.20 -33522 -257044 542938 4482776
06/26/00 50441 17.45 128400 17.42 -77959 -335003 1355983 5838759
06/27/00 22780 16.92 108335 16.91 -85555 -420558 1446201 7284960
06/28/00 2593 16.57 32300 16.45 -29707 -450265 488386 7773346
06/29/00 8371 15.97 21300 16.03 -12929 -463194 207669 7981015
06/30/00 19772 14.68 60687 14.57 -40915 -504109 593847 8574862
07/04/00 28410 14.72 53014 14.67 -24604 -528713 359583 8934445
07/05/00 5571 14.72 6360 14.89 -789 -529502 12689 8947134
07/06/00 10693 13.53 32115 13.79 -21422 -550924 298175 9245309
Total 440143 17.38 991067 17.05 -550924 9245309
House Positions for HML from 06/07/2000 to 07/06/2000
Ex House Bought Av/Sh Sold Av/Sh Net $Net
T 9 Nesbitt 440143 17.38 991067 17.05 -550924 9245309
T 11 Yorkton 1163260 17.90 1621725 18.19 -458465 8671979
T 26 Commission Direct 0 0.00 265700 17.12 -265700 4549740
T 61 IPO 1700 17.14 88200 15.86 -86500 1369645
T 80 National Bank 228431 17.06 272318 16.72 -43887 656075
T 85 Scotia 209823 17.62 226867 18.27 -17044 448316
T 6 Union 7100 16.62 18600 16.50 -11500 188965
T 73 Sprott 0 0.00 10000 13.34 -10000 133365
T 48 BLC 9260 18.24 12306 18.56 -3046 59517
T 36 Latimer 807174 17.29 809731 17.33 -2557 80998
T 77 Peters 2000 16.40 2500 16.42 -500 8250
T 93 Groome 0 0.00 400 16.80 -400 6720
T 29 Retraite 0 0.00 300 16.55 -300 4965
T 46 First 4100 21.22 4400 18.98 -300 -3485
T 65 Goldman 0 0.00 200 16.20 -200 3240
T 67 Brenark 950 22.05 1000 13.35 -50 -7600
T 4 Dlouhy 9300 16.72 9300 16.98 0 2485
T 17 Brawley Cathers 5000 16.08 5000 16.19 0 575
T 41 Standard 2000 15.80 2000 15.87 0 140
T 66 Pope 1000 15.60 1000 16.00 0 400
T 68 Rogers 15100 16.27 15100 16.35 0 1275
T 71 Brant 5000 17.00 5000 16.50 0 -2500
T 131 ECE 7400 18.01 7400 18.40 0 2875
T 135 135 3600 16.05 3600 16.05 0 0
T 60 Refco 100 17.80 0 0.00 100 -1780
T 62 Haywood 2600 16.82 2500 17.09 100 -1015
T 69 Taurus 100 16.50 0 0.00 100 -1650
T 12 Harris 300 16.42 0 0.00 300 -4925
T 64 Octagon 400 16.20 0 0.00 400 -6480
T 18 Georgia Pacific 800 16.55 0 0.00 800 -13240
T 31 Dominick 1500 16.83 500 18.25 1000 -16125
T 37 MacDougall 2150 16.28 900 17.72 1250 -19050
T 54 Global 1500 16.77 200 24.00 1300 -20350
T 38 Golden Capital 1700 16.25 200 19.90 1500 -23650
T 95 Wolverton 26400 15.29 24800 16.04 1600 -5770
T 83 Research Capital 4400 17.98 2400 18.04 2000 -35830
T 74 Griffiths 3000 15.15 0 0.00 3000 -45450
T 28 Newcrest 3500 15.23 205 14.30 3295 -50369
T 43 Caldwell 22600 16.88 18700 18.15 3900 -42055
T 22 Thomson Kernaghan 19750 16.44 15300 16.81 4450 -67530
T 59 PI 10850 16.25 6200 17.00 4650 -70955
T 15 Bunting 10736 16.74 6000 17.00 4736 -77700
T 13 Instinet 5500 16.22 0 0.00 5500 -89215
T 27 Dundee 12000 17.24 5600 16.98 6400 -111850
T 45 Loewen 12000 19.05 4040 16.22 7960 -163108
T 19 Desjardins 23233 17.48 14875 17.25 8358 -149632
T 23 Schwab 29720 17.41 21220 17.77 8500 -140553
T 87 Rampart 8700 14.89 0 0.00 8700 -129555
T 98 NBC 17995 16.75 7744 16.66 10251 -172497
T 25 Odlum 16750 16.75 5450 16.98 11300 -188028
T 72 First Boston 45000 19.28 25000 16.53 20000 -454315
T 89 Goepel 29250 16.10 8600 16.69 20650 -327336
T 39 Merrill Lynch 148026 16.52 122143 16.29 25883 -456468
T 44 Jones Gable 37480 16.84 7800 17.55 29680 -494249
T 132 Acker Finley 30700 17.77 700 18.10 30000 -532805
T 63 National Bank 84020 17.37 29115 17.86 54905 -939817
T 88 Versus 112494 17.02 51936 16.69 60558 -1047566
T 33 Canaccord 682231 17.85 610390 17.82 71841 -1297028
T 81 HSBC 591920 17.65 469500 17.79 122420 -2097942
T 79 CIBC 260608 17.54 121210 17.52 139398 -2445887
T 2 DS 818063 17.80 528407 17.35 289656 -5391987
T 7 Green Line 1067273 17.43 582341 17.72 484932 -8287467
Total 7067690 17.54 7067690 17.54 0 0
Werde diese mir jetzt erst mal in ruhe anschauen.
bis dann
CoolMax
leider kann ich Dir nichts fundiertes sagen, da es keine NEWS gegeben hat.
Ich kann Dir höchstens eine CAN/US Adresse geben, bei der auch wie bei WO gut diskutiert wird.
http://www.stockhouse.com/bullboards/forum.asp?Symbol=HML&ta…
Hier sind auch einige ratlos und mit möglichen theorien befaßt.
Denke es wird in kürze wieder eine neue Nachricht geben.
Habe aber dennoch eine interessante INFO auf der oben genannten Adresse gefunden. Hier werden die Verkaufs und Kauf zahlen der letzten wochen gesamt und auf die einzelnen Broker aufgezeigt
This is the last months activity for Nesbitt, it doesn`t seem to support any major sell off although there is clearly a trend. It is only 551M net shares sold. Having said that,
I don`t have any doubt that what is being suggested here does in fact happen.
Sorry for the length, but the first list is Nesbitt and the 2nd list is by all brokers.
Broker Position Summary
Broker Code: 9
Exchange: T
Symbol: HML
Date Range: 06/07/00 - 07/06/00
Date Bought Av/Sh Sold Av/Sh Day Net Position $Net $Position
06/07/00 10758 24.26 9802 24.37 956 956 -22111 -22111
06/08/00 10415 24.52 6450 24.53 3965 4921 -97167 -119278
06/09/00 1160 25.06 18245 25.13 -17085 -12164 429359 310081
06/12/00 88447 19.12 126274 18.85 -37827 -49991 689167 999248
06/13/00 56593 16.19 62619 16.33 -6026 -56017 106069 1105317
06/14/00 46264 17.77 102428 17.86 -56164 -112181 1007315 2112632
06/15/00 15155 17.44 49800 17.33 -34645 -146826 598745 2711377
06/16/00 27180 16.91 10975 17.03 16205 -130621 -272768 2438609
06/19/00 9840 16.05 25520 16.09 -15680 -146301 252786 2691395
06/20/00 10540 16.30 21720 16.25 -11180 -157481 181231 2872626
06/21/00 4800 16.23 34173 16.20 -29373 -186854 475811 3348437
06/22/00 4632 16.10 41300 16.12 -36668 -223522 591401 3939838
06/23/00 5728 16.23 39250 16.20 -33522 -257044 542938 4482776
06/26/00 50441 17.45 128400 17.42 -77959 -335003 1355983 5838759
06/27/00 22780 16.92 108335 16.91 -85555 -420558 1446201 7284960
06/28/00 2593 16.57 32300 16.45 -29707 -450265 488386 7773346
06/29/00 8371 15.97 21300 16.03 -12929 -463194 207669 7981015
06/30/00 19772 14.68 60687 14.57 -40915 -504109 593847 8574862
07/04/00 28410 14.72 53014 14.67 -24604 -528713 359583 8934445
07/05/00 5571 14.72 6360 14.89 -789 -529502 12689 8947134
07/06/00 10693 13.53 32115 13.79 -21422 -550924 298175 9245309
Total 440143 17.38 991067 17.05 -550924 9245309
House Positions for HML from 06/07/2000 to 07/06/2000
Ex House Bought Av/Sh Sold Av/Sh Net $Net
T 9 Nesbitt 440143 17.38 991067 17.05 -550924 9245309
T 11 Yorkton 1163260 17.90 1621725 18.19 -458465 8671979
T 26 Commission Direct 0 0.00 265700 17.12 -265700 4549740
T 61 IPO 1700 17.14 88200 15.86 -86500 1369645
T 80 National Bank 228431 17.06 272318 16.72 -43887 656075
T 85 Scotia 209823 17.62 226867 18.27 -17044 448316
T 6 Union 7100 16.62 18600 16.50 -11500 188965
T 73 Sprott 0 0.00 10000 13.34 -10000 133365
T 48 BLC 9260 18.24 12306 18.56 -3046 59517
T 36 Latimer 807174 17.29 809731 17.33 -2557 80998
T 77 Peters 2000 16.40 2500 16.42 -500 8250
T 93 Groome 0 0.00 400 16.80 -400 6720
T 29 Retraite 0 0.00 300 16.55 -300 4965
T 46 First 4100 21.22 4400 18.98 -300 -3485
T 65 Goldman 0 0.00 200 16.20 -200 3240
T 67 Brenark 950 22.05 1000 13.35 -50 -7600
T 4 Dlouhy 9300 16.72 9300 16.98 0 2485
T 17 Brawley Cathers 5000 16.08 5000 16.19 0 575
T 41 Standard 2000 15.80 2000 15.87 0 140
T 66 Pope 1000 15.60 1000 16.00 0 400
T 68 Rogers 15100 16.27 15100 16.35 0 1275
T 71 Brant 5000 17.00 5000 16.50 0 -2500
T 131 ECE 7400 18.01 7400 18.40 0 2875
T 135 135 3600 16.05 3600 16.05 0 0
T 60 Refco 100 17.80 0 0.00 100 -1780
T 62 Haywood 2600 16.82 2500 17.09 100 -1015
T 69 Taurus 100 16.50 0 0.00 100 -1650
T 12 Harris 300 16.42 0 0.00 300 -4925
T 64 Octagon 400 16.20 0 0.00 400 -6480
T 18 Georgia Pacific 800 16.55 0 0.00 800 -13240
T 31 Dominick 1500 16.83 500 18.25 1000 -16125
T 37 MacDougall 2150 16.28 900 17.72 1250 -19050
T 54 Global 1500 16.77 200 24.00 1300 -20350
T 38 Golden Capital 1700 16.25 200 19.90 1500 -23650
T 95 Wolverton 26400 15.29 24800 16.04 1600 -5770
T 83 Research Capital 4400 17.98 2400 18.04 2000 -35830
T 74 Griffiths 3000 15.15 0 0.00 3000 -45450
T 28 Newcrest 3500 15.23 205 14.30 3295 -50369
T 43 Caldwell 22600 16.88 18700 18.15 3900 -42055
T 22 Thomson Kernaghan 19750 16.44 15300 16.81 4450 -67530
T 59 PI 10850 16.25 6200 17.00 4650 -70955
T 15 Bunting 10736 16.74 6000 17.00 4736 -77700
T 13 Instinet 5500 16.22 0 0.00 5500 -89215
T 27 Dundee 12000 17.24 5600 16.98 6400 -111850
T 45 Loewen 12000 19.05 4040 16.22 7960 -163108
T 19 Desjardins 23233 17.48 14875 17.25 8358 -149632
T 23 Schwab 29720 17.41 21220 17.77 8500 -140553
T 87 Rampart 8700 14.89 0 0.00 8700 -129555
T 98 NBC 17995 16.75 7744 16.66 10251 -172497
T 25 Odlum 16750 16.75 5450 16.98 11300 -188028
T 72 First Boston 45000 19.28 25000 16.53 20000 -454315
T 89 Goepel 29250 16.10 8600 16.69 20650 -327336
T 39 Merrill Lynch 148026 16.52 122143 16.29 25883 -456468
T 44 Jones Gable 37480 16.84 7800 17.55 29680 -494249
T 132 Acker Finley 30700 17.77 700 18.10 30000 -532805
T 63 National Bank 84020 17.37 29115 17.86 54905 -939817
T 88 Versus 112494 17.02 51936 16.69 60558 -1047566
T 33 Canaccord 682231 17.85 610390 17.82 71841 -1297028
T 81 HSBC 591920 17.65 469500 17.79 122420 -2097942
T 79 CIBC 260608 17.54 121210 17.52 139398 -2445887
T 2 DS 818063 17.80 528407 17.35 289656 -5391987
T 7 Green Line 1067273 17.43 582341 17.72 484932 -8287467
Total 7067690 17.54 7067690 17.54 0 0
Werde diese mir jetzt erst mal in ruhe anschauen.
bis dann
CoolMax
Vielleicht könnte das auch ein Grund sein:06.07.2000
Hemosol verkaufen
Telebörse
Die Analysten des Börsenmagazins "Die Telebörse" empfehlen die Hemosol Aktie (WKN 886290) zum Verkauf.
Zwar seien bei einigen Produkten bereits wichtige Entwicklungs- und Teststufen durchschritten wurden, bis zur Marktreife stehen jedoch noch zahlreiche Genehmigungsverfahren aus.
Nennenswerte Umsätze seien bisher nicht erwirtschaftet wurden. Auch aus charttechnischen Gründen sei der Wert zu meiden.
Der Vermögensverwalter Dr. Jens Erhardt aus München, empfiehlt dem Anleger die Hemosol Aktei zu verkaufen.
Hemosol verkaufen
Telebörse
Die Analysten des Börsenmagazins "Die Telebörse" empfehlen die Hemosol Aktie (WKN 886290) zum Verkauf.
Zwar seien bei einigen Produkten bereits wichtige Entwicklungs- und Teststufen durchschritten wurden, bis zur Marktreife stehen jedoch noch zahlreiche Genehmigungsverfahren aus.
Nennenswerte Umsätze seien bisher nicht erwirtschaftet wurden. Auch aus charttechnischen Gründen sei der Wert zu meiden.
Der Vermögensverwalter Dr. Jens Erhardt aus München, empfiehlt dem Anleger die Hemosol Aktei zu verkaufen.
vermögensverwalter dr.jens erhardt aus münchen,
möchte entweder nur schön billig an hemosolaktien ran oder er hat tatsächlich keine ahnung.
er schreibt: zwar seien bei einigen produkten bereits wichtige entwicklungs-und teststufen durchschritten, bis zur marktreife stehen jedoch noch zahlreiche genehmigungsverfahren aus.
ich sage:
1. wenn ein produkt wichtige entwicklungs-und teststufen bereits erfolgreich durchlaufen hat, dann hat dieses produkt, wie hemolink, seine marktreife erlangt, ein vorteil, auf den alle hemosolanleger gewartet haben. jahrelange forschungsprozeduren sind erfolgreich abgeschlossen, jetzt geht es endlich los, denn die marktreife ist erreicht.
2. daß die genehmigungsverfahren nun anlaufen, ist eine grandiose, einfach tolle sache, denn die meisten produkte schaffen es nicht bis zu diesen genehmigungsverfahren auf zulassung in den einzelnen staaten, hemosol hat es geschafft!!! ...wieder ein riesen vorteil, der gerade für den kauf dieser aktie spricht, denn das lange warten ist endlich vorbei, nun geht es los, hemosol hat sich damit zu einem wichtigen unternehmen mit hohem potential gewandelt, weil sie es geschafft haben, ihr produkt hemolink, bis zur marktreife zu führen!
3. daß dieser herr erhardt aus münchen bei einer aktie wie hemosol auf charttechnische gründe verweist, mutet an, als würde er seine argumente aus einem blick in die sterne ziehen.
alles in allem, ist der beitrag jenes herrn erhardt, nicht ernstzunehmen...!
möchte entweder nur schön billig an hemosolaktien ran oder er hat tatsächlich keine ahnung.
er schreibt: zwar seien bei einigen produkten bereits wichtige entwicklungs-und teststufen durchschritten, bis zur marktreife stehen jedoch noch zahlreiche genehmigungsverfahren aus.
ich sage:
1. wenn ein produkt wichtige entwicklungs-und teststufen bereits erfolgreich durchlaufen hat, dann hat dieses produkt, wie hemolink, seine marktreife erlangt, ein vorteil, auf den alle hemosolanleger gewartet haben. jahrelange forschungsprozeduren sind erfolgreich abgeschlossen, jetzt geht es endlich los, denn die marktreife ist erreicht.
2. daß die genehmigungsverfahren nun anlaufen, ist eine grandiose, einfach tolle sache, denn die meisten produkte schaffen es nicht bis zu diesen genehmigungsverfahren auf zulassung in den einzelnen staaten, hemosol hat es geschafft!!! ...wieder ein riesen vorteil, der gerade für den kauf dieser aktie spricht, denn das lange warten ist endlich vorbei, nun geht es los, hemosol hat sich damit zu einem wichtigen unternehmen mit hohem potential gewandelt, weil sie es geschafft haben, ihr produkt hemolink, bis zur marktreife zu führen!
3. daß dieser herr erhardt aus münchen bei einer aktie wie hemosol auf charttechnische gründe verweist, mutet an, als würde er seine argumente aus einem blick in die sterne ziehen.
alles in allem, ist der beitrag jenes herrn erhardt, nicht ernstzunehmen...!
@ Zladi,
verwundert micht etwas die Aussage von diesem Dr., denn ich gehe davon aus, dass die News oder Meinung der Telebörse aus deutschland
stammen und der Kursrutsch gestern in Canada verursacht mit einem Verkauf von 1.000 Aktien.
Also denke nicht, dass diese Nachricht all zu hart ist, denn der Kurs von 8.90 EUR ist heute schon alt den 9.40 EUR sind wieder da. Daher wiederum
meine Frage warum wird die Aktie dann dennoch gekauft?????????????
verwundert micht etwas die Aussage von diesem Dr., denn ich gehe davon aus, dass die News oder Meinung der Telebörse aus deutschland
stammen und der Kursrutsch gestern in Canada verursacht mit einem Verkauf von 1.000 Aktien.
Also denke nicht, dass diese Nachricht all zu hart ist, denn der Kurs von 8.90 EUR ist heute schon alt den 9.40 EUR sind wieder da. Daher wiederum
meine Frage warum wird die Aktie dann dennoch gekauft?????????????
@CoolMax,
Danke für die Adresse.
Ich bin der Meinung, daß wir den Tiefpunkt jetzt erreicht haben, denn die zwischenzeitlichen Tiefststände von Ende Januar/Anfang Februar (kurz nach dem rasanten Anstieg) wurden nicht nachhaltig unterschritten. Der Kurs wird m.E. die nächsten Tage/Wochen irgendwo zwischen knapp unter 9€ und knapp über 10€ pendeln und auf positive Neuigkeiten warten.
Wenn diese kommen, sehe ich zwei Möglichkeiten:
A) Weil über Hemosol in den letzten Wochen soviel geredet wurde, wie meines Erachtens noch nie, seit ich diesen Wert verfolge, ist er verstärkt in den Blickpunkt der Anleger gerückt (wenn z.Z. auch negativ)Folge: bei einem Anspringen der Kurse geht es steil (und ich meine STEIL) nach oben, da viele naja, nennen wir sie ruhig Lemminge, noch auf den Zug mit aufspringen werden und den Kurs in 2-3 Tagen wieder bis an die 20€ katapultieren werden (All Time High).
oder
B) Das Vertrauen der Anleger ist nachhaltig so erschüttert(bzw. sie sind verunsichert), daß auch richtig positive Meldungen fast wirkungslos verpuffen und der Kurs nur leicht zuckt, in dem Fall könnte es ein langwieriger und sehr zäher Prozeß werden bis Hemosol wieder wirklich interessant wird, so daß sich mittelfristig orientierte Anleger, die noch im Plus sind (oder nur wenig im Minus) fragen sollten, ob sie ihr Geld nicht anderswo gewinnbringender investieren wollen.
Für den Fall, daß in den nächsten Tagen die 8 Euro nachhaltig unterschritten werden, werde ich meine Anteile (wenn auch mit einem weinenden Auge) verkaufen, denn dann ist bis 4-5€ kein Widerstand mehr und eine weitere Entwicklung ist für diesen Fall sehr schwer vorherzusagen.
Ich denke allerdings nicht, daß dieser Fall eintritt und bin nach wie vor von dem riesigen Potential dieser Aktie überzeugt.
Gruß und bitte um Meinungen
Nucleus
Danke für die Adresse.
Ich bin der Meinung, daß wir den Tiefpunkt jetzt erreicht haben, denn die zwischenzeitlichen Tiefststände von Ende Januar/Anfang Februar (kurz nach dem rasanten Anstieg) wurden nicht nachhaltig unterschritten. Der Kurs wird m.E. die nächsten Tage/Wochen irgendwo zwischen knapp unter 9€ und knapp über 10€ pendeln und auf positive Neuigkeiten warten.
Wenn diese kommen, sehe ich zwei Möglichkeiten:
A) Weil über Hemosol in den letzten Wochen soviel geredet wurde, wie meines Erachtens noch nie, seit ich diesen Wert verfolge, ist er verstärkt in den Blickpunkt der Anleger gerückt (wenn z.Z. auch negativ)Folge: bei einem Anspringen der Kurse geht es steil (und ich meine STEIL) nach oben, da viele naja, nennen wir sie ruhig Lemminge, noch auf den Zug mit aufspringen werden und den Kurs in 2-3 Tagen wieder bis an die 20€ katapultieren werden (All Time High).
oder
B) Das Vertrauen der Anleger ist nachhaltig so erschüttert(bzw. sie sind verunsichert), daß auch richtig positive Meldungen fast wirkungslos verpuffen und der Kurs nur leicht zuckt, in dem Fall könnte es ein langwieriger und sehr zäher Prozeß werden bis Hemosol wieder wirklich interessant wird, so daß sich mittelfristig orientierte Anleger, die noch im Plus sind (oder nur wenig im Minus) fragen sollten, ob sie ihr Geld nicht anderswo gewinnbringender investieren wollen.
Für den Fall, daß in den nächsten Tagen die 8 Euro nachhaltig unterschritten werden, werde ich meine Anteile (wenn auch mit einem weinenden Auge) verkaufen, denn dann ist bis 4-5€ kein Widerstand mehr und eine weitere Entwicklung ist für diesen Fall sehr schwer vorherzusagen.
Ich denke allerdings nicht, daß dieser Fall eintritt und bin nach wie vor von dem riesigen Potential dieser Aktie überzeugt.
Gruß und bitte um Meinungen
Nucleus
Hallo HML-Gemeinde,
vorab: auch ich kann den Rutsch nach dem 26.6. nicht erklären. Sicher ist es nicht die Telebörse, weil der Kurs nicht hier, sondern nur in Toronto bestimmt wird. Mit charttechnik hab ich hier auch meine Probleme, weil HML bisher ausschließlich auf News und Spekulationen reagiert hat und weniger charttechnisch bestimmt war. Für die nächsten Monate sehe ich hier auch nicht allzuviel Grund zum Optimismus - erst wenn P3 in den USA abgeschlossen ist, wird es richtig spannend, und die hat noch nicht mal begonnen. Ich seh die Aktie zwischen 12 - 14 C$ für die nächste Zeit. Aber ich werde sie
mit Sicherheit halten bis zum TagX, an dem die Zulassung in USA beantragt wird, evtl. bis über die Zulassung entschieden wird. Wer nur gering investiert ist, sollte jetzt günstig nachkaufen, dann aber warten, warten, warten....Es sollte sich lohnen. Ich kauf nicht nach, weil ich schon ziemlich dick drinstecke (zu 4,3 bzw. 15 € gekauft, Einstand bei 6,51 und davon genug). Aber diese kurzfristigen Kurschschwankungen machen mich nicht (oder nur wenig :-) nervös, bei HML muß man Geduld bis mindestens Ende 2001 haben.
vorab: auch ich kann den Rutsch nach dem 26.6. nicht erklären. Sicher ist es nicht die Telebörse, weil der Kurs nicht hier, sondern nur in Toronto bestimmt wird. Mit charttechnik hab ich hier auch meine Probleme, weil HML bisher ausschließlich auf News und Spekulationen reagiert hat und weniger charttechnisch bestimmt war. Für die nächsten Monate sehe ich hier auch nicht allzuviel Grund zum Optimismus - erst wenn P3 in den USA abgeschlossen ist, wird es richtig spannend, und die hat noch nicht mal begonnen. Ich seh die Aktie zwischen 12 - 14 C$ für die nächste Zeit. Aber ich werde sie
mit Sicherheit halten bis zum TagX, an dem die Zulassung in USA beantragt wird, evtl. bis über die Zulassung entschieden wird. Wer nur gering investiert ist, sollte jetzt günstig nachkaufen, dann aber warten, warten, warten....Es sollte sich lohnen. Ich kauf nicht nach, weil ich schon ziemlich dick drinstecke (zu 4,3 bzw. 15 € gekauft, Einstand bei 6,51 und davon genug). Aber diese kurzfristigen Kurschschwankungen machen mich nicht (oder nur wenig :-) nervös, bei HML muß man Geduld bis mindestens Ende 2001 haben.
Hallo HML- freunde
Meist hat es einen Grund wenn eine Aktie fällt.
Hat Hemosol eigentlich schon begonnen eine Fabrik zu bauen?
Warum verzögert sich das?
Da schrumpft vielleicht doch das Vertrauen.
Wie seht Ihr das?
Gruß
Meist hat es einen Grund wenn eine Aktie fällt.
Hat Hemosol eigentlich schon begonnen eine Fabrik zu bauen?
Warum verzögert sich das?
Da schrumpft vielleicht doch das Vertrauen.
Wie seht Ihr das?
Gruß
Seit 1995 kaufe und beobachte ich HEMOSOL. Ich habe alle meine Aktien
noch in Toronto gekauft, allerdings zum Kurs von Can$ 1.6. Ich kann allen Anlegern nur dringend empfehlen, ihre Aktien zu behalten und nachzukaufen, weil der Erfolg in den nächsten 3 Jahren ansteht. Zur Frage nach Gebäuden und Fabrikation: Im Zweifel könnte es ein kleiner, aber leider nur sehr schwacher Hinweis auf einen Erfolg der Fa. HEMOSOL sein, da eine unweit größere Firma, nämlich die Fa. Baxter, ihre Fabrikationsanlagen in 1999 für das Produkt HEMASSIST zwar gebaut hat, das Produkt aber in der Zwischenzeit vom Markt genommen hat. Baxter hat in der Folge dieser Ereignisse dann aber umgehend die Firma SOMATOGEN übernommen, die in der Phase II mit BIOTECH HEMOGLOBIN arbeiten. HEMOSOL ist vor dem sicheren Marktgang, der jetzige Kurs sollte für jeden Investor ein Nachkaufsignal sein.
Und Tschüß... (Bin von Beruf Medizinmann)
noch in Toronto gekauft, allerdings zum Kurs von Can$ 1.6. Ich kann allen Anlegern nur dringend empfehlen, ihre Aktien zu behalten und nachzukaufen, weil der Erfolg in den nächsten 3 Jahren ansteht. Zur Frage nach Gebäuden und Fabrikation: Im Zweifel könnte es ein kleiner, aber leider nur sehr schwacher Hinweis auf einen Erfolg der Fa. HEMOSOL sein, da eine unweit größere Firma, nämlich die Fa. Baxter, ihre Fabrikationsanlagen in 1999 für das Produkt HEMASSIST zwar gebaut hat, das Produkt aber in der Zwischenzeit vom Markt genommen hat. Baxter hat in der Folge dieser Ereignisse dann aber umgehend die Firma SOMATOGEN übernommen, die in der Phase II mit BIOTECH HEMOGLOBIN arbeiten. HEMOSOL ist vor dem sicheren Marktgang, der jetzige Kurs sollte für jeden Investor ein Nachkaufsignal sein.
Und Tschüß... (Bin von Beruf Medizinmann)
aktuell in Frankfurt:
886290 FRA 10,00 17:28:42 11.07.00
(d.h. über +23 %)!!!! (Freu!!)
Quelle: www.hemosol.com/news
Hemolink(TM) Effective and Safe in Heart (Cardiac) Surgery
TORONTO, July 11 /CNW/ - Hemosol Inc.(TSE:HML) reports that in today`s
edition of the National Post, there is an incorrect report on the outcome of
Hemosol`s recently completed Phase III trial of Hemolink(TM), the Company`s
lead product. The company with this release seeks to clarify the current
status of Hemolink(TM).
Hemosol reiterated today that the results of its pivotal Canadian/U.K.
Phase III trial definitively and clearly proved that Hemolink(TM) is both
effective and safe. "For whatever reason there appears to be confusion over
the results reported in our release dated June 26, 2000," stated John W.
Kennedy, President and C.E.O. "These results prove that Hemolink(TM) is highly
effective in avoiding the need for donor blood in surgery. Further,
Hemolink(TM) is clearly safe in patients undergoing cardiac surgery. Hemosol
will file a New Drug Submission (NDS) with Health Canada within three weeks.
This will be the first North American submission for a product of this kind. I
am very proud that Hemosol will be the first to file in this important new
product category," added Mr. Kennedy.
Based on the strength and clarity of the results from this trial the
Company purchased seven acres of land in Mississauga, Ontario and have filed a
site application plan and are now in the final phases of commencing
construction of the first commercial facility. Mr. Kennedy further reported
that Hemosol is on track, on time and confident about the commercial potential
of Hemolink(TM).
Hemosol is an integrated biopharmaceutical company developing a multi-
product pipeline for global markets based on proprietary technologies for use
initially in the treatment of hemoglobin deficiencies.
Hemosol media releases are available on the company`s Internet web site
(http://www.hemosol.com) and Canada NewsWire (http://www.newswire.ca).
886290 FRA 10,00 17:28:42 11.07.00
(d.h. über +23 %)!!!! (Freu!!)
Quelle: www.hemosol.com/news
Hemolink(TM) Effective and Safe in Heart (Cardiac) Surgery
TORONTO, July 11 /CNW/ - Hemosol Inc.(TSE:HML) reports that in today`s
edition of the National Post, there is an incorrect report on the outcome of
Hemosol`s recently completed Phase III trial of Hemolink(TM), the Company`s
lead product. The company with this release seeks to clarify the current
status of Hemolink(TM).
Hemosol reiterated today that the results of its pivotal Canadian/U.K.
Phase III trial definitively and clearly proved that Hemolink(TM) is both
effective and safe. "For whatever reason there appears to be confusion over
the results reported in our release dated June 26, 2000," stated John W.
Kennedy, President and C.E.O. "These results prove that Hemolink(TM) is highly
effective in avoiding the need for donor blood in surgery. Further,
Hemolink(TM) is clearly safe in patients undergoing cardiac surgery. Hemosol
will file a New Drug Submission (NDS) with Health Canada within three weeks.
This will be the first North American submission for a product of this kind. I
am very proud that Hemosol will be the first to file in this important new
product category," added Mr. Kennedy.
Based on the strength and clarity of the results from this trial the
Company purchased seven acres of land in Mississauga, Ontario and have filed a
site application plan and are now in the final phases of commencing
construction of the first commercial facility. Mr. Kennedy further reported
that Hemosol is on track, on time and confident about the commercial potential
of Hemolink(TM).
Hemosol is an integrated biopharmaceutical company developing a multi-
product pipeline for global markets based on proprietary technologies for use
initially in the treatment of hemoglobin deficiencies.
Hemosol media releases are available on the company`s Internet web site
(http://www.hemosol.com) and Canada NewsWire (http://www.newswire.ca).
Hallo Leute,
zunächst möchte ich mich entschuldigen, dass ich mich seit ein paar Tagen nicht gemeldet habe.
Aber bevor ich auf die heutige Kursexplosion eingehe, möchte ich zu meinem Trade weitere Nachforschungsergebnisse einbringen.
Meine Grundüberlegung, dass die "dumme Nachricht" der Auslöser des Kursstruzes war, ist so nicht ganz richtig. Denn die meisten von uns, haben ein interessantes Pokerspiel übersehen.
Zum Zeitpunkt der Bekanntgabe der Ergebnisse aus PIII wurde exakt an diesem Tag die bereits vorher angekündigte Kapitalerhöhung vorgenommen zu ca. 18 C$/Aktie bei einem Kurs (hich glaube es war Freitag) von ca. 25C$/Aktie.
So nun kann man davon ausgehen, dass die Kapitalerhöhung, die eine deutliche Differenz zwischen Ausgabe und Tageskurs hatte durch "DIE NACHRICHT" abgedeckt wird. Nur hat keiner damit gerechnet, dass diese "NACHRICHT" nicht 100% Wasserdicht ist und durch den niedrigen Kurs ist zusätzlich ein Verunsicherungspotentail hervorgerufen worden.
Zudem muß mann betrachten, dass bei Hemosol mit niedrigen Stückzahlen gehandelt wird und dadurch der Kurs sehr leicht steuerbar ist. Durch die Kapitalerhöhung ist wieder eine relativ hohe Menge in den Umlauf gebracht worden.
Die darauf folgenden Nachrichten, die die Mißverständnisse aus dem Weg räumen sollten, wahren auch nicht griffest nach der ersten Verunsicherungen (zuviele Wörter: wenn dann .... möglich.....). Die Unsicherheit blieb nachwievor da und mann konnte seine 100 Aktien bei einem Kurs von 16C$ nur für 15,5 C$ veräusern.
Durch die heutige Nachricht, sind deutliche Worte von Hemosol mit bestimmten Zielen bekannt gegeben worden. Was als deutliches Zeichen zur Vertrauensgewinnung zu sehen ist, denn Mr. Kennedy hat wenn man so betrachtet all seine Versprechen bis heute eingehalten.
Daher bin ich von meiner Aufstellung Pkt. 1 wieder voll überzeugt, so dass Hemosol jetz am Kehrpunkt ist.
Gruß an Alle Hemo´s
CoolMax
zunächst möchte ich mich entschuldigen, dass ich mich seit ein paar Tagen nicht gemeldet habe.
Aber bevor ich auf die heutige Kursexplosion eingehe, möchte ich zu meinem Trade weitere Nachforschungsergebnisse einbringen.
Meine Grundüberlegung, dass die "dumme Nachricht" der Auslöser des Kursstruzes war, ist so nicht ganz richtig. Denn die meisten von uns, haben ein interessantes Pokerspiel übersehen.
Zum Zeitpunkt der Bekanntgabe der Ergebnisse aus PIII wurde exakt an diesem Tag die bereits vorher angekündigte Kapitalerhöhung vorgenommen zu ca. 18 C$/Aktie bei einem Kurs (hich glaube es war Freitag) von ca. 25C$/Aktie.
So nun kann man davon ausgehen, dass die Kapitalerhöhung, die eine deutliche Differenz zwischen Ausgabe und Tageskurs hatte durch "DIE NACHRICHT" abgedeckt wird. Nur hat keiner damit gerechnet, dass diese "NACHRICHT" nicht 100% Wasserdicht ist und durch den niedrigen Kurs ist zusätzlich ein Verunsicherungspotentail hervorgerufen worden.
Zudem muß mann betrachten, dass bei Hemosol mit niedrigen Stückzahlen gehandelt wird und dadurch der Kurs sehr leicht steuerbar ist. Durch die Kapitalerhöhung ist wieder eine relativ hohe Menge in den Umlauf gebracht worden.
Die darauf folgenden Nachrichten, die die Mißverständnisse aus dem Weg räumen sollten, wahren auch nicht griffest nach der ersten Verunsicherungen (zuviele Wörter: wenn dann .... möglich.....). Die Unsicherheit blieb nachwievor da und mann konnte seine 100 Aktien bei einem Kurs von 16C$ nur für 15,5 C$ veräusern.
Durch die heutige Nachricht, sind deutliche Worte von Hemosol mit bestimmten Zielen bekannt gegeben worden. Was als deutliches Zeichen zur Vertrauensgewinnung zu sehen ist, denn Mr. Kennedy hat wenn man so betrachtet all seine Versprechen bis heute eingehalten.
Daher bin ich von meiner Aufstellung Pkt. 1 wieder voll überzeugt, so dass Hemosol jetz am Kehrpunkt ist.
Gruß an Alle Hemo´s
CoolMax
Hallo CoolMax, was für Kurse hälst denn bei Hemosol für möglich. Ich bin voll von dem Produkt überzeugt, und habe deshalb wohl etwas zu früh eingekauft. Kurse von 17 Euro wieder möglich???
@ariesmei
Grundsätzlich möchte ich keine Zielkurse abgeben oder prognostiezieren.
Ich bin lediglich davon überzeugt, dass Hemosol den Fakten nach eine Solide Basis für einen Wachstum für das Unternehmen und somit auch für die Aktie geschaffen hat.
Auch wenn der Kurs derzeit nicht wie erhofft explosionsartig anspringt, sehe ich für die nächste Zeit großes Wachstumspotential.
Denn der Kurs von 17 EUR bzw. schon mal über 19 EUR ist aus reinen Spekulationen endstanden und jetzt sind Fakten da.
1. Produkt kann vermarktet werden
2. Hemosol kann mit den geplanten Erweiterungen der Kapazitäten beginnen
3. Hemosol kann nun Wachsend denken, das heißt durch dieses Produkt aus den roten Zahlen kommen.
4..........
5..........
Das sind alles Punkte die jetzt nach und nach präsentiert werden von Mr. Kennedy
In den unten beigefügten Bericht kannst Du auch erkennen, warum der Kurs gleich wieder abgeflaut hat (Bitte lesen).
Auch wenn ein Super Biotech-Analyst den wirtschaftlichen Erfolg in Frage stellt ist es für mich verwunderlich warum er zwei zeilen später ein Kursziel von 36C$ angiebt, was einer knappen verdreifachung entspricht vom heutigen Kurs gesehen.
Spätestens dann, wenn Mr. Kennedy Planzahlen bekannt giebt ist dieser Bericht vergessen.
Also bis dann und nun nicht mehr nervös werden
CoolMax
Hemosol stanches the bleeding
by Leonard Zehr - Wednesday, July 12, 2000
Blood substitute developer Hemosol Inc., fighting investor confusion about its clinical test results, appears to have
stemmed the bleeding that has nearly halved its stock price in a four-week selloff.
Yesterday, the stock jumped $2.50 to $13.65 on the Toronto Stock Exchange, as the company blasted a published report
that claimed its Hemolink treatment may not be effective in avoiding blood transfusions.
The company said results of a recent Phase III clinical trial with patients undergoing heart-bypass surgery in Canada and
Britain "definitively and clearly proved that Hemolink is both effective and safe."
Moreover, "Hemosol is on track, on time and confident about the commercial potential of Hemolink," said president and
chief executive officer John Kennedy.
While many industry observers concur, some question how quickly and widely blood substitute products like Hemolink will
be adopted as a mainstream treatment during surgery.
"This is by far the more difficult question," said biotech analyst Cameron Groome of National Bank Financial Inc. "There`s
no clear answer whether surgeons and insurers will accept this product."
Indeed, a recent editorial in the New England Journal of Medicine said new products like Hemolink are not miracle drugs.
"We should temper our expectations until we learn more about their advantages and limitations," the editorial concluded.
"Red-cell substitutes will not entirely answer the need for red cells, but they will probably reduce or eliminate the need for
transfused blood in some patients."
Originally developed by the Canadian military, Hemolink is made from human hemoglobin, the oxygen-carrying component
of red blood cells. The company buys outdated blood from various collection agencies, and then purifies and chemically
stabilizes the hemoglobin so that it is virtually virus-free.
But the thing that has investors scratching their heads occurred on June 12. In a vaguely worded statement, Hemosol
reported a higher-than-expected level of transfusion avoidance by patients receiving a control agent in the Phase III
Canadian-British study.
What it failed to address was whether Hemolink was statistically superior in avoiding transfusions. That sent the stock
careening to $17 from $24.90, a 32-per-cent one-day plunge.
But after further analysis, specifically eliminating 11 patients in the study that required a transfusion because of surgical
errors and other complications, the company on June 26 reported that Hemolink was 37 per cent better than the control
treatment at reducing the need for transfusions, a level considered statistically significant.
In addition to safety and effectiveness, Hemolink also reduced the amount of blood used and gave patients a longer overall
time before a transfusion was administered.
The company plans to file for regulatory approval to sell Hemolink in Canada by the end of the month.
"I`m a little surprised that the stock is down as much as it is," said biotech analyst Vera Belaoussoff of Northern Securities
Inc., who continues to recommend the stock as a "buy," with a 12-month price target of $36.50.
"There`s a lot of misunderstanding out there among investors," she said. "I like the stock because I think the product works.
Until the time lines [for product development] change significantly, I`m sticking with $36.50."
Mr. Groome used the latest clinical results to initiate coverage of Hemosol, with a "speculative buy" rating and a
12-to-18-month target price of $25. "I put the stock on the `buy` list, knowing it would go lower before it went higher."
Nevertheless, he figures that the big Phase III study in the United States set to begin in the fall -- also with heart-bypass
patients -- combined with interim results from the trial early next year and possible approval by Canadian regulators later
that year, together have the potential to lift the stock price back to its 52-week high of $27.
"By then, we`ll have some comfort about how sales will unfold," he said. "If they do, we`ll hold on. If they don`t, we`ll sell at
a profit. There`s a potential 100-per-cent return if the stock returns to its previous high in the next 12-to-18 months."
For now, he figures first-year sales of Hemolink will hit $9-million next year, climbing to $55-million in 2002 -- levels he
admits are below many street forecasts.
Ms. Belaoussoff expects Hemolink to perform better in the U.S. trial, which will use high-risk patients instead of low-risk
patients used in the Canadian-British trial. "Doctors won`t be so willing to push the dose of control agent into patients in
order to avoid a transfusion."
She said the company is also making a number of design changes in the U.S. study, which will give surgeons greater
flexibility and should favour Hemolink.
But when asked what it will take to get Hemolink approved, she figures that regulators will lean more towards "improved
patient outcomes and clinical benefits" that already have been obtained, than transfusion rates between two study groups of
patients.
Bottom Line
Believers in Hemolink aren`t deterred by this latest bump in the road. Analysts suggest that positive clinical and regulatory
news will be translated in the price of the stock.
HEMOSOL: VITAL STATISTICS
Business description
A biopharmaceutical company which focuses on the development of blood-related proteins.
Head office: Toronto
Telephone: 416-798-0700
Web site: http://www.hemosol.com
TSE symbol: HML
Employees: 94
Share values, $
Trailing 12-month earnings per share...-$1.08
52-week intraday high $27
52-week intraday low $4.10
Yesterday`s close $13.65
Change from previous +$2.50
1-year total return 173.55%
59-month average annual return 17.34%
Top mutual fund holdings
% of total market value, as of Mar. 31.
-*as of May 31.
Scotia Canadian Small Cap 3.2
National Equities* 2.7
Altamira Special Growth 1.8
Royal Canadian Small Cap 2.2
IG AGF Cdn Diversified Growth* 1.4
Clarington Canadian Micro-Cap 4.5
NN Life Canadian Small Cap 1.8
Source: Bloomberg Financial Services; Datastream, http://www.globeinvestor.com
Grundsätzlich möchte ich keine Zielkurse abgeben oder prognostiezieren.
Ich bin lediglich davon überzeugt, dass Hemosol den Fakten nach eine Solide Basis für einen Wachstum für das Unternehmen und somit auch für die Aktie geschaffen hat.
Auch wenn der Kurs derzeit nicht wie erhofft explosionsartig anspringt, sehe ich für die nächste Zeit großes Wachstumspotential.
Denn der Kurs von 17 EUR bzw. schon mal über 19 EUR ist aus reinen Spekulationen endstanden und jetzt sind Fakten da.
1. Produkt kann vermarktet werden
2. Hemosol kann mit den geplanten Erweiterungen der Kapazitäten beginnen
3. Hemosol kann nun Wachsend denken, das heißt durch dieses Produkt aus den roten Zahlen kommen.
4..........
5..........
Das sind alles Punkte die jetzt nach und nach präsentiert werden von Mr. Kennedy
In den unten beigefügten Bericht kannst Du auch erkennen, warum der Kurs gleich wieder abgeflaut hat (Bitte lesen).
Auch wenn ein Super Biotech-Analyst den wirtschaftlichen Erfolg in Frage stellt ist es für mich verwunderlich warum er zwei zeilen später ein Kursziel von 36C$ angiebt, was einer knappen verdreifachung entspricht vom heutigen Kurs gesehen.
Spätestens dann, wenn Mr. Kennedy Planzahlen bekannt giebt ist dieser Bericht vergessen.
Also bis dann und nun nicht mehr nervös werden
CoolMax
Hemosol stanches the bleeding
by Leonard Zehr - Wednesday, July 12, 2000
Blood substitute developer Hemosol Inc., fighting investor confusion about its clinical test results, appears to have
stemmed the bleeding that has nearly halved its stock price in a four-week selloff.
Yesterday, the stock jumped $2.50 to $13.65 on the Toronto Stock Exchange, as the company blasted a published report
that claimed its Hemolink treatment may not be effective in avoiding blood transfusions.
The company said results of a recent Phase III clinical trial with patients undergoing heart-bypass surgery in Canada and
Britain "definitively and clearly proved that Hemolink is both effective and safe."
Moreover, "Hemosol is on track, on time and confident about the commercial potential of Hemolink," said president and
chief executive officer John Kennedy.
While many industry observers concur, some question how quickly and widely blood substitute products like Hemolink will
be adopted as a mainstream treatment during surgery.
"This is by far the more difficult question," said biotech analyst Cameron Groome of National Bank Financial Inc. "There`s
no clear answer whether surgeons and insurers will accept this product."
Indeed, a recent editorial in the New England Journal of Medicine said new products like Hemolink are not miracle drugs.
"We should temper our expectations until we learn more about their advantages and limitations," the editorial concluded.
"Red-cell substitutes will not entirely answer the need for red cells, but they will probably reduce or eliminate the need for
transfused blood in some patients."
Originally developed by the Canadian military, Hemolink is made from human hemoglobin, the oxygen-carrying component
of red blood cells. The company buys outdated blood from various collection agencies, and then purifies and chemically
stabilizes the hemoglobin so that it is virtually virus-free.
But the thing that has investors scratching their heads occurred on June 12. In a vaguely worded statement, Hemosol
reported a higher-than-expected level of transfusion avoidance by patients receiving a control agent in the Phase III
Canadian-British study.
What it failed to address was whether Hemolink was statistically superior in avoiding transfusions. That sent the stock
careening to $17 from $24.90, a 32-per-cent one-day plunge.
But after further analysis, specifically eliminating 11 patients in the study that required a transfusion because of surgical
errors and other complications, the company on June 26 reported that Hemolink was 37 per cent better than the control
treatment at reducing the need for transfusions, a level considered statistically significant.
In addition to safety and effectiveness, Hemolink also reduced the amount of blood used and gave patients a longer overall
time before a transfusion was administered.
The company plans to file for regulatory approval to sell Hemolink in Canada by the end of the month.
"I`m a little surprised that the stock is down as much as it is," said biotech analyst Vera Belaoussoff of Northern Securities
Inc., who continues to recommend the stock as a "buy," with a 12-month price target of $36.50.
"There`s a lot of misunderstanding out there among investors," she said. "I like the stock because I think the product works.
Until the time lines [for product development] change significantly, I`m sticking with $36.50."
Mr. Groome used the latest clinical results to initiate coverage of Hemosol, with a "speculative buy" rating and a
12-to-18-month target price of $25. "I put the stock on the `buy` list, knowing it would go lower before it went higher."
Nevertheless, he figures that the big Phase III study in the United States set to begin in the fall -- also with heart-bypass
patients -- combined with interim results from the trial early next year and possible approval by Canadian regulators later
that year, together have the potential to lift the stock price back to its 52-week high of $27.
"By then, we`ll have some comfort about how sales will unfold," he said. "If they do, we`ll hold on. If they don`t, we`ll sell at
a profit. There`s a potential 100-per-cent return if the stock returns to its previous high in the next 12-to-18 months."
For now, he figures first-year sales of Hemolink will hit $9-million next year, climbing to $55-million in 2002 -- levels he
admits are below many street forecasts.
Ms. Belaoussoff expects Hemolink to perform better in the U.S. trial, which will use high-risk patients instead of low-risk
patients used in the Canadian-British trial. "Doctors won`t be so willing to push the dose of control agent into patients in
order to avoid a transfusion."
She said the company is also making a number of design changes in the U.S. study, which will give surgeons greater
flexibility and should favour Hemolink.
But when asked what it will take to get Hemolink approved, she figures that regulators will lean more towards "improved
patient outcomes and clinical benefits" that already have been obtained, than transfusion rates between two study groups of
patients.
Bottom Line
Believers in Hemolink aren`t deterred by this latest bump in the road. Analysts suggest that positive clinical and regulatory
news will be translated in the price of the stock.
HEMOSOL: VITAL STATISTICS
Business description
A biopharmaceutical company which focuses on the development of blood-related proteins.
Head office: Toronto
Telephone: 416-798-0700
Web site: http://www.hemosol.com
TSE symbol: HML
Employees: 94
Share values, $
Trailing 12-month earnings per share...-$1.08
52-week intraday high $27
52-week intraday low $4.10
Yesterday`s close $13.65
Change from previous +$2.50
1-year total return 173.55%
59-month average annual return 17.34%
Top mutual fund holdings
% of total market value, as of Mar. 31.
-*as of May 31.
Scotia Canadian Small Cap 3.2
National Equities* 2.7
Altamira Special Growth 1.8
Royal Canadian Small Cap 2.2
IG AGF Cdn Diversified Growth* 1.4
Clarington Canadian Micro-Cap 4.5
NN Life Canadian Small Cap 1.8
Source: Bloomberg Financial Services; Datastream, http://www.globeinvestor.com
Wann kommen endlich die langersehnten guten Nachrichten von Hemosol ?
Ich dachte Mitte Juli - oder so ?
Ich dachte Mitte Juli - oder so ?
Hi Leute,
leider konnte ich mich eine weile nicht melden, da mein Computer durch einen mysteriösen Virus ausser Gefecht gesetz wurde.
Nach dem ich die weiteren Diskusionen wieder verfolgen konnte, muß ich feststellen, dass Hemosol auf dem Weg ist den ich vorgezeigt habe.
Nun warten wir mal den 28.08.00 ab, was dann passiert, ich sehe diesen Termin als Schlüsselfunktion an, denn dann wird die von mir lang ersehnte Marketingarbeit so richtig losgehen. Die besten Anzeichen dafür sind ja schon da, denn in den letzten Tagen hat Hemosol wieder kräftig bei niedrigen Umsätzen zugelegt, der heutige Abrutscher sollte keinen in die Versuchung treiben seine Aktien ausser Hand zu geben.
Ich habe mich auch vor kurzer Zeit geäußert, dass ich keine Kursziel abgeben möchte, dass einzige wass ich noch hinzufügen möchte, dass ich wie wir alle darauf hoffe und vertraue, dass es nicht um Prozente, sonder um Faktoren gehen wird.
Gruß
CoolMax
leider konnte ich mich eine weile nicht melden, da mein Computer durch einen mysteriösen Virus ausser Gefecht gesetz wurde.
Nach dem ich die weiteren Diskusionen wieder verfolgen konnte, muß ich feststellen, dass Hemosol auf dem Weg ist den ich vorgezeigt habe.
Nun warten wir mal den 28.08.00 ab, was dann passiert, ich sehe diesen Termin als Schlüsselfunktion an, denn dann wird die von mir lang ersehnte Marketingarbeit so richtig losgehen. Die besten Anzeichen dafür sind ja schon da, denn in den letzten Tagen hat Hemosol wieder kräftig bei niedrigen Umsätzen zugelegt, der heutige Abrutscher sollte keinen in die Versuchung treiben seine Aktien ausser Hand zu geben.
Ich habe mich auch vor kurzer Zeit geäußert, dass ich keine Kursziel abgeben möchte, dass einzige wass ich noch hinzufügen möchte, dass ich wie wir alle darauf hoffe und vertraue, dass es nicht um Prozente, sonder um Faktoren gehen wird.
Gruß
CoolMax
@ alle
wo bekommt Ihr den Kanadakurs her ?
ich gehe immer über www.tse.com ist langsam und mühsam !
Danke
crumb
wo bekommt Ihr den Kanadakurs her ?
ich gehe immer über www.tse.com ist langsam und mühsam !
Danke
crumb
hallo crumb
Du hast zwei Möglichkeiten um dir den KURS VON Hemosol in Kanada
anzuschauen:
www.hemosol.com/html/investor/stock_fs.htm oder
www.hemosol.com und dann über die links auf der homepage
investor information
stock quote
In Kanada wird von 15.30 bis 22.00 Uhr gehandelt
hoffe ,ich konnte dir helfen -jerrry -
Du hast zwei Möglichkeiten um dir den KURS VON Hemosol in Kanada
anzuschauen:
www.hemosol.com/html/investor/stock_fs.htm oder
www.hemosol.com und dann über die links auf der homepage
investor information
stock quote
In Kanada wird von 15.30 bis 22.00 Uhr gehandelt
hoffe ,ich konnte dir helfen -jerrry -
Hallo Crumb! Du kannst es auch über www.telenium.ca/freestocks.html versuchen. Das Börsenkürzel ist wie immer HML!
UND SCHON WIEDER EINE GUTE NACHRICHT:
-- Health Canada Guidelines Call For 180 Day Review Period --
TORONTO, Aug. 28 /CNW/ - Hemosol Inc. (TSE:HML), today announced that
Health Canada`s Therapeutic Products Program (TPP) has granted Priority Review
status to the Hemolink(TM) New Drug Submission (NDS). Priority Review status
is granted to a small number of potentially important new products. The target
review period of 180 days for priority products is significantly shorter than
the usual review period.
"We are very pleased that Health Canada has granted a priority review for
the Hemolink(TM) New Drug Submission. We believe that this recognizes the need
for hemoglobin replacement therapy and, specifically, the potential importance
of Hemolink(TM) treatment," said John W. Kennedy President and CEO of Hemosol.
The NDS, filed on July 31, 2000, seeks approval to market Hemolink(TM) to
avoid or reduce the use of donor red blood cells (RBCs) in scheduled surgery
such as coronary artery by-pass grafting (CABG). The Company anticipates that
the TPP will begin the priority review in mid September.
Ich denke, es wird weiter bergauf gehen.....
-- Health Canada Guidelines Call For 180 Day Review Period --
TORONTO, Aug. 28 /CNW/ - Hemosol Inc. (TSE:HML), today announced that
Health Canada`s Therapeutic Products Program (TPP) has granted Priority Review
status to the Hemolink(TM) New Drug Submission (NDS). Priority Review status
is granted to a small number of potentially important new products. The target
review period of 180 days for priority products is significantly shorter than
the usual review period.
"We are very pleased that Health Canada has granted a priority review for
the Hemolink(TM) New Drug Submission. We believe that this recognizes the need
for hemoglobin replacement therapy and, specifically, the potential importance
of Hemolink(TM) treatment," said John W. Kennedy President and CEO of Hemosol.
The NDS, filed on July 31, 2000, seeks approval to market Hemolink(TM) to
avoid or reduce the use of donor red blood cells (RBCs) in scheduled surgery
such as coronary artery by-pass grafting (CABG). The Company anticipates that
the TPP will begin the priority review in mid September.
Ich denke, es wird weiter bergauf gehen.....
Und was sehen meine Blut-Augen da??? Hemosol in Canada über ACHT Prozent im Plus!! Wenn das mal keine richtig gute Nachricht war....
@ ROADRUNNER
D A N K E ! ! ! !
D A N K E ! ! ! !
Hallo Crumb,
Du kannst es auch unter www.stockpoint.com versuchen, Kurse sind aber 15 Minuten zeitversetzt, als Kürzel, klar HML.
Oder kann mir jemand mit ner Seite mit Realtime weiterhelfen, Datek hat ja keine CAN.-Werte.
Zu Hemosol selbst: Gehöre zu den Glücklichen, die die Aktie seit über nem Jahr haben, und sehe nicht ein, warum ich mir den Kurs vor Ende nächsten Jahres anschauen sollte. Will heißen: Bei Erfolg kommen die guten Kurse nicht vor Ende 2001 oder gar 2002 (evtl. Zulassung in USA), bei Mißerfolg - schade eigentlich. Aber ich glaub dran.
Du kannst es auch unter www.stockpoint.com versuchen, Kurse sind aber 15 Minuten zeitversetzt, als Kürzel, klar HML.
Oder kann mir jemand mit ner Seite mit Realtime weiterhelfen, Datek hat ja keine CAN.-Werte.
Zu Hemosol selbst: Gehöre zu den Glücklichen, die die Aktie seit über nem Jahr haben, und sehe nicht ein, warum ich mir den Kurs vor Ende nächsten Jahres anschauen sollte. Will heißen: Bei Erfolg kommen die guten Kurse nicht vor Ende 2001 oder gar 2002 (evtl. Zulassung in USA), bei Mißerfolg - schade eigentlich. Aber ich glaub dran.
Gefunden bei Siliconinvestor. Einige Boardmitglieder halten Cannacord allerdings für zwielichtig.
Another Strong Buy from Cannacord
Hemosol Inc. (HML : TSE : $15.15) Wayne Schnarr, Ph.D. (416) 869-3028
Recommendation: STRONG BUY
12 to 18-month target price: $40.00
52-week price range: $27.00-4.10
Shares O/S: basic 31.7M
fully diluted 32.7M
Year end: December 31
Dividend: None
Cash (June 30): $65M
Major shareholder: MDS & related funds, 7.3M
Weekly trading volume (3 mos): 1.07M shares
Market capitalization: $480.3M
Sector: Biotechnology
Web site address: www.hemosol.com
Yesterday`s Daily Letter included the wrong update on the company. We
apologize for the error.
Alliance Pharmaceutical Corp. (ALLP : NASDAQ) announced that it had
completed an initial analysis of its European Phase III study of
Oxygent, its perflubron-based RBC substitute. Alliance uses a
normovolemic hemodilution protocol similar to the one used by Hemosol.
The European Phase III study enrolled patients undergoing a variety of
general surgery procedures. The evaluation of the entire study
population showed that patients who received Oxygent during surgery
required a statistically significant (p=0.01) fewer number of units of
donor blood and there was a trend to avoidance of donor blood in the
Oxygent versus control groups (p=0.06). When only high blood loss
patients were included in the analysis, the reduction and avoidance of
donor blood were both highly significant (p<0.001). This segregated
data supports our contention that there will be select patient
populations that will benefit more from the use of RBC substitutes and
that will be the initial target markets.
Alliance will release more detailed information later this year at a
scientific conference and discuss its data with the European
regulatory agencies in terms of its submission strategy. The US Phase
III trial in CABG surgery should complete enrollment in Q1/01.
Biopure Corp. (BPUR : NASDAQ) announced that it had completed
enrollment in its Phase III study of Hemopure, its RBC substitute
derived from bovine blood, in patients undergoing orthopedic surgery.
The company stated that it expects to file with the FDA by mid-2001,
followed by submissions in Europe and Canada. Preliminary data should
be available shortly after the evaluation period for the last patient
is completed in mid-October. Biopure did not use a normovolemic
hemodilution procedure in its clinical trials.
These announcements do not have any substantial impact on Hemosol`s
competitive position as an RBC substitute. There is insufficient data
to change our position that all four RBC substitutes have
approximately equal efficacy. The FDA approvals of the Alliance,
Biopure, and Hemosol products should all occur within a few months of
each other in late 2001 and early 2002.
We expect two announcements from Hemosol this month. First, the
groundbreaking for the manufacturing facility will be on September 20.
Second, the US Phase III clinical trial is expected to enroll its
first patients before the end of September. While the exact details
of the trial structure have not been released, it will be similar to
the Canada/UK trial and about 700 patients will be enrolled from about
45 clinical centers. Hemosol has stated previously that the main
concern of the FDA is safety. The US Phase III trial is expected to
have an interim analysis after about 400 patients. We expect this
will be completed in late Q1/01 and that the combination of this data
and the Canada/UK Phase III data will be sufficient to file for
regulatory approval in the US and the EU in mid-2001. The US Phase
III trial is expected to be complete in Q3 or Q4/01, depending upon
the rate of patient enrolment. The final data from the trial is
expected to be available prior to an FDA advisory committee meeting.
The meeting of the FDA advisory committee and subsequent FDA approval
are expected in late 2001 or early 2002.
Our recommendation remains a STRONG BUY with a 12 to 18-month target
of $40.00.
Another Strong Buy from Cannacord
Hemosol Inc. (HML : TSE : $15.15) Wayne Schnarr, Ph.D. (416) 869-3028
Recommendation: STRONG BUY
12 to 18-month target price: $40.00
52-week price range: $27.00-4.10
Shares O/S: basic 31.7M
fully diluted 32.7M
Year end: December 31
Dividend: None
Cash (June 30): $65M
Major shareholder: MDS & related funds, 7.3M
Weekly trading volume (3 mos): 1.07M shares
Market capitalization: $480.3M
Sector: Biotechnology
Web site address: www.hemosol.com
Yesterday`s Daily Letter included the wrong update on the company. We
apologize for the error.
Alliance Pharmaceutical Corp. (ALLP : NASDAQ) announced that it had
completed an initial analysis of its European Phase III study of
Oxygent, its perflubron-based RBC substitute. Alliance uses a
normovolemic hemodilution protocol similar to the one used by Hemosol.
The European Phase III study enrolled patients undergoing a variety of
general surgery procedures. The evaluation of the entire study
population showed that patients who received Oxygent during surgery
required a statistically significant (p=0.01) fewer number of units of
donor blood and there was a trend to avoidance of donor blood in the
Oxygent versus control groups (p=0.06). When only high blood loss
patients were included in the analysis, the reduction and avoidance of
donor blood were both highly significant (p<0.001). This segregated
data supports our contention that there will be select patient
populations that will benefit more from the use of RBC substitutes and
that will be the initial target markets.
Alliance will release more detailed information later this year at a
scientific conference and discuss its data with the European
regulatory agencies in terms of its submission strategy. The US Phase
III trial in CABG surgery should complete enrollment in Q1/01.
Biopure Corp. (BPUR : NASDAQ) announced that it had completed
enrollment in its Phase III study of Hemopure, its RBC substitute
derived from bovine blood, in patients undergoing orthopedic surgery.
The company stated that it expects to file with the FDA by mid-2001,
followed by submissions in Europe and Canada. Preliminary data should
be available shortly after the evaluation period for the last patient
is completed in mid-October. Biopure did not use a normovolemic
hemodilution procedure in its clinical trials.
These announcements do not have any substantial impact on Hemosol`s
competitive position as an RBC substitute. There is insufficient data
to change our position that all four RBC substitutes have
approximately equal efficacy. The FDA approvals of the Alliance,
Biopure, and Hemosol products should all occur within a few months of
each other in late 2001 and early 2002.
We expect two announcements from Hemosol this month. First, the
groundbreaking for the manufacturing facility will be on September 20.
Second, the US Phase III clinical trial is expected to enroll its
first patients before the end of September. While the exact details
of the trial structure have not been released, it will be similar to
the Canada/UK trial and about 700 patients will be enrolled from about
45 clinical centers. Hemosol has stated previously that the main
concern of the FDA is safety. The US Phase III trial is expected to
have an interim analysis after about 400 patients. We expect this
will be completed in late Q1/01 and that the combination of this data
and the Canada/UK Phase III data will be sufficient to file for
regulatory approval in the US and the EU in mid-2001. The US Phase
III trial is expected to be complete in Q3 or Q4/01, depending upon
the rate of patient enrolment. The final data from the trial is
expected to be available prior to an FDA advisory committee meeting.
The meeting of the FDA advisory committee and subsequent FDA approval
are expected in late 2001 or early 2002.
Our recommendation remains a STRONG BUY with a 12 to 18-month target
of $40.00.
Hallo Leute,
der heutige Chart,zeigt mal, dass hier wieder etwas Bewegung ins Spiel kommt.
http://investdb.theglobeandmail.com/invest/investSQL/gx.stoc…
http://investdb.theglobeandmail.com/invest/investSQL/gx.show…
http://investdb.theglobeandmail.com/invest/investSQL/gx.show…
Leider weis ich nicht, wie ich Grafiken hier hereinkopieren kann! So verkürzt es aber die Ladezeiten.
Die Kurzfassung des heutigen Tages:
Canada ca. 350.000 Umsatz im vergleich zu den letzten Tagen zwischen 15 und 30 Tausen. Da könnte man das Gefühl bekommen hier steigt wiedermal jemand groß ein.
Na mal guken was der 16.1. bring.
Gruß
CoolMax
der heutige Chart,zeigt mal, dass hier wieder etwas Bewegung ins Spiel kommt.
http://investdb.theglobeandmail.com/invest/investSQL/gx.stoc…
http://investdb.theglobeandmail.com/invest/investSQL/gx.show…
http://investdb.theglobeandmail.com/invest/investSQL/gx.show…
Leider weis ich nicht, wie ich Grafiken hier hereinkopieren kann! So verkürzt es aber die Ladezeiten.
Die Kurzfassung des heutigen Tages:
Canada ca. 350.000 Umsatz im vergleich zu den letzten Tagen zwischen 15 und 30 Tausen. Da könnte man das Gefühl bekommen hier steigt wiedermal jemand groß ein.
Na mal guken was der 16.1. bring.
Gruß
CoolMax
Sorry,
bin einen Tag daneben gelegen.
Gruß
CoolMax
bin einen Tag daneben gelegen.
Gruß
CoolMax
Sorry,
hier nochmal für alle die Nachricht
Hemosol Files a Registration Statement in the United States and a
Preliminary Prospectus in Canada with Respect to the Offering of
7,000,000 Common Shares
17:11 EST Wednesday, January 17, 2001
TORONTO, Jan. 17 /CNW/ - Hemosol Inc. (TSE: HML) announced today that it has filed a registration statement in the
United States and a short-form preliminary prospectus in Canada under the Canada/US multijurisdictional disclosure
system in connection with its proposed initial public offering of 7,000,000 common shares in the United States. All
common shares will be offered by the Company. In addition, Hemosol will grant to the underwriters an option to purchase
an additional 1,050,000 common shares to cover over- allotments, if any. Hemosol is an integrated biopharmaceutical
company focused on the development of a portfolio of products for the treatment of hemoglobin deficiencies, or anemia.
The managing underwriters for the offering are UBS Warburg LLC and Dain Rauscher Wessels. Copies of the
preliminary prospectus relating to this offering may be obtained from UBS Warburg LLC, 299 Park Avenue, New York,
NY 10171.
A registration statement relating to these securities has been filed with the US Securities and Exchange Commission but
has not yet become effective. These securities may not be sold nor may offers to buy these securities be accepted prior
to the time the registration statement becomes effective. This news release shall not constitute an offer to sell or the
solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation or
sale would be unlawful prior to registration or qualification under the securities law of any such state. © 2001 Canada
Newswire Ltd.
CoolMax
hier nochmal für alle die Nachricht
Hemosol Files a Registration Statement in the United States and a
Preliminary Prospectus in Canada with Respect to the Offering of
7,000,000 Common Shares
17:11 EST Wednesday, January 17, 2001
TORONTO, Jan. 17 /CNW/ - Hemosol Inc. (TSE: HML) announced today that it has filed a registration statement in the
United States and a short-form preliminary prospectus in Canada under the Canada/US multijurisdictional disclosure
system in connection with its proposed initial public offering of 7,000,000 common shares in the United States. All
common shares will be offered by the Company. In addition, Hemosol will grant to the underwriters an option to purchase
an additional 1,050,000 common shares to cover over- allotments, if any. Hemosol is an integrated biopharmaceutical
company focused on the development of a portfolio of products for the treatment of hemoglobin deficiencies, or anemia.
The managing underwriters for the offering are UBS Warburg LLC and Dain Rauscher Wessels. Copies of the
preliminary prospectus relating to this offering may be obtained from UBS Warburg LLC, 299 Park Avenue, New York,
NY 10171.
A registration statement relating to these securities has been filed with the US Securities and Exchange Commission but
has not yet become effective. These securities may not be sold nor may offers to buy these securities be accepted prior
to the time the registration statement becomes effective. This news release shall not constitute an offer to sell or the
solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation or
sale would be unlawful prior to registration or qualification under the securities law of any such state. © 2001 Canada
Newswire Ltd.
CoolMax
Hallo Nachbar @Cooler Max, Du hypnotisierst ja schon wieder das Blutgerinnsel, warum hast Du mir nicht rechtzeitig Bescheid gesagt? Komm doch mal hoch!!!
Gruß Glubsch
Gruß Glubsch
Red Letter Day
Mon, Jan. 22, 2001 20:56
By Crystal Quast, Canada-iNvest.com
Hemosol’s (HML) plan to sell up to US$80.5 million worth of stock and apply for a NASDAQ listing should have U.S. investors sitting up and taking notice, according to one portfolio manager.
“I think it will be good for them to be listed in the States, and get some coverage by U.S. analysts, and for the U.S. investors to be able to compare Hemosol against Biopure (US),” says Allaster MacLean of Scotia Cassels. The portfolio manager believes a larger U.S. investor base could narrow the gap between the two companies. “U.S. investors seem to pay more for these sorts of companies than Canadians do.”
The Ontario-based biotech has developed a blood substitute called Hemolink for use during surgery. Even with its recent surge higher to $14, Hemosol is still far off of its 52-week high of $27. It has a 52-week low of $10.25 and a market cap of $359 million. MacLean believes the company deserves a higher valuation. “It looks like Hemosol has a good chance to get approval first, and be on a market first.”
In July, the company announced it would file with the Canadian Therapeutics Products Programme (TPP) to market Hemolink for use in coronary artery by-pass grafting surgery. Pending approval, which is expected in the first quarter of this year, the company expects to be selling Hemolink in Canada in 2001. Regulatory submissions in Europe are expected shortly with the States following suit.
Biopure of Cambridge, MA, which is considered to be Hemosol’s main threat, has a market capitalization of US$586 million. It trades at around US$24, and has a 52-week range of US$14.62 to US$52.50.
And while Hemosol may indeed get approval for its human blood substitute sooner and on to the market before Biopure, Phil Nablone of Salomon Smith Barney says current market conditions have left investors skeptical of Biopure. “As promising as the technology is, investors will probably shy away from it until the company reports its definitive data from its phase three trials,” says Nablone.
Unable to comment specifically about Hemosol, Nablone spoke generally about the industry. “The human blood substitute is a huge market but so many companies have either failed or fallen so far behind that investors remain, I would say quite appropriately, skeptical. Really, the only true driver of value for these companies is probably going to be reporting good safety and efficacy data from pivotal trials.”
Results from Hemosol’s Phase III trials in the U.S. for use in coronary bypass surgery are expected by the end of the first quarter this year. And while the study is only for the use of Hemolink in that type of surgery, it could have several different applications. “It could be used in almost any operation, “ states MacLean. “But once they get approval there (coronary bypass) I think the move down the line will be fairly quick.”
In a bid to broaden potential applications for the product, in December the company filed for a Phase I/II open label study of the effectiveness and safety of Hemolink in patients with non-small cell lung cancer who are suffering from anemia associated with chemotherapy. The trial is expected to be complete by the end of 2001.
As for the dilutive effects of the financing, MacLean maintains the move was a necessary one that should keep the company’s coffers full for some time, allowing them to continue to expand their manufacturing capacity and to fund more clinical trials. And while the Toronto-based MacLean is expecting the Hemosol to post losses for 2001, he is focusing on the company’s long term potential. “ What we’re looking for it approvals in Canada and Europe, and the then completion of the Phase III trials in the U.S. So those are the major milestones.”
Asked where he could see Hemosol trading given increased exposure to the U.S. markets, MacLean replied, “Considerably higher than it is today.”
And while Hemosol may indeed get approval for its human blood substitute sooner and on to the market before Biopure, Phil Nablone of Salomon Smith Barney says current market conditions have left investors skeptical. “As promising as the technology is, investors will probably shy away from it until the company reports its definitive data from its phase three trials,” says Nablone of Biopure. Trial results are expected to be reported during the first half of 2001.
Mon, Jan. 22, 2001 20:56
By Crystal Quast, Canada-iNvest.com
Hemosol’s (HML) plan to sell up to US$80.5 million worth of stock and apply for a NASDAQ listing should have U.S. investors sitting up and taking notice, according to one portfolio manager.
“I think it will be good for them to be listed in the States, and get some coverage by U.S. analysts, and for the U.S. investors to be able to compare Hemosol against Biopure (US),” says Allaster MacLean of Scotia Cassels. The portfolio manager believes a larger U.S. investor base could narrow the gap between the two companies. “U.S. investors seem to pay more for these sorts of companies than Canadians do.”
The Ontario-based biotech has developed a blood substitute called Hemolink for use during surgery. Even with its recent surge higher to $14, Hemosol is still far off of its 52-week high of $27. It has a 52-week low of $10.25 and a market cap of $359 million. MacLean believes the company deserves a higher valuation. “It looks like Hemosol has a good chance to get approval first, and be on a market first.”
In July, the company announced it would file with the Canadian Therapeutics Products Programme (TPP) to market Hemolink for use in coronary artery by-pass grafting surgery. Pending approval, which is expected in the first quarter of this year, the company expects to be selling Hemolink in Canada in 2001. Regulatory submissions in Europe are expected shortly with the States following suit.
Biopure of Cambridge, MA, which is considered to be Hemosol’s main threat, has a market capitalization of US$586 million. It trades at around US$24, and has a 52-week range of US$14.62 to US$52.50.
And while Hemosol may indeed get approval for its human blood substitute sooner and on to the market before Biopure, Phil Nablone of Salomon Smith Barney says current market conditions have left investors skeptical of Biopure. “As promising as the technology is, investors will probably shy away from it until the company reports its definitive data from its phase three trials,” says Nablone.
Unable to comment specifically about Hemosol, Nablone spoke generally about the industry. “The human blood substitute is a huge market but so many companies have either failed or fallen so far behind that investors remain, I would say quite appropriately, skeptical. Really, the only true driver of value for these companies is probably going to be reporting good safety and efficacy data from pivotal trials.”
Results from Hemosol’s Phase III trials in the U.S. for use in coronary bypass surgery are expected by the end of the first quarter this year. And while the study is only for the use of Hemolink in that type of surgery, it could have several different applications. “It could be used in almost any operation, “ states MacLean. “But once they get approval there (coronary bypass) I think the move down the line will be fairly quick.”
In a bid to broaden potential applications for the product, in December the company filed for a Phase I/II open label study of the effectiveness and safety of Hemolink in patients with non-small cell lung cancer who are suffering from anemia associated with chemotherapy. The trial is expected to be complete by the end of 2001.
As for the dilutive effects of the financing, MacLean maintains the move was a necessary one that should keep the company’s coffers full for some time, allowing them to continue to expand their manufacturing capacity and to fund more clinical trials. And while the Toronto-based MacLean is expecting the Hemosol to post losses for 2001, he is focusing on the company’s long term potential. “ What we’re looking for it approvals in Canada and Europe, and the then completion of the Phase III trials in the U.S. So those are the major milestones.”
Asked where he could see Hemosol trading given increased exposure to the U.S. markets, MacLean replied, “Considerably higher than it is today.”
And while Hemosol may indeed get approval for its human blood substitute sooner and on to the market before Biopure, Phil Nablone of Salomon Smith Barney says current market conditions have left investors skeptical. “As promising as the technology is, investors will probably shy away from it until the company reports its definitive data from its phase three trials,” says Nablone of Biopure. Trial results are expected to be reported during the first half of 2001.
* Two competitors make major announcements; Biopure confirms that
their FDA filing is expected in 2001 whereas Alliance halts a Phase
III trial due to serious adverse events
* It now appears that there will only be two RBC substitutes filed
with the FDA in mid 2001, Biopure and Hemosol
Recommendation: STRONG BUY
12 to 18-month target price: $40.00
52-week price range: $27.00-7.35
Shares O/S: basic 31.7M
fully diluted 32.7M
Year end: December 31
Dividend: None
Cash (Sept. 29): $53.6M
Major shareholder: MDS & related funds, 7M
Weekly trading volume (3 mos): 317,224 shares
Market capitalization: $352M
Sector: Biotechnology
Web site address: www.hemosol.com
Hemosol Inc. ("Hemosol") has previously stated that it plans to
complete enrollment and treatment in the US Phase III trial of its RBC
substitute, Hemolink, by June 2001 and file with the FDA in early
Q3/01. Assuming a 12-month review and approval time, the validation
and FDA pre-approval inspection of the plant would be completed at
about the same time that the FDA has completed the safety and efficacy
review. We believe that this is a worst-case scenario, since
statistically significant data from interim analyses could lead to
earlier regulatory filing.
We had previously expected that the FDA approvals of the Alliance,
Biopure, and Hemosol products should all occur within a few months of
each other in 2002. The two competitors have each made recent press
releases that change the competitive landscape.
Alliance Pharmaceutical Corp. (ALLP : NASDAQ): Alliance announced on
January 8 that it had suspended enrolment in its Phase III cardiac
surgery trial of its RBC substitute, Oxygent(tm), due to a larger
number of adverse events, including stroke, in the treatment group
versus the control group. Alliance stated that the actual incidence
in the treatment group was similar to that in published data but the
incidence in the control group was substantially lower. This pattern
was not seen in the Phase II cardiopulmonary bypass trial or the Phase
III general surgery trial conducted by Alliance. Alliance will now
review all of the data from the estimated 400 patients treated in the
Phase III trial to determine whether the data imbalance is due to the
drug, improper or biased enrolment, improper treatment, the increased
level of hemodilution, or other single or multiple causes.
Is a similar result possible with the Hemolink US Phase III trial?
Hemolink is a cross-linked hemoglobin molecule whereas Oxygent is a
chemical perfluorocarbon emulsion. If the Oxygent side effect profile
were due to the drug, we would not expect a similar result for
Hemolink. The data imbalance could also be due to the structure or
execution of the study. Alliance has stated that their study is a
single-blinded design, meaning that only the patient does not know
what treatment will be administered. Hemosol`s trial is a
double-blind study, with not only blinding at the time of surgery but
also blinding at the time of certain analyses during the trial. In
conclusion, we do not expect a similar result during the Hemolink US
Phase III trial.
Biopure Corporation (BPUR : NASDAQ): Biopure announced on January 8
that it is on track to file a BLA with the FDA in 2001 seeking
approval of its RBC substitute, Hemopure(r), which is cross-linked
bovine hemoglobin. Phase III trial results will be released in the
first half of 2001 after the database has been locked in order to
avoid any potential bias in the analysis. The company also announced
that it expects to complete asset-based debt financing of a
large-scale manufacturing facility soon.
What is the effect on the competitive landscape for RBC substitutes?
Hemosol and Biopure appear to be on track for regulatory filings in
mid 2001. The length of Alliance`s delay will depend upon the results
of their findings. The minimum delay is probably several months to
analyze the data and agree on the appropriate action with the FDA. If
the required action is another Phase III trial in cardiac surgery, the
delay would increase by 1-2 years. If the action is to get initial
approval only in general surgery, the question is whether the FDA will
accept the data from a single Phase III trial. Since the FDA
generally errs on the side of safety, we expect that Alliance will
probably be at least 12 months behind Hemosol and Biopure in obtaining
FDA approval. If Hemosol and Biopure are both approved at about the
same time, it sets up an interesting marketing battle. Hemosol uses
hemodilution, which leads to a higher absolute RBC avoidance rate,
whereas Biopure does not use hemodilution. Hemosol uses human
hemoglobin whereas Biopure uses bovine hemoglobin. Even though there
has not been a documented case of BSE in the US and Biopure has both
viral and prion removal steps in its manufacturing process, we believe
that a bovine product will be a very difficult sell in Europe and a
difficult sell even in the US.
Our recommendation for Hemosol remains a STRONG BUY with a 12 to
18-month target of $40.00.
their FDA filing is expected in 2001 whereas Alliance halts a Phase
III trial due to serious adverse events
* It now appears that there will only be two RBC substitutes filed
with the FDA in mid 2001, Biopure and Hemosol
Recommendation: STRONG BUY
12 to 18-month target price: $40.00
52-week price range: $27.00-7.35
Shares O/S: basic 31.7M
fully diluted 32.7M
Year end: December 31
Dividend: None
Cash (Sept. 29): $53.6M
Major shareholder: MDS & related funds, 7M
Weekly trading volume (3 mos): 317,224 shares
Market capitalization: $352M
Sector: Biotechnology
Web site address: www.hemosol.com
Hemosol Inc. ("Hemosol") has previously stated that it plans to
complete enrollment and treatment in the US Phase III trial of its RBC
substitute, Hemolink, by June 2001 and file with the FDA in early
Q3/01. Assuming a 12-month review and approval time, the validation
and FDA pre-approval inspection of the plant would be completed at
about the same time that the FDA has completed the safety and efficacy
review. We believe that this is a worst-case scenario, since
statistically significant data from interim analyses could lead to
earlier regulatory filing.
We had previously expected that the FDA approvals of the Alliance,
Biopure, and Hemosol products should all occur within a few months of
each other in 2002. The two competitors have each made recent press
releases that change the competitive landscape.
Alliance Pharmaceutical Corp. (ALLP : NASDAQ): Alliance announced on
January 8 that it had suspended enrolment in its Phase III cardiac
surgery trial of its RBC substitute, Oxygent(tm), due to a larger
number of adverse events, including stroke, in the treatment group
versus the control group. Alliance stated that the actual incidence
in the treatment group was similar to that in published data but the
incidence in the control group was substantially lower. This pattern
was not seen in the Phase II cardiopulmonary bypass trial or the Phase
III general surgery trial conducted by Alliance. Alliance will now
review all of the data from the estimated 400 patients treated in the
Phase III trial to determine whether the data imbalance is due to the
drug, improper or biased enrolment, improper treatment, the increased
level of hemodilution, or other single or multiple causes.
Is a similar result possible with the Hemolink US Phase III trial?
Hemolink is a cross-linked hemoglobin molecule whereas Oxygent is a
chemical perfluorocarbon emulsion. If the Oxygent side effect profile
were due to the drug, we would not expect a similar result for
Hemolink. The data imbalance could also be due to the structure or
execution of the study. Alliance has stated that their study is a
single-blinded design, meaning that only the patient does not know
what treatment will be administered. Hemosol`s trial is a
double-blind study, with not only blinding at the time of surgery but
also blinding at the time of certain analyses during the trial. In
conclusion, we do not expect a similar result during the Hemolink US
Phase III trial.
Biopure Corporation (BPUR : NASDAQ): Biopure announced on January 8
that it is on track to file a BLA with the FDA in 2001 seeking
approval of its RBC substitute, Hemopure(r), which is cross-linked
bovine hemoglobin. Phase III trial results will be released in the
first half of 2001 after the database has been locked in order to
avoid any potential bias in the analysis. The company also announced
that it expects to complete asset-based debt financing of a
large-scale manufacturing facility soon.
What is the effect on the competitive landscape for RBC substitutes?
Hemosol and Biopure appear to be on track for regulatory filings in
mid 2001. The length of Alliance`s delay will depend upon the results
of their findings. The minimum delay is probably several months to
analyze the data and agree on the appropriate action with the FDA. If
the required action is another Phase III trial in cardiac surgery, the
delay would increase by 1-2 years. If the action is to get initial
approval only in general surgery, the question is whether the FDA will
accept the data from a single Phase III trial. Since the FDA
generally errs on the side of safety, we expect that Alliance will
probably be at least 12 months behind Hemosol and Biopure in obtaining
FDA approval. If Hemosol and Biopure are both approved at about the
same time, it sets up an interesting marketing battle. Hemosol uses
hemodilution, which leads to a higher absolute RBC avoidance rate,
whereas Biopure does not use hemodilution. Hemosol uses human
hemoglobin whereas Biopure uses bovine hemoglobin. Even though there
has not been a documented case of BSE in the US and Biopure has both
viral and prion removal steps in its manufacturing process, we believe
that a bovine product will be a very difficult sell in Europe and a
difficult sell even in the US.
Our recommendation for Hemosol remains a STRONG BUY with a 12 to
18-month target of $40.00.
@All,
so wie es aussieht, wird es bei Hemosol in geraumerzukunft signifikante News geben. Die Umsätze ziehen deutlich an. Ich denke, dass gewisse Informationen über die Marktfreigabe in Canade schon durchgesickert sind.
Und wie von mir bereits am Anfang angesprochen, muß Hemosol etwas mehr für das Marketing unternehemen, aber dass das Marketing für die Aktie nun vorangetrieben wird (Notierung Nasdaq) topt das ganze noch etwas.
Ich wünsche uns allen nun ein fröhliches Jahr mit Hemosol
so wie es aussieht, wird es bei Hemosol in geraumerzukunft signifikante News geben. Die Umsätze ziehen deutlich an. Ich denke, dass gewisse Informationen über die Marktfreigabe in Canade schon durchgesickert sind.
Und wie von mir bereits am Anfang angesprochen, muß Hemosol etwas mehr für das Marketing unternehemen, aber dass das Marketing für die Aktie nun vorangetrieben wird (Notierung Nasdaq) topt das ganze noch etwas.
Ich wünsche uns allen nun ein fröhliches Jahr mit Hemosol
@Cool Max!
Coole Fakten!!
Verkauf Hemosol schnell, denn heute spricht Grünspan, dann geht die Nasdaq hoch und die Notausweichaktie Hemosol wieder runter
Glubsch
Coole Fakten!!
Verkauf Hemosol schnell, denn heute spricht Grünspan, dann geht die Nasdaq hoch und die Notausweichaktie Hemosol wieder runter
Glubsch
@Glubsch,
ich möchte Dich bitten, unsere Diskusionen (@All Glubsch ist mein Nachbar) nicht an jedem Bord zu komentieren, denn wenn hier über Werte gesprochen wird, sollten keine persönlichen Aspekte (zankerein zwischen zwei Profibrokern wie uns) einfliesen, die andere Thrader beeinflussen können. Denn dein heutiger Komentar ist eine kindische Trotzreaktion auf unser Gespräch von gestern Abend. Du bestehst darauf als alter erfahrener Hase behandelt zu werden, dann verhalte dich auch entsprechend.
CoolMax
ich möchte Dich bitten, unsere Diskusionen (@All Glubsch ist mein Nachbar) nicht an jedem Bord zu komentieren, denn wenn hier über Werte gesprochen wird, sollten keine persönlichen Aspekte (zankerein zwischen zwei Profibrokern wie uns) einfliesen, die andere Thrader beeinflussen können. Denn dein heutiger Komentar ist eine kindische Trotzreaktion auf unser Gespräch von gestern Abend. Du bestehst darauf als alter erfahrener Hase behandelt zu werden, dann verhalte dich auch entsprechend.
CoolMax
...und außerdem ist es Blödsinn, was er da schreibt.
Gruß
Nucleus
Gruß
Nucleus
@COOL(HOT)MAX
Vertragen wir uns wieder?
Du bist doch der "einzigste" ProfiBroker von uns beiden !!
PS
Warum hat Hemosol nachgelassen, obwohl meine ziemlich "DUMME" Vorhersage in Punkto Nasdaq falsch war?
Verzeitung
Glubsch
Vertragen wir uns wieder?
Du bist doch der "einzigste" ProfiBroker von uns beiden !!
PS
Warum hat Hemosol nachgelassen, obwohl meine ziemlich "DUMME" Vorhersage in Punkto Nasdaq falsch war?
Verzeitung
Glubsch
Pardon: Hemosol ist schon an der Nasdaq!
Gruß Glubsch
Ergebnisse: Hemosol
Name Börse WKN/Local ID Aktuell Diff. Diff. (%) Handelsvol. Kurszeit
HEMOSOL INC Nasdaq OTC - 11,56 -0,22 -1,87% - 00:37/15.02.
HEMOSOL INC. SHARES O.N. Frankfurt 886290 12,50 -0,10 -0,79% 290.462,05 18:50/14.02.
Stuttgart 886290 12,75 +0,75 +6,25% 3.615,00 12:58/14.02.
Berlin 886290 12,30 G +0,30 +2,50% 1.306,00 19:45/14.02.
XETRA 886290 12,02 +1,06 +9,67% 601,00 13:34/12.02.
München 886290 12,80 G +0,30 +2,40% - 09:22/13.02.
Düsseldorf 886290 12,50 G +0,20 +1,63% 2.295,00 19:42/14.02.
Gruß Glubsch
Ergebnisse: Hemosol
Name Börse WKN/Local ID Aktuell Diff. Diff. (%) Handelsvol. Kurszeit
HEMOSOL INC Nasdaq OTC - 11,56 -0,22 -1,87% - 00:37/15.02.
HEMOSOL INC. SHARES O.N. Frankfurt 886290 12,50 -0,10 -0,79% 290.462,05 18:50/14.02.
Stuttgart 886290 12,75 +0,75 +6,25% 3.615,00 12:58/14.02.
Berlin 886290 12,30 G +0,30 +2,50% 1.306,00 19:45/14.02.
XETRA 886290 12,02 +1,06 +9,67% 601,00 13:34/12.02.
München 886290 12,80 G +0,30 +2,40% - 09:22/13.02.
Düsseldorf 886290 12,50 G +0,20 +1,63% 2.295,00 19:42/14.02.
@Glubsch
Hemosol ist mitnichten an der Nasdaq sondern wird im OTC gehandelt-das ist nicht die Nasdaq, steht doch in Deinem letzten Posting auch dahinter. Und nachgelassen, meinst Du etwa die paar Prozentchen gestern?
Profibroker....ts,ts,ts.
Gruß
Nucleus
Hemosol ist mitnichten an der Nasdaq sondern wird im OTC gehandelt-das ist nicht die Nasdaq, steht doch in Deinem letzten Posting auch dahinter. Und nachgelassen, meinst Du etwa die paar Prozentchen gestern?
Profibroker....ts,ts,ts.
Gruß
Nucleus
Hi Leute,
wenn meine trüben Augen am heutigen morgen alles richtig erfasst haben und ich meine sieben Sinne richtig ordne,
wurde gestern Hemosol an der NESDAQ erfolgreich eingeführt
Fakten ca. 4 Mio$ Umsatz mit gut 8,25% Plus. Wenn meine Infos richtig sind, wurde ein Ausgabepreis von 8$ für die neuen Aktien
angelegt und nun bei 9,625$.
Ich Sage es euch, die Amis sind alle Vampiere und wittern Blut.
Gruß
CoolMax
wenn meine trüben Augen am heutigen morgen alles richtig erfasst haben und ich meine sieben Sinne richtig ordne,
wurde gestern Hemosol an der NESDAQ erfolgreich eingeführt
Fakten ca. 4 Mio$ Umsatz mit gut 8,25% Plus. Wenn meine Infos richtig sind, wurde ein Ausgabepreis von 8$ für die neuen Aktien
angelegt und nun bei 9,625$.
Ich Sage es euch, die Amis sind alle Vampiere und wittern Blut.
Gruß
CoolMax
Nur für @Qoolmax
Laß doch Deine Ausführungen vor den Abschicken durch die Winword-Korrektur laufen:
Nicht Nesdaq sondern Nesquick
Nicht Vampiere sondern Vambiere
Ich denke, ich steige unterhalb von 8,5 ein
Laß doch Deine Ausführungen vor den Abschicken durch die Winword-Korrektur laufen:
Nicht Nesdaq sondern Nesquick
Nicht Vampiere sondern Vambiere
Ich denke, ich steige unterhalb von 8,5 ein
Hi Leute,
auf der H-Page, von HML wird angekündigt, dass nach Börsenschluß am 05.04.01 die Jahreszahlen 2000 bekannt gegeben werden. Vieleich wird dieser anlass zur Bekanntgabe der Markzulasssung genutzt,
damit das hohe Minus nicht ganz so erschreckend aussieht.
Gruß
CoolMax
auf der H-Page, von HML wird angekündigt, dass nach Börsenschluß am 05.04.01 die Jahreszahlen 2000 bekannt gegeben werden. Vieleich wird dieser anlass zur Bekanntgabe der Markzulasssung genutzt,
damit das hohe Minus nicht ganz so erschreckend aussieht.
Gruß
CoolMax
HI Leute,
lange nichtsmehr gehört oder gelesen, bin aber immernoch am Ball.
Heute hat es Q3 zahlen gegeben, der Kurs kracht ja richtig super ein nachdem es die letzten Tage so gut aufwerts ging, aber naja.
Leider kann ich mir momentan nicht die Mühe machen, den ganzen Text durch zu lesen und zu bewerten. Ich sehe jetzt auf den ersten Blick auch nichts über die "US-Zulassung"
vielleicht kann da mal jemand rein gucken.
gruß
CoolMax
Attention Business/Financial Editors:
Hemosol Announces Third Quarter Financial Results
Company Moves Ahead on Clinical Development Plan
TORONTO, Oct. 25 /CNW/ - Hemosol, Inc. (NASDAQ: HMSL, TSE: HML) today
announced financial results for the third quarter and nine months ended
September 30, 2001. The Company also reported on clinical development progress
with its lead product, Hemolink(TM). Unless otherwise stated, all dollar
values herein are Canadian dollars.
Following discussions with regulatory agencies in the United States and
the United Kingdom, the Company expects clinical trials of Hemolink(TM) to
recommence in November. Hemolink(TM) is Hemosol`s proprietary oxygen
therapeutic, designed to provide immediate and safe oxygen delivery to vital
organs and tissues to improve outcomes in patients undergoing cardiac,
orthopedic and other surgeries and chemotherapy.
The Company`s revised clinical program includes two cardiac bypass
grafting surgery (CABG) trials plus two additional studies, which will support
the ongoing global registration strategy and pave the way for the design and
execution of a pivotal U.S. study.
"Hemosol is moving forward with its clinical and regulatory programs
around the world. We have a clear plan and timeline in place to obtain
approvals and commercialize Hemolink(TM) in the United Kingdom in late 2002,
Europe in 2003, and to file a BLA in the U.S. in the first half of 2003," said
John W. Kennedy, President and Chief Executive Officer of Hemosol. "We believe
the modifications we have made to our existing clinical programs improve the
chances of obtaining the earliest possible approvals in these markets with
commercially advantageous labels."
Hemosol expects to commence the efficacy study in primary CABG surgery in
November. The trial will include 180 patients at more than 40 centres in the
United States and the United Kingdom. The Company expects to complete this
study and report results in the second quarter of 2002. The primary efficacy
endpoint of this randomized, controlled study is avoidance of donor red blood
cells at 28 days. The study is powered to detect a 50 percent reduction in the
rate of transfusion of donor red blood cells between the two arms.
The Company also plans to initiate a similar efficacy study in "re-do"
CABG surgery. Hemosol expects to enrol a total of 210 patients in this
randomized, controlled, three-arm study. All patients in this study will
undergo intraoperative autologous donation (IAD) with those patients
randomized to the Hemolink(TM) arm experiencing a more aggressive IAD with
Hemolink(TM) treatment. This study will be conducted at most of the same U.S.
sites and, pending U.S. Food and Drug Administration (FDA) clearance, will run
concurrently with the primary CABG trial. This trial should be completed with
results reported in the second quarter of 2002.
Hemosol expects that all patients in these studies will contribute to the
overall safety database, and all will undergo IAD. At the conclusion of these
studies, the Company will review the data with the FDA and design and initiate
a third study that will be pivotal for U.S. registration. The goal is to file
a Biologics License Application (BLA) in the United States in the first half
of 2003.
The Company expects to receive a final response from Health Canada on its
application to market Hemolink(TM) in Canada by the end of this year.
Hemosol plans to strengthen its regulatory filings in the United Kingdom
in mid-2002 with the results of the primary and "re-do" CABG studies. Hemosol
expects the Medicines Control Agency to complete its review before the end of
2002. If approval is received, marketing and distribution in the U.K. could
begin toward the end of 2002 or early in 2003. Hemosol will then follow the
Mutual Recognition Procedure, which could allow the Company to gain approval
in other European countries within 90 days of U.K. approval. The Company
believes that this approach provides the best chance of achieving
profitability by the end of 2003.
The Company also plans to run two additional studies: a high-dose general
surgery study, as a feasibility/exploratory study in high blood loss
orthopedic and general surgeries; and a study in patients experiencing
chemotherapy-induced anemia. Hemosol will provide additional details on these
two studies once the FDA has had the opportunity to review the revised
protocols.
Hemosol also reported that it has completed validation and scale-up of
its existing manufacturing facility, which currently has a capacity of 25,000
units per year. In addition to supplying finished product to the Company`s
clinical program, Hemosol plans to license this facility in both Europe and
Canada. Work on the Company`s new state-of-the-art facility is proceeding on
schedule. Installation of process equipment is expected to be finished by the
middle of 2002 with validation of this 300,000-unit facility to be completed
early in 2003 in time for the BLA filing. Once finished, Hemosol will be the
only company to have a commercial-scale manufacturing facility to produce
hemoglobin based oxygen therapeutics.
Financial Results
In the third quarter of 2001, Hemosol recorded a net loss of $6.9 million
or ($0.17) per share, compared with a loss of $6.9 million or ($0.22) per
share in the corresponding period in 2000. The loss included a foreign
exchange gain of $2.8 million or $0.07 per share related to cash and cash
equivalents held in U.S.-denominated funds.
Net loss for the nine months ended September 30, 2001 was $27.8 million
or ($0.72) per share, which includes a year-to-date foreign exchange gain of
$1.2 million or $0.03 per share. The loss for the comparable nine-month period
in 2000 totalled $18.6 million or ($0.60) per share.
Losses from operations in the third quarter reached $10.3 million,
compared to a loss in the same period in 2000 of $7.5 million. Losses from
operations for the first nine months of 2001 totalled $31.6 million, compared
to $20.9 million in 2000. The loss is primarily due to increased spending in
clinical, regulatory, process development and marketing activities. During the
first nine months of 2001, Hemosol realized interest income of $2.7 million,
compared to $2.3 million in the corresponding period of last year.
Capital expenditures on the Company`s new manufacturing facility during
the first nine months of 2001 totalled $32.4 million, bringing total
expenditures to date on this facility to approximately $45 million. As of
September 30, 2001, the Company had not drawn down any amounts to finance
construction of this facility from either its $35 million senior credit
facility or its $12.5 million subordinate credit facility. Hemosol is in the
process of updating its creditors with details of the revised clinical program
for Hemolink(TM).
Hemosol remains well financed with $95.8 million of cash, cash
equivalents and short-term investments at September 30, 2001, as compared to
$41.9 million at December 31, 2000. Substantial losses in the remainder of
2001 and in 2002 will be realized, as a result of the Company`s clinical trial
program, expenses related to regulatory approvals, increased manufacturing
output and increased spending in market development activities. Operating
expenses during 2001 and 2002 are expected to increase approximately 60% over
the level realized in 2000.
Conference Call Details
The Company will hold a conference call today at 4:30p.m. (Eastern time)
to discuss its third quarter results. A live audio webcast of the conference
call will be available through www.hemosol.com and www.financialdisclosure.ca.
The call will also be archived on these sites for 30 days.
A replay of the conference call will also be available by telephone from
approximately 6:30p.m. (Eastern time) on October 25 through November 2, 2001.
To access the replay, dial, 416-695-5800 or 1-800-408-3053 and enter
reservation number 940624.
About Hemosol Inc.
Hemosol is a near-term, commercial-stage biopharmaceutical company
focused initially on developing life-sustaining therapies for the treatment of
acute anemia resulting from hemoglobin deficiencies. Hemosol has a broad range
of products in development, including its flagship product Hemolink(TM), a
highly-purified, human derived hemoglobin replacement therapeutic designed to
rapidly and safely improve oxygen delivery to the circulatory system.
Hemolink(TM) is currently being evaluated in late-stage clinical trials. The
Company also is developing hemoglobin-based therapeutic products to treat
diseases such as hepatitis C and cancers of the liver, as well as cell therapy
for possible use to treat cancer, HIV and auto-immune diseases.
For more information visit Hemosol`s website at www.hemosol.com.
Hemosol Inc`s common shares are listed on The Nasdaq Stock Market under
the trading symbol "HMSL" and on the Toronto Stock Exchange under the trading
symbol "HML".
Certain statements concerning Hemosol`s future prospects are "forward-
looking statements" under the United States Private Securities Litigation
Reform Act of 1995. There can be no assurances that future results will be
achieved, and actual results could differ materially from forecasts and
estimates. Important factors that could cause actual results to differ
materially from forecasts and estimates include, but are not limited to:
Hemosol`s ability to obtain regulatory approvals for its products; Hemosol`s
ability to successfully complete clinical trials for its products; technical
or manufacturing or distribution issues; the competitive environment for
Hemosol`s products; the degree of market penetration of Hemosol`s products;
and other factors set forth in filings with Canadian securities regulatory
authorities and the U.S. Securities and Exchange Commission. These risks and
uncertainties, as well as others, are discussed in greater detail in the
filings of Hemosol with Canadian securities regulatory authorities and the
U.S. Securities and Exchange Commission. Hemosol makes no commitment to revise
or update any forward-looking statements in order to reflect events or
circumstances after the date any such statement is made.
Financial Statements to Follow:
<<
HEMOSOL INC.
CONSOLIDATED BALANCE SHEET
NINE MONTHS PERIOD ENDED
(THOUSANDS OF DOLLARS) Sept. 30, 2001 Dec. 31, 2000
-------------------------------------------------------------------------
ASSETS
CURRENT
Cash and cash equivalents 27,417 41,879
Short term investments 68,400 -
Accrued interest 327 148
Amounts receivable 378 339
GST receivable 686 733
Inventory and supplies 1,670 635
Investment tax credit receivable 250 250
Prepaid expenses 481 645
--------------------------------------------------------------------
TOTAL CURRENT ASSETS 99,609 44,629
--------------------------------------------------------------------
OTHER
Capital assets, net 49,455 17,089
Patents and trademarks, net 1,087 1,020
Deferred charges 7,190 7,690
--------------------------------------------------------------------
TOTAL OTHER ASSETS 57,732 25,799
--------------------------------------------------------------------
TOTAL ASSETS 157,341 70,428
--------------------------------------------------------------------
LIABILITIES AND SHAREHOLDERS` EQUITY
CURRENT
Accounts payable and accrued liabilities 16,527 5,358
--------------------------------------------------------------------
TOTAL CURRENT LIABILITIES 16,527 5,358
--------------------------------------------------------------------
SHAREHOLDERS` EQUITY
Share capital 305,389 192,923
Contributed surplus 8,535 8,535
Deficit (173,110) (136,388)
--------------------------------------------------------------------
TOTAL SHAREHOLDERS` EQUITY 140,814 65,070
--------------------------------------------------------------------
TOTAL LIABILITIES AND
SHAREHOLDERS` EQUITY 157,341 70,428
--------------------------------------------------------------------
HEMOSOL INC.
CONSOLIDATED STATEMENT OF LOSS AND DEFICIT
Three months period Nine months period
ended ended
(THOUSANDS OF DOLLARS, Sept. 30, Sept. 29, Sept. 30, Sept. 29,
EXCEPT SHARE DATA) 2001 2000 2001 2000
-------------------------------------------------------------------------
REVENUE
-------
Research and development - - - -
-------------------------------------------------------------------------
EXPENSES
--------
Research and development
Scientific and process 3,771 3,782 13,353 9,765
Regulatory and clinical 2,872 1,538 9,444 5,940
-------------------------------------------------------------------------
Total research and
development 6,643 5,320 22,797 15,705
Administration 2,335 1,280 5,246 3,186
Marketing & business
development 1,339 917 3,519 1,970
-------------------------------------------------------------------------
TOTAL EXPENSES 10,317 7,517 31,562 20,861
-------------------------------------------------------------------------
Loss from operations (10,317) (7,517) (31,562) (20,861)
Provision for income taxes (60) - (159) -
Foreign exchange gain 2,818 - 1,232 -
Interest income 694 639 2,660 2,252
-------------------------------------------------------------------------
NET LOSS FOR THE PERIOD (6,865) (6,878) (27,829) (18,609)
Deficit, beginning of
period (166,245) (120,522) (136,388) (104,174)
Share issue cost - - (8,893) (4,617)
-------------------------------------------------------------------------
DEFICIT, END OF PERIOD (173,110) (127,400) (173,110) (127,400)
-------------------------------------------------------------------------
Average number of shares 40,823,501 31,909,696 38,623,172 31,059,573
LOSS PER SHARE 0.17 0.22 0.72 0.60
-------------------------------------------------------------------------
HEMOSOL INC.
CONSOLIDATED STATEMENT OF CASH FLOWS
Three months period Nine months period
ended ended
Sept. 30, Sept. 29, Sept. 30, Sept. 29,
(THOUSANDS OF DOLLARS) 2001 2000 2001 2000
-------------------------------------------------------------------------
OPERATING ACTIVITIES
Net loss for the period (6,865) (6,878) (27,829) (18,609)
Add items not requiring
an outlay of cash
Unrealized foreign exchange
gain (2,442) - (856) -
Depreciation and amortization 557 351 1,520 1,119
-------------------------------------------------------------------------
(8,750) (6,527) (27,165) (17,490)
Net change in non-cash
working capital balances
related to operations 2,091 687 (1,460) (2,540)
-------------------------------------------------------------------------
CASH USED IN OPERATING
ACTIVITIES (6,659) (5,840) (28,625) (20,030)
-------------------------------------------------------------------------
INVESTING ACTIVITIES
Short term investments (68,400) - (68,400) -
Patent and trademark costs (27) (33) (119) (289)
Purchase of capital assets (8,592) (5,170) (22,247) (10,789)
-------------------------------------------------------------------------
CASH USED IN INVESTING
ACTIVITIES (77,019) (5,203) (90,766) (11,078)
-------------------------------------------------------------------------
FINANCING ACTIVITIES
Proceeds on issuance
of common shares 1,904 109 112,466 71,077
Proceeds on sale of
transferable option - - - 8,534
Deferred charges - - 500 -
Share issue costs - - (8,893) (4,617)
-------------------------------------------------------------------------
CASH PROVIDED BY FINANCING
ACTIVITIES 1,904 109 104,073 74,994
-------------------------------------------------------------------------
Effect of exchange rate
changes on cash and
cash equivalents 2,442 - 856 -
Net increase (decrease)
in cash and cash equivalent (79,332) (10,934) (14,462) 43,886
Cash and cash equivalents,
beginning of period 106,749 64,559 41,879 9,739
-------------------------------------------------------------------------
CASH AND CASH EQUIVALENTS,
END OF PERIOD 27,417 53,625 27,417 53,625
-------------------------------------------------------------------------
>>
-30-
For further information: Jason Hogan, Investor Relations,
416-361-1331, 800-789-3419, 416-815-0080 fax, ir@hemosol.com,
www.hemosol.com; Shari Beagelman, Media Relations, 973-781-0200 ext. 20,
917-626-7071 mobile, sbeagelman@hemosol.com
HEMOSOL INC. has 105 releases in this database.
lange nichtsmehr gehört oder gelesen, bin aber immernoch am Ball.
Heute hat es Q3 zahlen gegeben, der Kurs kracht ja richtig super ein nachdem es die letzten Tage so gut aufwerts ging, aber naja.
Leider kann ich mir momentan nicht die Mühe machen, den ganzen Text durch zu lesen und zu bewerten. Ich sehe jetzt auf den ersten Blick auch nichts über die "US-Zulassung"
vielleicht kann da mal jemand rein gucken.
gruß
CoolMax
Attention Business/Financial Editors:
Hemosol Announces Third Quarter Financial Results
Company Moves Ahead on Clinical Development Plan
TORONTO, Oct. 25 /CNW/ - Hemosol, Inc. (NASDAQ: HMSL, TSE: HML) today
announced financial results for the third quarter and nine months ended
September 30, 2001. The Company also reported on clinical development progress
with its lead product, Hemolink(TM). Unless otherwise stated, all dollar
values herein are Canadian dollars.
Following discussions with regulatory agencies in the United States and
the United Kingdom, the Company expects clinical trials of Hemolink(TM) to
recommence in November. Hemolink(TM) is Hemosol`s proprietary oxygen
therapeutic, designed to provide immediate and safe oxygen delivery to vital
organs and tissues to improve outcomes in patients undergoing cardiac,
orthopedic and other surgeries and chemotherapy.
The Company`s revised clinical program includes two cardiac bypass
grafting surgery (CABG) trials plus two additional studies, which will support
the ongoing global registration strategy and pave the way for the design and
execution of a pivotal U.S. study.
"Hemosol is moving forward with its clinical and regulatory programs
around the world. We have a clear plan and timeline in place to obtain
approvals and commercialize Hemolink(TM) in the United Kingdom in late 2002,
Europe in 2003, and to file a BLA in the U.S. in the first half of 2003," said
John W. Kennedy, President and Chief Executive Officer of Hemosol. "We believe
the modifications we have made to our existing clinical programs improve the
chances of obtaining the earliest possible approvals in these markets with
commercially advantageous labels."
Hemosol expects to commence the efficacy study in primary CABG surgery in
November. The trial will include 180 patients at more than 40 centres in the
United States and the United Kingdom. The Company expects to complete this
study and report results in the second quarter of 2002. The primary efficacy
endpoint of this randomized, controlled study is avoidance of donor red blood
cells at 28 days. The study is powered to detect a 50 percent reduction in the
rate of transfusion of donor red blood cells between the two arms.
The Company also plans to initiate a similar efficacy study in "re-do"
CABG surgery. Hemosol expects to enrol a total of 210 patients in this
randomized, controlled, three-arm study. All patients in this study will
undergo intraoperative autologous donation (IAD) with those patients
randomized to the Hemolink(TM) arm experiencing a more aggressive IAD with
Hemolink(TM) treatment. This study will be conducted at most of the same U.S.
sites and, pending U.S. Food and Drug Administration (FDA) clearance, will run
concurrently with the primary CABG trial. This trial should be completed with
results reported in the second quarter of 2002.
Hemosol expects that all patients in these studies will contribute to the
overall safety database, and all will undergo IAD. At the conclusion of these
studies, the Company will review the data with the FDA and design and initiate
a third study that will be pivotal for U.S. registration. The goal is to file
a Biologics License Application (BLA) in the United States in the first half
of 2003.
The Company expects to receive a final response from Health Canada on its
application to market Hemolink(TM) in Canada by the end of this year.
Hemosol plans to strengthen its regulatory filings in the United Kingdom
in mid-2002 with the results of the primary and "re-do" CABG studies. Hemosol
expects the Medicines Control Agency to complete its review before the end of
2002. If approval is received, marketing and distribution in the U.K. could
begin toward the end of 2002 or early in 2003. Hemosol will then follow the
Mutual Recognition Procedure, which could allow the Company to gain approval
in other European countries within 90 days of U.K. approval. The Company
believes that this approach provides the best chance of achieving
profitability by the end of 2003.
The Company also plans to run two additional studies: a high-dose general
surgery study, as a feasibility/exploratory study in high blood loss
orthopedic and general surgeries; and a study in patients experiencing
chemotherapy-induced anemia. Hemosol will provide additional details on these
two studies once the FDA has had the opportunity to review the revised
protocols.
Hemosol also reported that it has completed validation and scale-up of
its existing manufacturing facility, which currently has a capacity of 25,000
units per year. In addition to supplying finished product to the Company`s
clinical program, Hemosol plans to license this facility in both Europe and
Canada. Work on the Company`s new state-of-the-art facility is proceeding on
schedule. Installation of process equipment is expected to be finished by the
middle of 2002 with validation of this 300,000-unit facility to be completed
early in 2003 in time for the BLA filing. Once finished, Hemosol will be the
only company to have a commercial-scale manufacturing facility to produce
hemoglobin based oxygen therapeutics.
Financial Results
In the third quarter of 2001, Hemosol recorded a net loss of $6.9 million
or ($0.17) per share, compared with a loss of $6.9 million or ($0.22) per
share in the corresponding period in 2000. The loss included a foreign
exchange gain of $2.8 million or $0.07 per share related to cash and cash
equivalents held in U.S.-denominated funds.
Net loss for the nine months ended September 30, 2001 was $27.8 million
or ($0.72) per share, which includes a year-to-date foreign exchange gain of
$1.2 million or $0.03 per share. The loss for the comparable nine-month period
in 2000 totalled $18.6 million or ($0.60) per share.
Losses from operations in the third quarter reached $10.3 million,
compared to a loss in the same period in 2000 of $7.5 million. Losses from
operations for the first nine months of 2001 totalled $31.6 million, compared
to $20.9 million in 2000. The loss is primarily due to increased spending in
clinical, regulatory, process development and marketing activities. During the
first nine months of 2001, Hemosol realized interest income of $2.7 million,
compared to $2.3 million in the corresponding period of last year.
Capital expenditures on the Company`s new manufacturing facility during
the first nine months of 2001 totalled $32.4 million, bringing total
expenditures to date on this facility to approximately $45 million. As of
September 30, 2001, the Company had not drawn down any amounts to finance
construction of this facility from either its $35 million senior credit
facility or its $12.5 million subordinate credit facility. Hemosol is in the
process of updating its creditors with details of the revised clinical program
for Hemolink(TM).
Hemosol remains well financed with $95.8 million of cash, cash
equivalents and short-term investments at September 30, 2001, as compared to
$41.9 million at December 31, 2000. Substantial losses in the remainder of
2001 and in 2002 will be realized, as a result of the Company`s clinical trial
program, expenses related to regulatory approvals, increased manufacturing
output and increased spending in market development activities. Operating
expenses during 2001 and 2002 are expected to increase approximately 60% over
the level realized in 2000.
Conference Call Details
The Company will hold a conference call today at 4:30p.m. (Eastern time)
to discuss its third quarter results. A live audio webcast of the conference
call will be available through www.hemosol.com and www.financialdisclosure.ca.
The call will also be archived on these sites for 30 days.
A replay of the conference call will also be available by telephone from
approximately 6:30p.m. (Eastern time) on October 25 through November 2, 2001.
To access the replay, dial, 416-695-5800 or 1-800-408-3053 and enter
reservation number 940624.
About Hemosol Inc.
Hemosol is a near-term, commercial-stage biopharmaceutical company
focused initially on developing life-sustaining therapies for the treatment of
acute anemia resulting from hemoglobin deficiencies. Hemosol has a broad range
of products in development, including its flagship product Hemolink(TM), a
highly-purified, human derived hemoglobin replacement therapeutic designed to
rapidly and safely improve oxygen delivery to the circulatory system.
Hemolink(TM) is currently being evaluated in late-stage clinical trials. The
Company also is developing hemoglobin-based therapeutic products to treat
diseases such as hepatitis C and cancers of the liver, as well as cell therapy
for possible use to treat cancer, HIV and auto-immune diseases.
For more information visit Hemosol`s website at www.hemosol.com.
Hemosol Inc`s common shares are listed on The Nasdaq Stock Market under
the trading symbol "HMSL" and on the Toronto Stock Exchange under the trading
symbol "HML".
Certain statements concerning Hemosol`s future prospects are "forward-
looking statements" under the United States Private Securities Litigation
Reform Act of 1995. There can be no assurances that future results will be
achieved, and actual results could differ materially from forecasts and
estimates. Important factors that could cause actual results to differ
materially from forecasts and estimates include, but are not limited to:
Hemosol`s ability to obtain regulatory approvals for its products; Hemosol`s
ability to successfully complete clinical trials for its products; technical
or manufacturing or distribution issues; the competitive environment for
Hemosol`s products; the degree of market penetration of Hemosol`s products;
and other factors set forth in filings with Canadian securities regulatory
authorities and the U.S. Securities and Exchange Commission. These risks and
uncertainties, as well as others, are discussed in greater detail in the
filings of Hemosol with Canadian securities regulatory authorities and the
U.S. Securities and Exchange Commission. Hemosol makes no commitment to revise
or update any forward-looking statements in order to reflect events or
circumstances after the date any such statement is made.
Financial Statements to Follow:
<<
HEMOSOL INC.
CONSOLIDATED BALANCE SHEET
NINE MONTHS PERIOD ENDED
(THOUSANDS OF DOLLARS) Sept. 30, 2001 Dec. 31, 2000
-------------------------------------------------------------------------
ASSETS
CURRENT
Cash and cash equivalents 27,417 41,879
Short term investments 68,400 -
Accrued interest 327 148
Amounts receivable 378 339
GST receivable 686 733
Inventory and supplies 1,670 635
Investment tax credit receivable 250 250
Prepaid expenses 481 645
--------------------------------------------------------------------
TOTAL CURRENT ASSETS 99,609 44,629
--------------------------------------------------------------------
OTHER
Capital assets, net 49,455 17,089
Patents and trademarks, net 1,087 1,020
Deferred charges 7,190 7,690
--------------------------------------------------------------------
TOTAL OTHER ASSETS 57,732 25,799
--------------------------------------------------------------------
TOTAL ASSETS 157,341 70,428
--------------------------------------------------------------------
LIABILITIES AND SHAREHOLDERS` EQUITY
CURRENT
Accounts payable and accrued liabilities 16,527 5,358
--------------------------------------------------------------------
TOTAL CURRENT LIABILITIES 16,527 5,358
--------------------------------------------------------------------
SHAREHOLDERS` EQUITY
Share capital 305,389 192,923
Contributed surplus 8,535 8,535
Deficit (173,110) (136,388)
--------------------------------------------------------------------
TOTAL SHAREHOLDERS` EQUITY 140,814 65,070
--------------------------------------------------------------------
TOTAL LIABILITIES AND
SHAREHOLDERS` EQUITY 157,341 70,428
--------------------------------------------------------------------
HEMOSOL INC.
CONSOLIDATED STATEMENT OF LOSS AND DEFICIT
Three months period Nine months period
ended ended
(THOUSANDS OF DOLLARS, Sept. 30, Sept. 29, Sept. 30, Sept. 29,
EXCEPT SHARE DATA) 2001 2000 2001 2000
-------------------------------------------------------------------------
REVENUE
-------
Research and development - - - -
-------------------------------------------------------------------------
EXPENSES
--------
Research and development
Scientific and process 3,771 3,782 13,353 9,765
Regulatory and clinical 2,872 1,538 9,444 5,940
-------------------------------------------------------------------------
Total research and
development 6,643 5,320 22,797 15,705
Administration 2,335 1,280 5,246 3,186
Marketing & business
development 1,339 917 3,519 1,970
-------------------------------------------------------------------------
TOTAL EXPENSES 10,317 7,517 31,562 20,861
-------------------------------------------------------------------------
Loss from operations (10,317) (7,517) (31,562) (20,861)
Provision for income taxes (60) - (159) -
Foreign exchange gain 2,818 - 1,232 -
Interest income 694 639 2,660 2,252
-------------------------------------------------------------------------
NET LOSS FOR THE PERIOD (6,865) (6,878) (27,829) (18,609)
Deficit, beginning of
period (166,245) (120,522) (136,388) (104,174)
Share issue cost - - (8,893) (4,617)
-------------------------------------------------------------------------
DEFICIT, END OF PERIOD (173,110) (127,400) (173,110) (127,400)
-------------------------------------------------------------------------
Average number of shares 40,823,501 31,909,696 38,623,172 31,059,573
LOSS PER SHARE 0.17 0.22 0.72 0.60
-------------------------------------------------------------------------
HEMOSOL INC.
CONSOLIDATED STATEMENT OF CASH FLOWS
Three months period Nine months period
ended ended
Sept. 30, Sept. 29, Sept. 30, Sept. 29,
(THOUSANDS OF DOLLARS) 2001 2000 2001 2000
-------------------------------------------------------------------------
OPERATING ACTIVITIES
Net loss for the period (6,865) (6,878) (27,829) (18,609)
Add items not requiring
an outlay of cash
Unrealized foreign exchange
gain (2,442) - (856) -
Depreciation and amortization 557 351 1,520 1,119
-------------------------------------------------------------------------
(8,750) (6,527) (27,165) (17,490)
Net change in non-cash
working capital balances
related to operations 2,091 687 (1,460) (2,540)
-------------------------------------------------------------------------
CASH USED IN OPERATING
ACTIVITIES (6,659) (5,840) (28,625) (20,030)
-------------------------------------------------------------------------
INVESTING ACTIVITIES
Short term investments (68,400) - (68,400) -
Patent and trademark costs (27) (33) (119) (289)
Purchase of capital assets (8,592) (5,170) (22,247) (10,789)
-------------------------------------------------------------------------
CASH USED IN INVESTING
ACTIVITIES (77,019) (5,203) (90,766) (11,078)
-------------------------------------------------------------------------
FINANCING ACTIVITIES
Proceeds on issuance
of common shares 1,904 109 112,466 71,077
Proceeds on sale of
transferable option - - - 8,534
Deferred charges - - 500 -
Share issue costs - - (8,893) (4,617)
-------------------------------------------------------------------------
CASH PROVIDED BY FINANCING
ACTIVITIES 1,904 109 104,073 74,994
-------------------------------------------------------------------------
Effect of exchange rate
changes on cash and
cash equivalents 2,442 - 856 -
Net increase (decrease)
in cash and cash equivalent (79,332) (10,934) (14,462) 43,886
Cash and cash equivalents,
beginning of period 106,749 64,559 41,879 9,739
-------------------------------------------------------------------------
CASH AND CASH EQUIVALENTS,
END OF PERIOD 27,417 53,625 27,417 53,625
-------------------------------------------------------------------------
>>
-30-
For further information: Jason Hogan, Investor Relations,
416-361-1331, 800-789-3419, 416-815-0080 fax, ir@hemosol.com,
www.hemosol.com; Shari Beagelman, Media Relations, 973-781-0200 ext. 20,
917-626-7071 mobile, sbeagelman@hemosol.com
HEMOSOL INC. has 105 releases in this database.
Hi Leute,
der Tag ist gekommen auf den wir gewartet haben.
Kurze Zusammenfassung.
Hemosol hat von der US F.a.D den Auftrag erhalten bei 180 Personen Hemolink zu testen,
da bei den Wettbewerben zu hohe Risikofaktoren vorhanden sind.
http://investdb.theglobeandmail.com/invest/investSQL/gx.comp…
hier findet Ihr die ganzen gewaltigen superguten News.
Meine einschätzung ist es, dass die USA sehr schnell auf Hemolink zurückgreifen will.
Also Leute für die nächsten Tage weiterhin die 50% am Tag
CoolMax
der Tag ist gekommen auf den wir gewartet haben.
Kurze Zusammenfassung.
Hemosol hat von der US F.a.D den Auftrag erhalten bei 180 Personen Hemolink zu testen,
da bei den Wettbewerben zu hohe Risikofaktoren vorhanden sind.
http://investdb.theglobeandmail.com/invest/investSQL/gx.comp…
hier findet Ihr die ganzen gewaltigen superguten News.
Meine einschätzung ist es, dass die USA sehr schnell auf Hemolink zurückgreifen will.
Also Leute für die nächsten Tage weiterhin die 50% am Tag
CoolMax
Hallo Leute,
so, nun ist der erste Hype durch! Aber wie geht es weiter???
Ich bin der Meinung, dass es nun nicht mehr so spekulativ ist, dass Hemosol mit Hemolink weiter kommen wird,den Hemosol hat den Auftrag für das Weitermachen von der US FaD erhalten. Daher hat HML nun offizielles Vertrauen ausgerufen bekommen und nicht immer in Eigener Sache Aussagen getroffen, die dann irgend wann eingetroffen sind und durch dumme Kommentare in der Öffentlichkeit Panikreaktionen ausgelöst hat.
Den Angaben nach, werden die Test in den USA spätesten im Q2 2002 abgeschlossen sein. Aber weiter bin ich davon überzeugt, dass HML Hemoglobin schneller zur Verfügung stellen wird und muß, zumal es auch zur derzeitigen weltpolitischen Lage makaber klingen mag. Aber die USA vertaut nicht auf Hersteller im eigenen Land sondern treibt HML voran, somit denke ich, die USA wissen was Sie tun. Das Makabere ist, dass die Army schon vor längerer Zeit Interesse an diesem Produkt gezeigt hat und nun können sie es eventuell schnellst möglich gebrauchen!!!!!!!!!!!!!!
Ich bin davon überzeugt, dass wir in den nächsten Wochen noch viel zu hören bekommen.
Ich muß gestehen, jetzt habe ich wieder Vertrauen in HML und bin froh, dass ich nach dem ersten massiven Crash zu langsam reagiert habe und meine kompletten Bestand noch halte.
Würde mich freuen, wenn wir nun wieder mal Diskutieren können. Auch wenn ich mich über "DT" oft geärgert habe, aber es würde mich bei Dir besonders freuen, wie Du die momentane Situation einschätzt,zumal Du in der Vergangenheit beweisen konntest, dass Du hohe fachliche Kenntnisse im Bezug auf Hemoglobin hast.
CoolMax
so, nun ist der erste Hype durch! Aber wie geht es weiter???
Ich bin der Meinung, dass es nun nicht mehr so spekulativ ist, dass Hemosol mit Hemolink weiter kommen wird,den Hemosol hat den Auftrag für das Weitermachen von der US FaD erhalten. Daher hat HML nun offizielles Vertrauen ausgerufen bekommen und nicht immer in Eigener Sache Aussagen getroffen, die dann irgend wann eingetroffen sind und durch dumme Kommentare in der Öffentlichkeit Panikreaktionen ausgelöst hat.
Den Angaben nach, werden die Test in den USA spätesten im Q2 2002 abgeschlossen sein. Aber weiter bin ich davon überzeugt, dass HML Hemoglobin schneller zur Verfügung stellen wird und muß, zumal es auch zur derzeitigen weltpolitischen Lage makaber klingen mag. Aber die USA vertaut nicht auf Hersteller im eigenen Land sondern treibt HML voran, somit denke ich, die USA wissen was Sie tun. Das Makabere ist, dass die Army schon vor längerer Zeit Interesse an diesem Produkt gezeigt hat und nun können sie es eventuell schnellst möglich gebrauchen!!!!!!!!!!!!!!
Ich bin davon überzeugt, dass wir in den nächsten Wochen noch viel zu hören bekommen.
Ich muß gestehen, jetzt habe ich wieder Vertrauen in HML und bin froh, dass ich nach dem ersten massiven Crash zu langsam reagiert habe und meine kompletten Bestand noch halte.
Würde mich freuen, wenn wir nun wieder mal Diskutieren können. Auch wenn ich mich über "DT" oft geärgert habe, aber es würde mich bei Dir besonders freuen, wie Du die momentane Situation einschätzt,zumal Du in der Vergangenheit beweisen konntest, dass Du hohe fachliche Kenntnisse im Bezug auf Hemoglobin hast.
CoolMax
@all,
wie Ihr seht, die Brandneusten Nachrichten. Hemosol wird aufgewertet.
Hemosol Inc. (HML-TSE)
00:00 EST Friday, November 23, 2001
$6.50, down 69 cents
Profit-taking hit the stock yesterday after a big runup Wednesday on U.S. regulatory approval for the pharmaceutical company to resume testing its blood-substitute product. Trading volume jumped to 2.9 million shares from 1.7 million on Wednesday. Yorkton Securities Inc. downgraded Hemosol stock to "reduce" from "accumulate" but raised its target for the stock price to $6.25 from $6. Sprott Securities Inc. upgraded the stock to "buy" from "speculative buy."
Copyright © 2001 The Globe and Mail
es geht weiter
CoolMax
wie Ihr seht, die Brandneusten Nachrichten. Hemosol wird aufgewertet.
Hemosol Inc. (HML-TSE)
00:00 EST Friday, November 23, 2001
$6.50, down 69 cents
Profit-taking hit the stock yesterday after a big runup Wednesday on U.S. regulatory approval for the pharmaceutical company to resume testing its blood-substitute product. Trading volume jumped to 2.9 million shares from 1.7 million on Wednesday. Yorkton Securities Inc. downgraded Hemosol stock to "reduce" from "accumulate" but raised its target for the stock price to $6.25 from $6. Sprott Securities Inc. upgraded the stock to "buy" from "speculative buy."
Copyright © 2001 The Globe and Mail
es geht weiter
CoolMax
@all,
ich glaube langsam, da wird der Kurs gewaltig gedrückt!!!!!!!!!!!
1.
13:32 EST Monday, December 10, 2001
TORONTO (Reuters) - Shares of Hemosol Inc rose almost 18 percent on Monday on evidence that its artificial hemoglobin product may be an effective blood substitute in surgery.
Shares of Hemosol were up C$1.01 to C$6.78 on the Toronto Stock Exchange in early afternoon trade, and up 54 cents to $4.25 on Nasdaq. The stock is up 40 percent in December.
The company unveiled the results of it latest clinical trial at the annual meeting of the American Society of Hematologists on Monday. It said the trial showed that its artificial hemoglobin product, Hemolink, behaves much like hemoglobin in the way in which it carries and deposits oxygen through the bloodstream.
"(The results) are quite important because it means that what they are producing does act like natural blood, and blood`s major function, which is picking up oxygen in the lungs and delivering it to the tissues where it`s needed," said Ezra Lwowyski an analyst at Yorkton Securities.
After an 18-month slump, the stock has been taking big strides forward recently as investor optimism grows with each corporate announcement.
Last month Hemosol said U.S. regulators had approved an additional clinical trial of Hemolink, which will help pave the way for marketing approval in Britain as well as the United States.
($1=$1.58 Canadian)
© 2001 Reuters Limited. All Rights Reserved.
Reproduction or redistribution of Reuters content, including framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
2:
00:00 EST Tuesday, December 11, 2001
$6.75, up 98 cents
The shares of Hemosol Inc. rose 17 per cent on the Toronto Stock Exchange yesterday. A recent study of the Toronto-based company`s Hemolink product shows that Hemolink "delivers a significant amount of oxygen to tissues as compared to normal blood." In a release, Hemosol said the oxygen-carrying characteristics of Hemolink are similar to those of fresh blood. The biopharmaceutical company said a recent study "confirms what has been demonstrated in vivo, that the deoxygenated Hemolink can act as an oxygen therapeutic by travelling through the lungs and picking up oxygen to distribute to the body`s tissues." Hemosol said the study was conducted in vitro, using a cardiopulmonary bypass circuit, a device used during cardiac surgery to regulate blood and oxygen flow. It said the circuit gave the experiment the desired clinical conditions, while allowing researchers to control the amount of oxygen in the solution. Researchers found no oxygen-carrying characteristic difference between the oxygenated and deoxygenated cycles of Hemolink, which is the same result seen with whole human blood, it said. The study was conducted by Toronto`s St. Michael`s Hospital and the University of Toronto, and underwritten through an unrestricted educational grant from Hemosol, the company said. On the Nasdaq Stock Market, Hemosol rose 52 cents (U.S.) to $4.23.
Copyright © 2001 The Globe and Mail
Da kann was nicht mit rechten Dingen zu gehen, wenn so positive Nachrichten herausgebracht werden, da wird geblockt?!?
CoolMax
ich glaube langsam, da wird der Kurs gewaltig gedrückt!!!!!!!!!!!
1.
13:32 EST Monday, December 10, 2001
TORONTO (Reuters) - Shares of Hemosol Inc rose almost 18 percent on Monday on evidence that its artificial hemoglobin product may be an effective blood substitute in surgery.
Shares of Hemosol were up C$1.01 to C$6.78 on the Toronto Stock Exchange in early afternoon trade, and up 54 cents to $4.25 on Nasdaq. The stock is up 40 percent in December.
The company unveiled the results of it latest clinical trial at the annual meeting of the American Society of Hematologists on Monday. It said the trial showed that its artificial hemoglobin product, Hemolink, behaves much like hemoglobin in the way in which it carries and deposits oxygen through the bloodstream.
"(The results) are quite important because it means that what they are producing does act like natural blood, and blood`s major function, which is picking up oxygen in the lungs and delivering it to the tissues where it`s needed," said Ezra Lwowyski an analyst at Yorkton Securities.
After an 18-month slump, the stock has been taking big strides forward recently as investor optimism grows with each corporate announcement.
Last month Hemosol said U.S. regulators had approved an additional clinical trial of Hemolink, which will help pave the way for marketing approval in Britain as well as the United States.
($1=$1.58 Canadian)
© 2001 Reuters Limited. All Rights Reserved.
Reproduction or redistribution of Reuters content, including framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
2:
00:00 EST Tuesday, December 11, 2001
$6.75, up 98 cents
The shares of Hemosol Inc. rose 17 per cent on the Toronto Stock Exchange yesterday. A recent study of the Toronto-based company`s Hemolink product shows that Hemolink "delivers a significant amount of oxygen to tissues as compared to normal blood." In a release, Hemosol said the oxygen-carrying characteristics of Hemolink are similar to those of fresh blood. The biopharmaceutical company said a recent study "confirms what has been demonstrated in vivo, that the deoxygenated Hemolink can act as an oxygen therapeutic by travelling through the lungs and picking up oxygen to distribute to the body`s tissues." Hemosol said the study was conducted in vitro, using a cardiopulmonary bypass circuit, a device used during cardiac surgery to regulate blood and oxygen flow. It said the circuit gave the experiment the desired clinical conditions, while allowing researchers to control the amount of oxygen in the solution. Researchers found no oxygen-carrying characteristic difference between the oxygenated and deoxygenated cycles of Hemolink, which is the same result seen with whole human blood, it said. The study was conducted by Toronto`s St. Michael`s Hospital and the University of Toronto, and underwritten through an unrestricted educational grant from Hemosol, the company said. On the Nasdaq Stock Market, Hemosol rose 52 cents (U.S.) to $4.23.
Copyright © 2001 The Globe and Mail
Da kann was nicht mit rechten Dingen zu gehen, wenn so positive Nachrichten herausgebracht werden, da wird geblockt?!?
CoolMax
@Max
Ja, kommt mir auch so vor.
Irgendwie wirkt die Kursbewegung "unnatürlich", is aber nur so n Gefühl. Aber ich bin ja zum Glück nicht der einzige dem das auffällt.
Gruß
Nucleus
Ja, kommt mir auch so vor.
Irgendwie wirkt die Kursbewegung "unnatürlich", is aber nur so n Gefühl. Aber ich bin ja zum Glück nicht der einzige dem das auffällt.
Gruß
Nucleus
@All,
ich kann derzeit nicht auf die Hompage von HML zugreifen, aber der Kurs steigt derzeit minütlich z.Z. USA + 11,57% 4,57 US-$.
Frohe Weihnachten.
CoolMax
ich kann derzeit nicht auf die Hompage von HML zugreifen, aber der Kurs steigt derzeit minütlich z.Z. USA + 11,57% 4,57 US-$.
Frohe Weihnachten.
CoolMax
@all,
Schlußkurs 4,7 US-$ + 13% net schlecht!!!!!!!!
CoolMax
p.s. Canadian Newswire funktioniert leider nicht, was der Grund für den Anstieg ist, weiß ich bis lang nicht. Währe super, wenn jemand eine weitere INFO-Quell hat.
Schlußkurs 4,7 US-$ + 13% net schlecht!!!!!!!!
CoolMax
p.s. Canadian Newswire funktioniert leider nicht, was der Grund für den Anstieg ist, weiß ich bis lang nicht. Währe super, wenn jemand eine weitere INFO-Quell hat.
Hey Leute,
so langsam kommt der Hemosolzug wieder in Fahrt und der Wert scheint wieder an Interesse zu gewinnen...
Weiß vielleicht irgendjemand, worin der kntinuierlich Anstieg, vor allem heute, begründet ist?
Gruß Hefeknacker
so langsam kommt der Hemosolzug wieder in Fahrt und der Wert scheint wieder an Interesse zu gewinnen...
Weiß vielleicht irgendjemand, worin der kntinuierlich Anstieg, vor allem heute, begründet ist?
Gruß Hefeknacker
keiner weiss was genaues. aber von mir aus kann es so weiter gehen.
Hi leute,
es ist wirklich schön zu zusehen, wie der Kurs kontinuirlich steigt.
Leider ist Canadian News Wire seit wochen ausgefallen, zumindest kann man keine Inforamtionen zu einem wert abfragen.
Hat aber nichts mit HML zu tun ist generell. Leider habe ich auch sonst keine INFOQUELL, es währe aber beruhigender, wenn jemenad eine weitere hat.
GRuß
CoolMax
es ist wirklich schön zu zusehen, wie der Kurs kontinuirlich steigt.
Leider ist Canadian News Wire seit wochen ausgefallen, zumindest kann man keine Inforamtionen zu einem wert abfragen.
Hat aber nichts mit HML zu tun ist generell. Leider habe ich auch sonst keine INFOQUELL, es währe aber beruhigender, wenn jemenad eine weitere hat.
GRuß
CoolMax
Ist auf jeden Fall besser, wenn der Kurs still und leise vor sich hinsteigt, als +40(Zocker)Prozent an einem Tag und am nächsten Tag wieder abwärts.
Nucleus
Nucleus
Hallo Leute,
der Grund für den Kursanstieg liegt an der zu erwartenden Mitteilung von Health Canada(HC).Eigentlich war eine Mitteilung für Ende des Jahres 2001 vorgesehen.HC ist also überfällig.Schau mer mal was raus kommt.
gruezi
der Grund für den Kursanstieg liegt an der zu erwartenden Mitteilung von Health Canada(HC).Eigentlich war eine Mitteilung für Ende des Jahres 2001 vorgesehen.HC ist also überfällig.Schau mer mal was raus kommt.
gruezi
@paucius
was soll das für eine Meldung sein? Ich dachte die nächste Meldung kommt Ende des 2ten Quartals von Hemosol bezüglich des wiederholten, verbesserten Trials...
Erwarte eigentlich bis dahin nur ein dahinplätschern des Kurses um die 5 rum... wäre schön wenn es anders kommt... vielleicht weisst du ja mehr als ich...
good trades
dkF
was soll das für eine Meldung sein? Ich dachte die nächste Meldung kommt Ende des 2ten Quartals von Hemosol bezüglich des wiederholten, verbesserten Trials...
Erwarte eigentlich bis dahin nur ein dahinplätschern des Kurses um die 5 rum... wäre schön wenn es anders kommt... vielleicht weisst du ja mehr als ich...
good trades
dkF
@dieKapitalistischeFront
(ich musste den Namen einfach ausschreiben!)
Paucius hat schon Recht, Hemosol wartet nach wie vor auf Antwort von HC, die hatten ja nichts an den Phase3 Test auszusetzen (wenn ich mich recht entsinne).
Da hat sich nichts geändert.
Blöd wär nur, wenn die jetzt auch ein Re-design der Studie wollen, wie die FDA.
Andererseits ist Hemosol ja eine kanadische Firma...
Schaun mer mal.
Nucleus
(ich musste den Namen einfach ausschreiben!)
Paucius hat schon Recht, Hemosol wartet nach wie vor auf Antwort von HC, die hatten ja nichts an den Phase3 Test auszusetzen (wenn ich mich recht entsinne).
Da hat sich nichts geändert.
Blöd wär nur, wenn die jetzt auch ein Re-design der Studie wollen, wie die FDA.
Andererseits ist Hemosol ja eine kanadische Firma...
Schaun mer mal.
Nucleus
Hemosol Oxygen Therapeutic Research Shows Promise for the Prevention of Tissue Reperfusion Injury
Pre-Clinical Findings Presented at American Society
of Transplant Surgeons Winter Symposium
MIAMI, FL, Jan. 29 /CNW/ - A preclinical study conducted by Hemosol Inc.
(NASDAQ: HMSL, TSE: HML) has successfully demonstrated that HRC-102 (formally
HML-110), a conjugate of o-raffinose-polymerized hemoglobin and a soluble
vitamin E analogue with broad antioxidant properties, may have special
application in the treatment of reperfusion injury. These findings were
recently presented at Second Annual Winter Symposium of the American Society
of Transplant Surgeons (ASTS).
"This advancement in our pipeline illustrates both the strong research
and development capabilities of Hemosol and also our commitment to building a
portfolio of life-sustaining oxygen therapeutics," said David Bell, Ph.D.,
Vice President, Drug Development, Hemosol. "Based on these preliminary
findings, Hemosol can now begin testing HRC-102 through an expanded pre-
clinical development plan."
Hemoglobin-based oxygen carriers (HBOCs) are a new class of oxygen
therapeutics that may be useful in situations of acute anemia, ultimately
including the maintenance of isolated tissues and in the reperfusion of
transplanted organs. When oxygen is reintroduced to ischemic tissue by a range
of fluids, including blood, this can lead to local and systemic tissue injury
as a result of the formation of reactive oxygen species. Reperfusion injury is
very difficult to manage in the surgical setting. Accordingly, Hemosol
scientists have been investigating the effectiveness of a hemoglobin-
antioxidant conjugate as a potential agent to lessen reperfusion injury.
Study Design and Findings
The in vitro study, "A Hemoglobin-Based Oxygen Carrier with Antioxidant
Properties for Use in Tissue Reperfusion," was conducted by Hemosol
scientists.
Trolox, a water-soluble vitamin E analogue with broad antioxidant
activity, was conjugated to o-raffinose-polymerized hemoglobin to create a
HBOC with antioxidant properties. The following observations were made in
vitro:
- HRC-102 appeared to provide complete protection of red blood cells
exposed to peroxyl-mediated damage, making HRC-102 a viable candidate
for continued development.
- Neither Trolox`s antioxidant activity nor the oxygen carrying ability
of the hemoglobin was impaired following conjugation.
"Hemosol`s ability to modify or add new attributes to hemoglobin provides
an opportunity to address a variety of clinical needs such as reperfusion
injury," said Bell.
Pre-Clinical Findings Presented at American Society
of Transplant Surgeons Winter Symposium
MIAMI, FL, Jan. 29 /CNW/ - A preclinical study conducted by Hemosol Inc.
(NASDAQ: HMSL, TSE: HML) has successfully demonstrated that HRC-102 (formally
HML-110), a conjugate of o-raffinose-polymerized hemoglobin and a soluble
vitamin E analogue with broad antioxidant properties, may have special
application in the treatment of reperfusion injury. These findings were
recently presented at Second Annual Winter Symposium of the American Society
of Transplant Surgeons (ASTS).
"This advancement in our pipeline illustrates both the strong research
and development capabilities of Hemosol and also our commitment to building a
portfolio of life-sustaining oxygen therapeutics," said David Bell, Ph.D.,
Vice President, Drug Development, Hemosol. "Based on these preliminary
findings, Hemosol can now begin testing HRC-102 through an expanded pre-
clinical development plan."
Hemoglobin-based oxygen carriers (HBOCs) are a new class of oxygen
therapeutics that may be useful in situations of acute anemia, ultimately
including the maintenance of isolated tissues and in the reperfusion of
transplanted organs. When oxygen is reintroduced to ischemic tissue by a range
of fluids, including blood, this can lead to local and systemic tissue injury
as a result of the formation of reactive oxygen species. Reperfusion injury is
very difficult to manage in the surgical setting. Accordingly, Hemosol
scientists have been investigating the effectiveness of a hemoglobin-
antioxidant conjugate as a potential agent to lessen reperfusion injury.
Study Design and Findings
The in vitro study, "A Hemoglobin-Based Oxygen Carrier with Antioxidant
Properties for Use in Tissue Reperfusion," was conducted by Hemosol
scientists.
Trolox, a water-soluble vitamin E analogue with broad antioxidant
activity, was conjugated to o-raffinose-polymerized hemoglobin to create a
HBOC with antioxidant properties. The following observations were made in
vitro:
- HRC-102 appeared to provide complete protection of red blood cells
exposed to peroxyl-mediated damage, making HRC-102 a viable candidate
for continued development.
- Neither Trolox`s antioxidant activity nor the oxygen carrying ability
of the hemoglobin was impaired following conjugation.
"Hemosol`s ability to modify or add new attributes to hemoglobin provides
an opportunity to address a variety of clinical needs such as reperfusion
injury," said Bell.
will mich nur ganz kurz hier einklinken.
Da in den Beiträgen meines erachtens auch "Blut-Spezialisten" erkennbar waren, eine kurze Frage:
Hat diese US-Firma (HYRB.OB) mit ihren Forschungsergebnissen eine Chance?:
PALO ALTO, Calif.--(BUSINESS WIRE)--Dec. 13, 2001--HyperBaric Systems (OTCBB:HYRB - news), a California biomedical company, announced that it has achieved a ``major technical improvement`` with its patent-pending technology to preserve the shelf life of blood platelets, the congealing component of blood.
Dr. David Lucas, Scientific Director for the company, said they have discovered a method of ``significantly reducing loss of platelet function during the initial temperature reduction period. This is important because after the first 24 hours of storage, we experience very little loss of platelet functionality.``
HyperBaric Systems has already demonstrated that it can preserve platelets at refrigerated temperatures for ten days with up to 60 percent recovery of functioning platelets.
``It has been well documented for more than forty years that corporations and individuals have been attempting to preserve platelets under refrigerated conditions without success,`` Dr. Lucas said.
``Blood banks, hospitals and medical centers have been forced to store blood platelets at room temperatures because previous attempts to refrigerate them have resulted in loss of functionality within a few hours,`` Dr. Lucas stated. ``This phenomenon is primarily due to activation and a change in the shape of the platelet, which is then rejected by the recipient.``
``Our basic technology and methodology is unique in that we have developed a way in which to cool the platelets without activating them,`` he said.
``Although we have previously experienced at least a 40 percent loss of platelet functionality during the first 24 hours under refrigerated conditions, there was virtually no loss during the next seven to ten days,`` Lucas said.
``Currently our experiments in Russia are showing that we are achieving between seventy five and 100 percent recovery of platelet function during the first 24 hours while still retaining a very low drop-off rate during the following days. This is really very significant.``
HyperBaric President and CEO, Harry Masuda, said the company has achieved a major milestone in the development of cold-temperature storage process.
``It is very reasonable to assume that with this dramatically improved platelet survival rate in the initial stages of refrigeration, we may be able to extend the overall storage times significantly longer than we originally anticipated,`` he said.
``We have just recently announced the appointment of Victor Ivashin as Chief Technical Officer, and he is in the process of building a computerized cooling instrument to obtain consistent and precise results using our technology, and to help us prepare for human infusion.``
HyperBaric Systems recently completed a series of successful experiments to validate its cold-storage technology at the Blood Research Center in Sacramento, California. Dr. Lucas said they are continuing experiments at the center to refine the newly discovered process improvements and help lay the groundwork for FDA approval.
Dr. Luis Toledo, Chief Medical Officer for HyperBaric Systems, said, ``Our technology offers tremendous advantages for the medical industry and for patients who require infusions of blood platelets.``
``Our longer storage periods certainly makes the task of inventory control easier and less costly for blood centers and hospitals. The nature of our technology diminishes the growth of bacteria in the platelets making them much safer, and theoretically, of a higher quality than what is currently available,`` he said.
HyperBaric Systems is headquartered in Palo Alto, California, with additional offices in the greater San Francisco Bay area, Rancho Mirage, California and Michigan. The company also has research and testing facilities in Russia.
Certain statements contained herein are ``forward-looking`` statements (as such term is defined in the Private Securities Litigation Reform Act of 1995). Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to the future results of research and development of the Company`s products, the ability or inability to replicate test results, the ability to successfully commercialize the Company`s products, and other risk factors discussed in filings made by the Company with the Securities and Exchange Commission.
Da in den Beiträgen meines erachtens auch "Blut-Spezialisten" erkennbar waren, eine kurze Frage:
Hat diese US-Firma (HYRB.OB) mit ihren Forschungsergebnissen eine Chance?:
PALO ALTO, Calif.--(BUSINESS WIRE)--Dec. 13, 2001--HyperBaric Systems (OTCBB:HYRB - news), a California biomedical company, announced that it has achieved a ``major technical improvement`` with its patent-pending technology to preserve the shelf life of blood platelets, the congealing component of blood.
Dr. David Lucas, Scientific Director for the company, said they have discovered a method of ``significantly reducing loss of platelet function during the initial temperature reduction period. This is important because after the first 24 hours of storage, we experience very little loss of platelet functionality.``
HyperBaric Systems has already demonstrated that it can preserve platelets at refrigerated temperatures for ten days with up to 60 percent recovery of functioning platelets.
``It has been well documented for more than forty years that corporations and individuals have been attempting to preserve platelets under refrigerated conditions without success,`` Dr. Lucas said.
``Blood banks, hospitals and medical centers have been forced to store blood platelets at room temperatures because previous attempts to refrigerate them have resulted in loss of functionality within a few hours,`` Dr. Lucas stated. ``This phenomenon is primarily due to activation and a change in the shape of the platelet, which is then rejected by the recipient.``
``Our basic technology and methodology is unique in that we have developed a way in which to cool the platelets without activating them,`` he said.
``Although we have previously experienced at least a 40 percent loss of platelet functionality during the first 24 hours under refrigerated conditions, there was virtually no loss during the next seven to ten days,`` Lucas said.
``Currently our experiments in Russia are showing that we are achieving between seventy five and 100 percent recovery of platelet function during the first 24 hours while still retaining a very low drop-off rate during the following days. This is really very significant.``
HyperBaric President and CEO, Harry Masuda, said the company has achieved a major milestone in the development of cold-temperature storage process.
``It is very reasonable to assume that with this dramatically improved platelet survival rate in the initial stages of refrigeration, we may be able to extend the overall storage times significantly longer than we originally anticipated,`` he said.
``We have just recently announced the appointment of Victor Ivashin as Chief Technical Officer, and he is in the process of building a computerized cooling instrument to obtain consistent and precise results using our technology, and to help us prepare for human infusion.``
HyperBaric Systems recently completed a series of successful experiments to validate its cold-storage technology at the Blood Research Center in Sacramento, California. Dr. Lucas said they are continuing experiments at the center to refine the newly discovered process improvements and help lay the groundwork for FDA approval.
Dr. Luis Toledo, Chief Medical Officer for HyperBaric Systems, said, ``Our technology offers tremendous advantages for the medical industry and for patients who require infusions of blood platelets.``
``Our longer storage periods certainly makes the task of inventory control easier and less costly for blood centers and hospitals. The nature of our technology diminishes the growth of bacteria in the platelets making them much safer, and theoretically, of a higher quality than what is currently available,`` he said.
HyperBaric Systems is headquartered in Palo Alto, California, with additional offices in the greater San Francisco Bay area, Rancho Mirage, California and Michigan. The company also has research and testing facilities in Russia.
Certain statements contained herein are ``forward-looking`` statements (as such term is defined in the Private Securities Litigation Reform Act of 1995). Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to the future results of research and development of the Company`s products, the ability or inability to replicate test results, the ability to successfully commercialize the Company`s products, and other risk factors discussed in filings made by the Company with the Securities and Exchange Commission.
es gab Post von der FDA:
Hemosol Commences Second Hemolink(TM) Study in the U.S.
TORONTO, Jan. 31 /CNW/ - Hemosol Inc. (NASDAQ: HMSL, TSE: HML) today
announced that the U.S. Food and Drug Administration (FDA) has given the
Company notice to proceed with a key clinical trial of its lead oxygen
therapeutic, Hemolink(TM) (hemoglobin raffimer), in "re-do" cardiac bypass
grafting (CABG) surgery.
The two-armed study will investigate the efficacy of Hemolink(TM) in
approximately 140 patients at more than 40 centres in the United States.
Hemosol originally planned a three-arm study; after discussions with the FDA,
both parties concluded that the third arm was unnecessary as part of this
study and could be deleted from the protocol. All patients in the "re-do"
study will undergo the same intraoperative autologous donation (IAD)
procedure, with either Hemolink(TM) or allogeneic red blood cells administered
in response to transfusion triggers.
The "re-do" study design is very similar to the ongoing primary CABG
study, which received FDA approval in November of 2001 and is now actively
recruiting patients; both studies are expected to run concurrently and
conclude in the second quarter of 2002. Upon completion of the two studies,
the Company plans to review the data with the FDA and design and initiate a
third study that is expected to be pivotal for U.S. registration.
"As both the primary and `re-do` studies were designed to run
concurrently, much of the preparatory work required to initiate the `re-do`
study has already been done," said John W. Kennedy, President and Chief
Executive Officer of Hemosol. "As such, we expect site activation work to
commence immediately."
Data from the primary and "re-do" studies will be used to strengthen the
Company`s pending application in the U.K. Hemosol plans to respond to
questions from the U.K. Medicines Control Agency in the third quarter of 2002
and expects that the regulatory body`s review of the application will be
complete before the end of the same year. Hemosol intends to follow the Mutual
Recognition Procedure, which could allow the Company to gain approval in other
European countries shortly after U.K. approval.
In addition to the efficacy study in primary and "re-do" CABG patients,
the Company`s clinical program also includes a high-dose general surgery
study, and a study in patients experiencing chemotherapy-induced anemia. More
details of these trials will be made available once the FDA has had the
opportunity to complete their review of the protocols.
Hemolink(TM) (hemoglobin raffimer) is Hemosol`s proprietary oxygen
therapeutic, designed to sustain life by providing immediate and safe oxygen
delivery to vital organs and tissues to improve outcomes in patients
undergoing cardiac, orthopedic and other surgeries and chemotherapy.
Nucleus
Hemosol Commences Second Hemolink(TM) Study in the U.S.
TORONTO, Jan. 31 /CNW/ - Hemosol Inc. (NASDAQ: HMSL, TSE: HML) today
announced that the U.S. Food and Drug Administration (FDA) has given the
Company notice to proceed with a key clinical trial of its lead oxygen
therapeutic, Hemolink(TM) (hemoglobin raffimer), in "re-do" cardiac bypass
grafting (CABG) surgery.
The two-armed study will investigate the efficacy of Hemolink(TM) in
approximately 140 patients at more than 40 centres in the United States.
Hemosol originally planned a three-arm study; after discussions with the FDA,
both parties concluded that the third arm was unnecessary as part of this
study and could be deleted from the protocol. All patients in the "re-do"
study will undergo the same intraoperative autologous donation (IAD)
procedure, with either Hemolink(TM) or allogeneic red blood cells administered
in response to transfusion triggers.
The "re-do" study design is very similar to the ongoing primary CABG
study, which received FDA approval in November of 2001 and is now actively
recruiting patients; both studies are expected to run concurrently and
conclude in the second quarter of 2002. Upon completion of the two studies,
the Company plans to review the data with the FDA and design and initiate a
third study that is expected to be pivotal for U.S. registration.
"As both the primary and `re-do` studies were designed to run
concurrently, much of the preparatory work required to initiate the `re-do`
study has already been done," said John W. Kennedy, President and Chief
Executive Officer of Hemosol. "As such, we expect site activation work to
commence immediately."
Data from the primary and "re-do" studies will be used to strengthen the
Company`s pending application in the U.K. Hemosol plans to respond to
questions from the U.K. Medicines Control Agency in the third quarter of 2002
and expects that the regulatory body`s review of the application will be
complete before the end of the same year. Hemosol intends to follow the Mutual
Recognition Procedure, which could allow the Company to gain approval in other
European countries shortly after U.K. approval.
In addition to the efficacy study in primary and "re-do" CABG patients,
the Company`s clinical program also includes a high-dose general surgery
study, and a study in patients experiencing chemotherapy-induced anemia. More
details of these trials will be made available once the FDA has had the
opportunity to complete their review of the protocols.
Hemolink(TM) (hemoglobin raffimer) is Hemosol`s proprietary oxygen
therapeutic, designed to sustain life by providing immediate and safe oxygen
delivery to vital organs and tissues to improve outcomes in patients
undergoing cardiac, orthopedic and other surgeries and chemotherapy.
Nucleus
@ nucleus,
sind ja wirklich gute Aussichten. Aber woher hast Du die Infos????????. Ich habe nachwievor schwierigkeiten über CAN-News-wire Nachrichten zu bekommen. Währe nett, wenn Du den Link reinstellen könntest.
Danke
CoolMax
sind ja wirklich gute Aussichten. Aber woher hast Du die Infos????????. Ich habe nachwievor schwierigkeiten über CAN-News-wire Nachrichten zu bekommen. Währe nett, wenn Du den Link reinstellen könntest.
Danke
CoolMax
Hallo CoolMax,
alle relevanten Daten sind auf der Hemosol-Homepage verfügbar.
www.hemosol.com
In diesem Sinne
Gruß vom Hefeknacker
alle relevanten Daten sind auf der Hemosol-Homepage verfügbar.
www.hemosol.com
In diesem Sinne
Gruß vom Hefeknacker
jenau von da hab ich sie auch!
Nucleus
Nucleus
Bei uns steigt der Kurs und drüben fällt er leicht...da bin ich ja mal sehr auf die Zahlen heute abend gespannt.
Nucleus
Nucleus
@All,
zumindest habe ich einen neuen Link gefunden, auf dem alle neuigkeiten über HML ersichtlich sind. Die Hompage ist da doch etwas langsamer.
http://investdb.theglobeandmail.com/invest/investSQL/gx.comp…
Gruß
CoolMax
p.s. bei den Zahlen 2001 sollte sich keiner etwas erwarten, aber ich denke das sieht der Markt genauso.
zumindest habe ich einen neuen Link gefunden, auf dem alle neuigkeiten über HML ersichtlich sind. Die Hompage ist da doch etwas langsamer.
http://investdb.theglobeandmail.com/invest/investSQL/gx.comp…
Gruß
CoolMax
p.s. bei den Zahlen 2001 sollte sich keiner etwas erwarten, aber ich denke das sieht der Markt genauso.
UP´s
Zahlen sind schneller da als ich dachte:
(habes sie direkt reingestellt ohne durchzulesen)
16:01 EST Thursday, February 14, 2002
TORONTO, Feb. 14 /PRNewswire-FirstCall/ - Hemosol Inc. (NASDAQ: HMSL, TSE: HML) today announced financial results for the fourth quarter and year ended December 31, 2001. The Company also reported on clinical development progress with its lead product, Hemolink(TM) (hemoglobin raffimer). Unless otherwise stated, all dollar values herein are Canadian dollars.
In the fourth quarter of 2001, Hemosol recorded a net loss of $10.7 million or ($0.26) per share, compared to a loss of $9.0 million or ($0.28) per share in the corresponding period of 2000. Net loss for the year ended December 31, 2001 was $38.6 million ($0.98) per share, compared to a loss of $27.6 million or ($0.88) per share for the year ended December 31, 2000.
"We successfully addressed some major challenges in 2001 and as a result have put the Company in a strong position moving forward," said John Kennedy, President and Chief Executive Officer of Hemosol. "Our team worked closely with regulatory agencies worldwide and responded quickly and strategically to re-charge our clinical and regulatory programs. Both of our redesigned CABG studies are moving forward, and should be completed by the middle of this year with results available shortly thereafter. Our strategy is on course to bring Hemolink to market around the world. In addition, our new manufacturing facility is on schedule and gives us an early competitive advantage with the capacity to meet potential market demand."
Financial Results
The Company`s operating expenses in the fourth quarter totalled $10.9 million, an 11% increase of $1.1 million over the corresponding period in 2000. Operating expenses for the twelve-month period reached $42.5 million, an increase of $11.8 million or 39% over 2000. Total spending was somewhat lower than expected due to lower than projected patient enrolment in the Company`s clinical trial program. Increases in both the quarter and the year are attributed to increased personnel and related costs, consulting costs associated with manufacturing expansion and the Company`s clinical/regulatory program, and increased expenditures in medical education and communication.
Interest income in the quarter totalled $828,000, bringing total interest income for the year to $3.5 million compared to $3 million in 2000.
Capital expenditures during the year reached $46.1 million. These expenditures were incurred to expand the capacity of the Company`s existing pilot facility and continue construction of the new 300,000 unit commercial facility. To date the Company has expended $53.9 million on this facility, which includes $7.7 million in accounts payable and accrued liabilities. As of December 31, 2001, Hemosol had not drawn down on either of its debt facilities and had capital assets in excess of $60 million.
As of December 31, 2001, Hemosol remains well financed with $69.8 million in cash and cash equivalents and short-term investments.
Hemosol expects operating expenses to increase as enrolment in the clinical trial program progresses. Depending on the level of patient treatment per month, expenses are expected to average approximately $5 million per month for the next six months. Operating expenses beyond this period will depend on a number of factors and guidance will be updated accordingly.
The Company is currently negotiating appropriate amendments to its existing $35 million senior credit facility as a result of last year`s revisions to the clinical program for Hemolink and the subsequent extension of time lines for regulatory approval. With the considerable progress in construction of the new facility, Hemosol also is assessing its options concerning the economics of its $12.5 million subordinated debt facility and has not yet determined whether it will use this facility. If the Company decides to use this facility it will be necessary to negotiate similar amendments to those of the senior debt. Hemosol will not draw down under either facility until arrangements are finalized.
Clinical, Regulatory and Manufacturing Progress Update
- In November 2001, Hemosol received FDA approval to begin a 180-patient
clinical trial of Hemolink in primary coronary artery bypass grafting
(CABG) surgery;
- In January 2002, Hemosol received FDA approval to proceed with a
second clinical trial of Hemolink in 140 patients undergoing "re-do"
CABG surgery;
- Both studies have similar designs and will run concurrently. The
primary study is now actively treating patients and the "re-do" trial
is now being activated at the clinical study sites;
- Upon completion of the two studies, the Company plans to review data
with the FDA and design and initiate a third study pivotal for U.S.
registration;
- Data from these studies will also be used to strengthen the Company`s
pending U.K. and subsequent European applications;
- Hemosol plans to respond to questions from the U.K. Medicines Control
Agency (MCA) in the third quarter of 2002 and anticipates that the MCA
will complete its review by the end of 2002;
- Hemosol intends to follow the Mutual Recognition Procedure, which
could allow the Company to gain approval in other European countries
shortly after U.K. approval;
- The Company has submitted protocols to the FDA for a high-dose general
surgery study and a study in patients with chemotherapy-induced
anemia; active discussions regarding these trials are ongoing;
- A response from Health Canada on the Company`s New Drug Submission to
market Hemolink in Canada remains pending;
- The Company`s Meadowpine facility is proceeding on schedule.
Installation of process equipment is underway and expected to be
completed in the third quarter of 2002;
- Meadowpine is expected to be in production early in 2003, in time to
meet initial demand for Hemolink. Hemosol also plans to include the
300,000-unit Meadowpine facility in its U.S. BLA filing.
Conference Call Details
The Company will hold a conference call today at 4:30p.m. (Eastern time) to discuss its fourth quarter and year-end results. A live audio webcast of the conference call will be available through www.hemosol.com and www.financialdisclosure.ca. The call will also be archived on these sites for 30 days.
A replay of the conference call will also be available by telephone from approximately 6:30p.m. (Eastern time) on February 14, 2002 through February 21, 2002. To access the replay, dial, 416-695-5800 or 1-800-408-3053 and enter reservation number 1069532.
About Hemosol Inc.
Hemosol is a near-term, commercial-stage biopharmaceutical company focused initially on developing life-sustaining therapies for the treatment of acute anemia resulting from hemoglobin deficiencies. Hemosol has a broad range of products in development, including its flagship product Hemolink(TM) (hemoglobin raffimer), an oxygen therapeutic, that is designed to rapidly and safely improve oxygen delivery to the circulatory system. Hemolink(TM) is currently being evaluated in late-stage clinical trials. The Company also is developing additional oxygen therapeutics and a hemoglobin-based drug delivery platform to treat diseases such as hepatitis C and cancers of the liver, as well as a cell therapy initially directed to the treatment of cancer through its cell expansion and stem cell research activities.
For more information visit Hemosol`s website at www.hemosol.com.
Hemosol Inc.`s common shares are listed on The NASDAQ Stock Market under the trading symbol "HMSL" and on the Toronto Stock Exchange under the trading symbol "HML".
Hemolink(TM) is a registered trademark of Hemosol Inc.
Certain statements concerning Hemosol`s future prospects are "forward- looking statements" under the United States Private Securities Litigation Reform Act of 1995. There can be no assurances that future results will be achieved, and actual results could differ materially from forecasts and estimates. Important factors that could cause actual results to differ materially from forecasts and estimates include, but are not limited to: Hemosol`s ability to obtain regulatory approvals for its products; Hemosol`s ability to successfully complete clinical trials for its products; technical or manufacturing or distribution issues; the competitive environment for Hemosol`s products; the degree of market penetration of Hemosol`s products; and other factors set forth in filings with Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission. These risks and uncertainties, as well as others, are discussed in greater detail in the filings of Hemosol with Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission. Hemosol makes no commitment to revise or update any forward-looking statements in order to reflect events or circumstances after the date any such statement is made.
Financial Statements to Follow:
HEMOSOL INC.
CONSOLIDATED STATEMENT OF LOSS AND DEFICIT
Three Months Ending Twelve Months Ending
(THOUSANDS OF DOLLARS Dec. 31, Dec. 31, Dec. 31, Dec. 31,
EXCEPT SHARE DATA) 2001 2000 2001 2000
-------------------------------------------------------------------------
REVENUE
Research and development - - - -
-------------------------------------------------------------------------
EXPENSES
Research and development
Scientific and process 5,033 5,592 18,386 15,357
Regulatory and clinical 2,327 2,068 11,771 8,008
--------------------------------------------------- --------------------
Total research and development 7,360 7,660 30,157 23,365
Administration 1,485 678 6,731 3,864
Marketing & business
development 2,042 1,469 5,561 3,439
--------------------------------------------------- --------------------
TOTAL EXPENSES 10,887 9,807 42,449 30,668
--------------------------------------------------- --------------------
Loss from operations (10,887) (9,807) (42,449) (30,668)
Amortization of
deferred charges (360) - (360) -
Unrealised foreign
exchange gain (loss) (262) 29 970 29
Interest income 828 817 3,488 3,069
--------------------------------------------------- --------------------
Loss before income taxes (10,681) (8,961) (38,351) (27,570)
Provision for income taxes 67 27 226 27
--------------------------------------------------- --------------------
NET LOSS FOR THE YEAR (10,748) (8,988) (38,577) (27,597)
Deficit, beginning of period (173,110) (127,400) (136,388) (104,174)
Share issue cost - - (8,893) (4,617)
--------------------------------------------------- --------------------
DEFICIT, END OF PERIOD
(183,858) (136,388) (183,858) (136,388)
--------------------------------------------------- --------------------
Average number of shares 40,840,257 32,082,230 39,215,457 31,467,326
LOSS PER SHARE (0.26) (0.28) (0.98) (0.88)
--------------------------------------------------- --------------------
HEMOSOL INC.
CONSOLIDATED BALANCE SHEET
Twelve Months Period Ended
(THOUSANDS OF DOLLARS) December 31, 2001 December 31, 2000
-------------------------------------------------------------------------
ASSETS
CURRENT
Cash and cash equivalents 2,785 42,027
Short-term investments 67,052 -
Amounts receivable and other assets 3,156 1,967
Inventory and supplies 1,731 635
-------------------------------------------------------------------------
TOTAL CURRENT ASSETS 74,724 44,629
-------------------------------------------------------------------------
Capital assets, net 60,899 17,089
Patents and trademarks, net 1,964 1,020
Deferred charges, net 6,830 7,690
-------------------------------------------------------------------------
TOTAL OTHER ASSETS 69,693 25,799
-------------------------------------------------------------------------
TOTAL ASSETS 144,417 70,428
-------------------------------------------------------------------------
LIABILITIES AND SHAREHOLDERS` EQUITY
CURRENT
Accounts payable and accrued liabilities 13,605 5,358
-------------------------------------------------------------------------
TOTAL CURRENT LIABILITIES 13,605 5,358
-------------------------------------------------------------------------
SHAREHOLDERS` EQUITY
Share capital 306,135 192,923
Contributed surplus 8,535 8,535
Deficit (183,858) (136,388)
-------------------------------------------------------------------------
TOTAL SHAREHOLDERS` EQUITY 130,812 65,070
-------------------------------------------------------------------------
TOTAL LIABILITIES AND
SHAREHOLDERS` EQUITY 144,417 70,428
-------------------------------------------------------------------------
As at December 31, 2001, there were 40,993,861 issued and outstanding
common shares and 2,112,922 outstanding options to purchase common
shares.
HEMOSOL INC.
CONSOLIDATED STATEMENT OF CASH FLOWS
Three Months Twelve Months
Period Ended Period Ended
Dec 31, Dec 31, Dec 31, Dec 31,
(THOUSANDS OF DOLLARS) 2001 2000 2001 2000
-------------------------------------------------------------------------
OPERATING ACTIVITIES
Net loss for the period (10,748) (8,988) (38,577) (27,597)
Add items not requiring
an outlay of cash
Unrealized foreign exchange gain 814 - (42) -
Depreciation and amortization 1,217 649 2,737 1,672
Compensation cost for
non-employee stock option 134 - 134 -
-------------------------------------------------------------------------
(8,583) (8,339) (35,748) (25,925)
Net change in non-cash
working capital balances
related to operations (726) (1,213) (2,186) (3,536)
-------------------------------------------------------------------------
CASH USED IN OPERATING
ACTIVITIES (9,309) (9,552) (37,934) (29,461)
-------------------------------------------------------------------------
INVESTING ACTIVITIES
Short-term investments 1,348 - (67,052) -
Patent and trademark costs (449) (65) (568) (354)
Purchase of capital assets (16,168) (2,497) (38,415) (13,286)
-------------------------------------------------------------------------
CASH USED IN INVESTING
ACTIVITIES (15,269) (2,562) (106,035) (13,640)
-------------------------------------------------------------------------
FINANCING ACTIVITIES
Proceeds on issuance of
common shares 612 5,158 113,078 76,234
Proceeds on sale of
transferable option - - - 8,535
Deferred charges - (4,790) - (4,790)
Share issue costs - - (8,393) (4,617)
-------------------------------------------------------------------------
CASH PROVIDED BY
FINANCING ACTIVITIES 612 368 104,685 75,362
-------------------------------------------------------------------------
Effect of exchange
rate changes on cash
and cash equivalents (814) - 42 -
Net increase (decrease) in
cash and cash equivalent (23,966) (11,746) (39,284) 32,261
Cash and cash equivalents,
beginning of period 27,565 53,773 42,027 9,766
-------------------------------------------------------------------------
CASH AND CASH EQUIVALENTS,
END OF PERIOD 2,785 42,027 2,785 42,027
-------------------------------------------------------------------------
SOURCE Hemosol Inc.
CONTACT: Jason Hogan, Investor Relations, 416 361 1331, 800 789 3419, 416 815 0080 fax, ir@hemosol.com, www.hemosol.com; Shari Beagelman, Media Relations, 973 781 0200 ext. 20, 917 626 7071 mobile, sbeagelman@hemosol.com; Archived images on this organization are available through CNW E-Pix at http://www.newswire.ca. Images are free to members of The Canadian Press. To request a free copy of this organization`s annual report, please go to http://www.newswire.ca and click on reports@cnw.
Copyright © 2001, PR Newswire
Zahlen sind schneller da als ich dachte:
(habes sie direkt reingestellt ohne durchzulesen)
16:01 EST Thursday, February 14, 2002
TORONTO, Feb. 14 /PRNewswire-FirstCall/ - Hemosol Inc. (NASDAQ: HMSL, TSE: HML) today announced financial results for the fourth quarter and year ended December 31, 2001. The Company also reported on clinical development progress with its lead product, Hemolink(TM) (hemoglobin raffimer). Unless otherwise stated, all dollar values herein are Canadian dollars.
In the fourth quarter of 2001, Hemosol recorded a net loss of $10.7 million or ($0.26) per share, compared to a loss of $9.0 million or ($0.28) per share in the corresponding period of 2000. Net loss for the year ended December 31, 2001 was $38.6 million ($0.98) per share, compared to a loss of $27.6 million or ($0.88) per share for the year ended December 31, 2000.
"We successfully addressed some major challenges in 2001 and as a result have put the Company in a strong position moving forward," said John Kennedy, President and Chief Executive Officer of Hemosol. "Our team worked closely with regulatory agencies worldwide and responded quickly and strategically to re-charge our clinical and regulatory programs. Both of our redesigned CABG studies are moving forward, and should be completed by the middle of this year with results available shortly thereafter. Our strategy is on course to bring Hemolink to market around the world. In addition, our new manufacturing facility is on schedule and gives us an early competitive advantage with the capacity to meet potential market demand."
Financial Results
The Company`s operating expenses in the fourth quarter totalled $10.9 million, an 11% increase of $1.1 million over the corresponding period in 2000. Operating expenses for the twelve-month period reached $42.5 million, an increase of $11.8 million or 39% over 2000. Total spending was somewhat lower than expected due to lower than projected patient enrolment in the Company`s clinical trial program. Increases in both the quarter and the year are attributed to increased personnel and related costs, consulting costs associated with manufacturing expansion and the Company`s clinical/regulatory program, and increased expenditures in medical education and communication.
Interest income in the quarter totalled $828,000, bringing total interest income for the year to $3.5 million compared to $3 million in 2000.
Capital expenditures during the year reached $46.1 million. These expenditures were incurred to expand the capacity of the Company`s existing pilot facility and continue construction of the new 300,000 unit commercial facility. To date the Company has expended $53.9 million on this facility, which includes $7.7 million in accounts payable and accrued liabilities. As of December 31, 2001, Hemosol had not drawn down on either of its debt facilities and had capital assets in excess of $60 million.
As of December 31, 2001, Hemosol remains well financed with $69.8 million in cash and cash equivalents and short-term investments.
Hemosol expects operating expenses to increase as enrolment in the clinical trial program progresses. Depending on the level of patient treatment per month, expenses are expected to average approximately $5 million per month for the next six months. Operating expenses beyond this period will depend on a number of factors and guidance will be updated accordingly.
The Company is currently negotiating appropriate amendments to its existing $35 million senior credit facility as a result of last year`s revisions to the clinical program for Hemolink and the subsequent extension of time lines for regulatory approval. With the considerable progress in construction of the new facility, Hemosol also is assessing its options concerning the economics of its $12.5 million subordinated debt facility and has not yet determined whether it will use this facility. If the Company decides to use this facility it will be necessary to negotiate similar amendments to those of the senior debt. Hemosol will not draw down under either facility until arrangements are finalized.
Clinical, Regulatory and Manufacturing Progress Update
- In November 2001, Hemosol received FDA approval to begin a 180-patient
clinical trial of Hemolink in primary coronary artery bypass grafting
(CABG) surgery;
- In January 2002, Hemosol received FDA approval to proceed with a
second clinical trial of Hemolink in 140 patients undergoing "re-do"
CABG surgery;
- Both studies have similar designs and will run concurrently. The
primary study is now actively treating patients and the "re-do" trial
is now being activated at the clinical study sites;
- Upon completion of the two studies, the Company plans to review data
with the FDA and design and initiate a third study pivotal for U.S.
registration;
- Data from these studies will also be used to strengthen the Company`s
pending U.K. and subsequent European applications;
- Hemosol plans to respond to questions from the U.K. Medicines Control
Agency (MCA) in the third quarter of 2002 and anticipates that the MCA
will complete its review by the end of 2002;
- Hemosol intends to follow the Mutual Recognition Procedure, which
could allow the Company to gain approval in other European countries
shortly after U.K. approval;
- The Company has submitted protocols to the FDA for a high-dose general
surgery study and a study in patients with chemotherapy-induced
anemia; active discussions regarding these trials are ongoing;
- A response from Health Canada on the Company`s New Drug Submission to
market Hemolink in Canada remains pending;
- The Company`s Meadowpine facility is proceeding on schedule.
Installation of process equipment is underway and expected to be
completed in the third quarter of 2002;
- Meadowpine is expected to be in production early in 2003, in time to
meet initial demand for Hemolink. Hemosol also plans to include the
300,000-unit Meadowpine facility in its U.S. BLA filing.
Conference Call Details
The Company will hold a conference call today at 4:30p.m. (Eastern time) to discuss its fourth quarter and year-end results. A live audio webcast of the conference call will be available through www.hemosol.com and www.financialdisclosure.ca. The call will also be archived on these sites for 30 days.
A replay of the conference call will also be available by telephone from approximately 6:30p.m. (Eastern time) on February 14, 2002 through February 21, 2002. To access the replay, dial, 416-695-5800 or 1-800-408-3053 and enter reservation number 1069532.
About Hemosol Inc.
Hemosol is a near-term, commercial-stage biopharmaceutical company focused initially on developing life-sustaining therapies for the treatment of acute anemia resulting from hemoglobin deficiencies. Hemosol has a broad range of products in development, including its flagship product Hemolink(TM) (hemoglobin raffimer), an oxygen therapeutic, that is designed to rapidly and safely improve oxygen delivery to the circulatory system. Hemolink(TM) is currently being evaluated in late-stage clinical trials. The Company also is developing additional oxygen therapeutics and a hemoglobin-based drug delivery platform to treat diseases such as hepatitis C and cancers of the liver, as well as a cell therapy initially directed to the treatment of cancer through its cell expansion and stem cell research activities.
For more information visit Hemosol`s website at www.hemosol.com.
Hemosol Inc.`s common shares are listed on The NASDAQ Stock Market under the trading symbol "HMSL" and on the Toronto Stock Exchange under the trading symbol "HML".
Hemolink(TM) is a registered trademark of Hemosol Inc.
Certain statements concerning Hemosol`s future prospects are "forward- looking statements" under the United States Private Securities Litigation Reform Act of 1995. There can be no assurances that future results will be achieved, and actual results could differ materially from forecasts and estimates. Important factors that could cause actual results to differ materially from forecasts and estimates include, but are not limited to: Hemosol`s ability to obtain regulatory approvals for its products; Hemosol`s ability to successfully complete clinical trials for its products; technical or manufacturing or distribution issues; the competitive environment for Hemosol`s products; the degree of market penetration of Hemosol`s products; and other factors set forth in filings with Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission. These risks and uncertainties, as well as others, are discussed in greater detail in the filings of Hemosol with Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission. Hemosol makes no commitment to revise or update any forward-looking statements in order to reflect events or circumstances after the date any such statement is made.
Financial Statements to Follow:
HEMOSOL INC.
CONSOLIDATED STATEMENT OF LOSS AND DEFICIT
Three Months Ending Twelve Months Ending
(THOUSANDS OF DOLLARS Dec. 31, Dec. 31, Dec. 31, Dec. 31,
EXCEPT SHARE DATA) 2001 2000 2001 2000
-------------------------------------------------------------------------
REVENUE
Research and development - - - -
-------------------------------------------------------------------------
EXPENSES
Research and development
Scientific and process 5,033 5,592 18,386 15,357
Regulatory and clinical 2,327 2,068 11,771 8,008
--------------------------------------------------- --------------------
Total research and development 7,360 7,660 30,157 23,365
Administration 1,485 678 6,731 3,864
Marketing & business
development 2,042 1,469 5,561 3,439
--------------------------------------------------- --------------------
TOTAL EXPENSES 10,887 9,807 42,449 30,668
--------------------------------------------------- --------------------
Loss from operations (10,887) (9,807) (42,449) (30,668)
Amortization of
deferred charges (360) - (360) -
Unrealised foreign
exchange gain (loss) (262) 29 970 29
Interest income 828 817 3,488 3,069
--------------------------------------------------- --------------------
Loss before income taxes (10,681) (8,961) (38,351) (27,570)
Provision for income taxes 67 27 226 27
--------------------------------------------------- --------------------
NET LOSS FOR THE YEAR (10,748) (8,988) (38,577) (27,597)
Deficit, beginning of period (173,110) (127,400) (136,388) (104,174)
Share issue cost - - (8,893) (4,617)
--------------------------------------------------- --------------------
DEFICIT, END OF PERIOD
(183,858) (136,388) (183,858) (136,388)
--------------------------------------------------- --------------------
Average number of shares 40,840,257 32,082,230 39,215,457 31,467,326
LOSS PER SHARE (0.26) (0.28) (0.98) (0.88)
--------------------------------------------------- --------------------
HEMOSOL INC.
CONSOLIDATED BALANCE SHEET
Twelve Months Period Ended
(THOUSANDS OF DOLLARS) December 31, 2001 December 31, 2000
-------------------------------------------------------------------------
ASSETS
CURRENT
Cash and cash equivalents 2,785 42,027
Short-term investments 67,052 -
Amounts receivable and other assets 3,156 1,967
Inventory and supplies 1,731 635
-------------------------------------------------------------------------
TOTAL CURRENT ASSETS 74,724 44,629
-------------------------------------------------------------------------
Capital assets, net 60,899 17,089
Patents and trademarks, net 1,964 1,020
Deferred charges, net 6,830 7,690
-------------------------------------------------------------------------
TOTAL OTHER ASSETS 69,693 25,799
-------------------------------------------------------------------------
TOTAL ASSETS 144,417 70,428
-------------------------------------------------------------------------
LIABILITIES AND SHAREHOLDERS` EQUITY
CURRENT
Accounts payable and accrued liabilities 13,605 5,358
-------------------------------------------------------------------------
TOTAL CURRENT LIABILITIES 13,605 5,358
-------------------------------------------------------------------------
SHAREHOLDERS` EQUITY
Share capital 306,135 192,923
Contributed surplus 8,535 8,535
Deficit (183,858) (136,388)
-------------------------------------------------------------------------
TOTAL SHAREHOLDERS` EQUITY 130,812 65,070
-------------------------------------------------------------------------
TOTAL LIABILITIES AND
SHAREHOLDERS` EQUITY 144,417 70,428
-------------------------------------------------------------------------
As at December 31, 2001, there were 40,993,861 issued and outstanding
common shares and 2,112,922 outstanding options to purchase common
shares.
HEMOSOL INC.
CONSOLIDATED STATEMENT OF CASH FLOWS
Three Months Twelve Months
Period Ended Period Ended
Dec 31, Dec 31, Dec 31, Dec 31,
(THOUSANDS OF DOLLARS) 2001 2000 2001 2000
-------------------------------------------------------------------------
OPERATING ACTIVITIES
Net loss for the period (10,748) (8,988) (38,577) (27,597)
Add items not requiring
an outlay of cash
Unrealized foreign exchange gain 814 - (42) -
Depreciation and amortization 1,217 649 2,737 1,672
Compensation cost for
non-employee stock option 134 - 134 -
-------------------------------------------------------------------------
(8,583) (8,339) (35,748) (25,925)
Net change in non-cash
working capital balances
related to operations (726) (1,213) (2,186) (3,536)
-------------------------------------------------------------------------
CASH USED IN OPERATING
ACTIVITIES (9,309) (9,552) (37,934) (29,461)
-------------------------------------------------------------------------
INVESTING ACTIVITIES
Short-term investments 1,348 - (67,052) -
Patent and trademark costs (449) (65) (568) (354)
Purchase of capital assets (16,168) (2,497) (38,415) (13,286)
-------------------------------------------------------------------------
CASH USED IN INVESTING
ACTIVITIES (15,269) (2,562) (106,035) (13,640)
-------------------------------------------------------------------------
FINANCING ACTIVITIES
Proceeds on issuance of
common shares 612 5,158 113,078 76,234
Proceeds on sale of
transferable option - - - 8,535
Deferred charges - (4,790) - (4,790)
Share issue costs - - (8,393) (4,617)
-------------------------------------------------------------------------
CASH PROVIDED BY
FINANCING ACTIVITIES 612 368 104,685 75,362
-------------------------------------------------------------------------
Effect of exchange
rate changes on cash
and cash equivalents (814) - 42 -
Net increase (decrease) in
cash and cash equivalent (23,966) (11,746) (39,284) 32,261
Cash and cash equivalents,
beginning of period 27,565 53,773 42,027 9,766
-------------------------------------------------------------------------
CASH AND CASH EQUIVALENTS,
END OF PERIOD 2,785 42,027 2,785 42,027
-------------------------------------------------------------------------
SOURCE Hemosol Inc.
CONTACT: Jason Hogan, Investor Relations, 416 361 1331, 800 789 3419, 416 815 0080 fax, ir@hemosol.com, www.hemosol.com; Shari Beagelman, Media Relations, 973 781 0200 ext. 20, 917 626 7071 mobile, sbeagelman@hemosol.com; Archived images on this organization are available through CNW E-Pix at http://www.newswire.ca. Images are free to members of The Canadian Press. To request a free copy of this organization`s annual report, please go to http://www.newswire.ca and click on reports@cnw.
Copyright © 2001, PR Newswire
oh diese Amis!
Die Ablehnung durch HC bedueted für mich das entgültige aus für HML.
für heute würde ich sagen GUTE NACHT
jetzt moment mal...
Hemosol war doch schon immer eine long Anlage... und VIEL ändert sich doch nach so einer Absage auch nicht...
Ausserdem, die Entscheidung in England liegt noch aus und auch von den anderen(US,Europa).
Aber schön dass man jetzt endlich zu wirklich resonablen Preisen einkaufen kann... :-)))))
Also, hier ist noch lang nicht alle Tage Abend...
...oder doch?
Hemosol war doch schon immer eine long Anlage... und VIEL ändert sich doch nach so einer Absage auch nicht...
Ausserdem, die Entscheidung in England liegt noch aus und auch von den anderen(US,Europa).
Aber schön dass man jetzt endlich zu wirklich resonablen Preisen einkaufen kann... :-)))))
Also, hier ist noch lang nicht alle Tage Abend...
...oder doch?
Was soll die Panikmache?
Ein geringfügig höherer Verlust in 2001 im Vergleich zu 2000.Dies hängt doch wohl mit den klinischen Tests zusammen, die für die nächsten 9 Monate weitergehen können. Eine Absage von HC kann ich aus der adhoc nicht herauslesen, nur das eine Antwort noch aussteht. Kapital ist noch genug da bis zum Ende der Testreihe und danach sehen wir weiter. Der Bedarf an Plasma ist nach wie vor vohanden, also ist das Produkt noch gut im Rennen.
Ich bleibe jedenfalls drin so wie die Kapfront als long term investment.
Bangbüxen.
Ein geringfügig höherer Verlust in 2001 im Vergleich zu 2000.Dies hängt doch wohl mit den klinischen Tests zusammen, die für die nächsten 9 Monate weitergehen können. Eine Absage von HC kann ich aus der adhoc nicht herauslesen, nur das eine Antwort noch aussteht. Kapital ist noch genug da bis zum Ende der Testreihe und danach sehen wir weiter. Der Bedarf an Plasma ist nach wie vor vohanden, also ist das Produkt noch gut im Rennen.
Ich bleibe jedenfalls drin so wie die Kapfront als long term investment.
Bangbüxen.
@ all,
so wird´s bald ausschauen. Leider heute nur ein "systemfehler", habe die Info bei Lycos gefunden.
p.s. schaut euch unter meinenm Link Posting #69 von CoolMax 14.02.02 22:00:55 Beitrag Nr.: 5.593.251
den Komentar der Analysten an, da wird immer noch "stron buy" Kursziel 10$ angepreisen
CoolMax
Suchergebnisse hemosol Ergebnisse 1-8
Land Name Börse WKN
Börse - + Kurs Diff. Diff. % Vol. Kurszeit
CAN HEMOSOL INC TOR 43,40 +39,20 +933,33% 2,99 Mio. 16:53
USA HEMOSOL INC (Q) NAS 2,729 $ +0,059 +2,21% 67.057,75 16:46
GER HEMOSOL INC. FSE 886290 3,20 € +0,20 +6,67% 38.915,90 16:49
GER HEMOSOL INC. STU 886290 3,30 € +0,35 +11,86% 1.320,00 15:29
GER HEMOSOL INC. MUN 886290 3,00 € +0,15 +5,26% 450,00 09:26
GER HEMOSOL INC. DUS 886290 2,90 € G -1,25 -30,12% - 09:23
GER HEMOSOL INC. ETR 886290 5,00 € +0,00 +0,00% 5,00 13:41
GER HEMOSOL INC. BER 886290 3,30 € +0,60 +22,22% 9.004,00 15:44
so wird´s bald ausschauen. Leider heute nur ein "systemfehler", habe die Info bei Lycos gefunden.
p.s. schaut euch unter meinenm Link Posting #69 von CoolMax 14.02.02 22:00:55 Beitrag Nr.: 5.593.251
den Komentar der Analysten an, da wird immer noch "stron buy" Kursziel 10$ angepreisen
CoolMax
Suchergebnisse hemosol Ergebnisse 1-8
Land Name Börse WKN
Börse - + Kurs Diff. Diff. % Vol. Kurszeit
CAN HEMOSOL INC TOR 43,40 +39,20 +933,33% 2,99 Mio. 16:53
USA HEMOSOL INC (Q) NAS 2,729 $ +0,059 +2,21% 67.057,75 16:46
GER HEMOSOL INC. FSE 886290 3,20 € +0,20 +6,67% 38.915,90 16:49
GER HEMOSOL INC. STU 886290 3,30 € +0,35 +11,86% 1.320,00 15:29
GER HEMOSOL INC. MUN 886290 3,00 € +0,15 +5,26% 450,00 09:26
GER HEMOSOL INC. DUS 886290 2,90 € G -1,25 -30,12% - 09:23
GER HEMOSOL INC. ETR 886290 5,00 € +0,00 +0,00% 5,00 13:41
GER HEMOSOL INC. BER 886290 3,30 € +0,60 +22,22% 9.004,00 15:44
schon wieder vom handel ausgesetzt.
@deti01
Wie was warum wer????????
CoolMax
Wie was warum wer????????
CoolMax
@all
kann ich auch nur bestätigen... Aktie wird andauernd vom Handel ausgesetzt...
will die ganze Zeit kaufen und... NIX GEHT!!!
wenn jemand den Grund weiss, bitte posten...
Good Trades
dkF
kann ich auch nur bestätigen... Aktie wird andauernd vom Handel ausgesetzt...
will die ganze Zeit kaufen und... NIX GEHT!!!
wenn jemand den Grund weiss, bitte posten...
Good Trades
dkF
Hallo, zusammen,
könnte das der Grund sein, und müsste der Kurs dann jetzt nicht steigen?
Hemosol Receives Clearance from U.S. FDA to Begin Study of HEMOLINK as a Treatment for Chemotherapy-Induced Anemia
TORONTO, ON, March 26, 2002 - Hemosol Inc. (NASDAQ: HMSL, TSE: HML) today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) to begin a Phase II clinical trial of its flagship product, Hemolinkª [hemoglobin raffimer], as a treatment for chemotherapy-induced anemia.
The single-blind, dose-comparison study will evaluate the safety and tolerability of a short course of HEMOLINK in 50 patients with lung or ovarian cancer who are being treated with erythropoietin for chemotherapy-induced anemia. The multi-centre study will be led by investigators at Duke University and is expected to begin enrolling patients in June of 2002.
"The market opportunity created by chemotherapy-induced anemia is substantial," said John W. Kennedy, President and Chief Executive Officer of Hemosol. "This study aims to validate our belief in the broad clinical potential of HEMOLINK beyond surgical anemia. It represents the first stage of a clinical development program to establish HEMOLINK`s safety and efficacy in another indication, while adding to a growing body of evidence that supports the potential merits of HEMOLINK."
The primary objective of the study is to examine the safety and tolerability of two doses of HEMOLINK compared to a placebo in patients receiving erythropoietin therapy. In addition, the study will explore the effects of HEMOLINK on a number of parameters which measure erythropoietic effect to identify if HEMOLINK can potentiate the effect of the current treatment for chemotherapy-induced anemia.
"Although erythropoietin is currently the standard therapy for these patients, there are limitations to its use as it may take up to two weeks to effectively resolve the anemia and a significant number never adequately respond," said Michael Shannon MD, Vice President, Medical Sciences of Hemosol. "This trial will begin to assess if the addition of HEMOLINK to this therapy may allow more patients to feel better and recover faster."
Hemosol currently has two additional clinical trials underway with HEMOLINK in primary and "re-do" coronary artery bypass grafting (CABG) surgery. Designed to meet U.K. and U.S. regulatory requirements, the trials remain on schedule to be completed in the second quarter of 2002. Results are expected to be available and reported in the third quarter of 2002.
About Chemotherapy-induced Anemia
Chemotherapy treatment can result in acute hemoglobin deficiencies since it suppresses the body`s ability to replenish red blood cells. It has been estimated that over 60 percent of all cancer patients experience some chemotherapy-induced anemia at some point during their therapy. The consequences of this include fatigue, weakness and drowsiness, all of which can significantly reduce the patient`s feeling of physical well being. Many patients suffering from chemotherapy-induced anemia receive erythropoietin as a treatment for their symptoms; however, approximately 30-40% either do not respond or respond in a less than optimal fashion. The Company hopes to demonstrate that the combination of HEMOLINK and erythropoietin is a superior therapy for a greater number of patients than erythropoietin alone.
Each year in the U.S., over 40 percent of the 187,000 patients diagnosed with lung and ovarian cancer require RBC transfusion because of chemotherapy-induced anemia. In addition, a significant percentage of the 275,000 patients diagnosed with other cancers (including breast cancer, lymphoma and leukemia) experience chemotherapy-induced anemia. The potential market for HEMOLINK, which is anticipated to make these patients feel better earlier, recover faster, and better able to tolerate cancer treatment, is therefore sizable.
Grüße!
könnte das der Grund sein, und müsste der Kurs dann jetzt nicht steigen?
Hemosol Receives Clearance from U.S. FDA to Begin Study of HEMOLINK as a Treatment for Chemotherapy-Induced Anemia
TORONTO, ON, March 26, 2002 - Hemosol Inc. (NASDAQ: HMSL, TSE: HML) today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) to begin a Phase II clinical trial of its flagship product, Hemolinkª [hemoglobin raffimer], as a treatment for chemotherapy-induced anemia.
The single-blind, dose-comparison study will evaluate the safety and tolerability of a short course of HEMOLINK in 50 patients with lung or ovarian cancer who are being treated with erythropoietin for chemotherapy-induced anemia. The multi-centre study will be led by investigators at Duke University and is expected to begin enrolling patients in June of 2002.
"The market opportunity created by chemotherapy-induced anemia is substantial," said John W. Kennedy, President and Chief Executive Officer of Hemosol. "This study aims to validate our belief in the broad clinical potential of HEMOLINK beyond surgical anemia. It represents the first stage of a clinical development program to establish HEMOLINK`s safety and efficacy in another indication, while adding to a growing body of evidence that supports the potential merits of HEMOLINK."
The primary objective of the study is to examine the safety and tolerability of two doses of HEMOLINK compared to a placebo in patients receiving erythropoietin therapy. In addition, the study will explore the effects of HEMOLINK on a number of parameters which measure erythropoietic effect to identify if HEMOLINK can potentiate the effect of the current treatment for chemotherapy-induced anemia.
"Although erythropoietin is currently the standard therapy for these patients, there are limitations to its use as it may take up to two weeks to effectively resolve the anemia and a significant number never adequately respond," said Michael Shannon MD, Vice President, Medical Sciences of Hemosol. "This trial will begin to assess if the addition of HEMOLINK to this therapy may allow more patients to feel better and recover faster."
Hemosol currently has two additional clinical trials underway with HEMOLINK in primary and "re-do" coronary artery bypass grafting (CABG) surgery. Designed to meet U.K. and U.S. regulatory requirements, the trials remain on schedule to be completed in the second quarter of 2002. Results are expected to be available and reported in the third quarter of 2002.
About Chemotherapy-induced Anemia
Chemotherapy treatment can result in acute hemoglobin deficiencies since it suppresses the body`s ability to replenish red blood cells. It has been estimated that over 60 percent of all cancer patients experience some chemotherapy-induced anemia at some point during their therapy. The consequences of this include fatigue, weakness and drowsiness, all of which can significantly reduce the patient`s feeling of physical well being. Many patients suffering from chemotherapy-induced anemia receive erythropoietin as a treatment for their symptoms; however, approximately 30-40% either do not respond or respond in a less than optimal fashion. The Company hopes to demonstrate that the combination of HEMOLINK and erythropoietin is a superior therapy for a greater number of patients than erythropoietin alone.
Each year in the U.S., over 40 percent of the 187,000 patients diagnosed with lung and ovarian cancer require RBC transfusion because of chemotherapy-induced anemia. In addition, a significant percentage of the 275,000 patients diagnosed with other cancers (including breast cancer, lymphoma and leukemia) experience chemotherapy-induced anemia. The potential market for HEMOLINK, which is anticipated to make these patients feel better earlier, recover faster, and better able to tolerate cancer treatment, is therefore sizable.
Grüße!
wenn nachbörslich - oder auch vorbörslich in toronto ask / bid auf null gesetzt ist, wurde hemosol vom handel ausgesetzt.dann kannet du auch hier in deutschland keine order herausgeben. wenn es telefonisch gemacht wird , bekommst du es bestätigt. ich würde sagen hemosol sammelt wieder geld ein, alles sieht nach einer kapitalerhöhung aus zu 4,5 dollar . da kann der kurs ja nich steigen.
Hallo zusammen,
Grund ist eine Kapitalerhöhung durch Ausgabe neuer Aktien zu $ 4,50. Damit dürfte die Finanzierung gesichert sein bis die Zulassung von Hemolink erfolgt. (hoffentlich !)
Grund ist eine Kapitalerhöhung durch Ausgabe neuer Aktien zu $ 4,50. Damit dürfte die Finanzierung gesichert sein bis die Zulassung von Hemolink erfolgt. (hoffentlich !)
seit 3 jahren schaue ich mir das spielchen mit hemosol schon an, warte auf eine pos.hammermeldung. doch kommt der kurs mal empor, giebt es kapitalerhöhungen. dieses beobachte ich schon seit 3 jahren. doch eine produkteinführung ist mangelware,immer wieder vertröstungen auf später. phase 3 war doch in can und GB positiv durch. jetzt wird auf einmal alles nur noch in den USA dingfest gemacht. sie könnten doch hemolink für can und GB produzieren, haben doch grössere produktionsstätten gebaut, doch lieber werden kapitalerh. durchgeführt. und so kann der kurs ja schlecht steigen.
seit 3 jahren schaue ich mir das spielchen mit hemosol schon an, warte auf eine pos.hammermeldung. doch kommt der kurs mal empor, giebt es kapitalerhöhungen. dieses beobachte ich schon seit 3 jahren. doch eine produkteinführung ist mangelware,immer wieder vertröstungen auf später. phase 3 war doch in can und GB positiv durch. jetzt wird auf einmal alles nur noch in den USA dingfest gemacht. sie könnten doch hemolink für can und GB produzieren, haben doch grössere produktionsstätten gebaut, doch lieber werden kapitalerh. durchgeführt. und so kann der kurs ja schlecht steigen.
seit 3 jahren schaue ich mir das spielchen mit hemosol schon an, warte auf eine pos.hammermeldung. doch kommt der kurs mal empor, giebt es kapitalerhöhungen. dieses beobachte ich schon seit 3 jahren. doch eine produkteinführung ist mangelware,immer wieder vertröstungen auf später. phase 3 war doch in can und GB positiv durch. jetzt wird auf einmal alles nur noch in den USA dingfest gemacht. sie könnten doch hemolink für can und GB produzieren, haben doch grössere produktionsstätten gebaut, doch lieber werden kapitalerh. durchgeführt. und so kann der kurs ja schlecht steigen.
seit 3 jahren schaue ich mir das spielchen mit hemosol schon an, warte auf eine pos.hammermeldung. doch kommt der kurs mal empor, giebt es kapitalerhöhungen. dieses beobachte ich schon seit 3 jahren. doch eine produkteinführung ist mangelware,immer wieder vertröstungen auf später. phase 3 war doch in can und GB positiv durch. jetzt wird auf einmal alles nur noch in den USA dingfest gemacht. sie könnten doch hemolink für can und GB produzieren, haben doch grössere produktionsstätten gebaut, doch lieber werden kapitalerh. durchgeführt. und so kann der kurs ja schlecht steigen.
seit 3 jahren schaue ich mir das spielchen mit hemosol schon an, warte auf eine pos.hammermeldung. doch kommt der kurs mal empor, giebt es kapitalerhöhungen. dieses beobachte ich schon seit 3 jahren. doch eine produkteinführung ist mangelware,immer wieder vertröstungen auf später. phase 3 war doch in can und GB positiv durch. jetzt wird auf einmal alles nur noch in den USA dingfest gemacht. sie könnten doch hemolink für can und GB produzieren, haben doch grössere produktionsstätten gebaut, doch lieber werden kapitalerh. durchgeführt. und so kann der kurs ja schlecht steigen.
seit 3 jahren schaue ich mir das spielchen mit hemosol schon an, warte auf eine pos.hammermeldung. doch kommt der kurs mal empor, giebt es kapitalerhöhungen. dieses beobachte ich schon seit 3 jahren. doch eine produkteinführung ist mangelware,immer wieder vertröstungen auf später. phase 3 war doch in can und GB positiv durch. jetzt wird auf einmal alles nur noch in den USA dingfest gemacht. sie könnten doch hemolink für can und GB produzieren, haben doch grössere produktionsstätten gebaut, doch lieber werden kapitalerh. durchgeführt. und so kann der kurs ja schlecht steigen.
seit 3 jahren schaue ich mir das spie
lchen mit hemosol schon an, warte auf eine pos.hammermeldung. doch kommt der kurs mal empor, giebt es kapitalerhöhungen. dieses beobachte ich schon seit 3 jahren. doch eine produkteinführung ist mangelware,immer wieder vertröstungen auf später. phase 3 war doch in can und GB positiv durch. jetzt wird auf einmal alles nur noch in den USA dingfest gemacht. sie könnten doch hemolink für can und GB produzieren, haben doch grössere produktionsstätten gebaut, doch lieber werden kapitalerh. durchgeführt. und so kann der kurs ja schlecht steigen.
lchen mit hemosol schon an, warte auf eine pos.hammermeldung. doch kommt der kurs mal empor, giebt es kapitalerhöhungen. dieses beobachte ich schon seit 3 jahren. doch eine produkteinführung ist mangelware,immer wieder vertröstungen auf später. phase 3 war doch in can und GB positiv durch. jetzt wird auf einmal alles nur noch in den USA dingfest gemacht. sie könnten doch hemolink für can und GB produzieren, haben doch grössere produktionsstätten gebaut, doch lieber werden kapitalerh. durchgeführt. und so kann der kurs ja schlecht steigen.
sorry : war länger in der warteschleife und habe ein paar mal nachgeknipst .
seit ein paar tagen kann ich den kurs in toronto nicht mehr sehen.
über die neue seite von hemosol.com eingabe " HML" unter
stock Quote bleibe ich hängen. ist jemand weiter oder ist die seite
noch nicht bereit. danke .
über die neue seite von hemosol.com eingabe " HML" unter
stock Quote bleibe ich hängen. ist jemand weiter oder ist die seite
noch nicht bereit. danke .
Hemosol Announces First Quarter 2002 Financial Results
TORONTO, ON, April 25, 2002 – Hemosol Inc. (NASDAQ: HMSL, TSE: HML, HML.WT) today announced financial results for the first quarter ended March 31, 2002. Unless otherwise stated, all dollar amounts presented herein are Canadian dollars.
For the first quarter ended March 31, 2002, the Company recorded a net loss of $11.7 million or $(0.29) per share compared to a loss of $6.9 million or $(0.20) per share in the corresponding prior year quarter. The prior year’s quarterly loss included an unrealized foreign exchange gain of $2.5 million or $0.07 per share.
“Throughout the first quarter, we made significant progress in our clinical development and manufacturing programs as we continue toward HEMOLINKTM [hemoglobin raffimer] registrations,” said John W. Kennedy, President and Chief Executive Officer of Hemosol. “Results from our ongoing clinical program are expected to strengthen the efficacy and safety database for HEMOLINK. These accomplishments put us in a sound position to respond to the U.K. regulatory authorities later this year, paving the way for them to complete their review of our application by the end of 2002.”
Recent Highlights and Achievements
· The U.S. Food and Drug Administration (FDA) cleared Hemosol to conduct a clinical trial of HEMOLINK in “re-do” coronary artery bypass grafting (CABG) surgery. The Company is running this trial parallel to a very similar study in primary CABG patients that received FDA clearance last November and is currently enrolling patients.
· Subsequent to the end of the quarter, Health Canada cleared Hemosol to add Canadian sites to both ongoing CABG trials.
· The FDA cleared Hemosol to conduct a Phase II clinical trial of HEMOLINK as a treatment for chemotherapy-induced anemia, which could substantially expand the market opportunity beyond surgical anemia. The multi-centre study will be led by investigators at Duke University and is expected to begin enrolling patients in June of 2002.
· Hemosol raised over $22 million to fund ongoing clinical trials and for general working capital purposes.
· The Company entered into an agreement amending its $35 million senior credit facility and plans to begin drawing down funds in May of 2002. The 300,000-unit HEMOLINK production facility is on schedule for completion by the end of the third quarter of 2002 with validation early in 2003.
Financial Results
The Company’s operating expenses in the first quarter totalled $11.6 million, an increase of $1.5 million or 14.6% over the corresponding quarter of the prior year. This increase resulted primarily from costs incurred for medical education events held in conjunction with international conferences and increased market development expenses to correctly position HEMOLINK and to increase the product`s profile within the medical community. In the near-term, the Company believes these expenditures will also enhance patient enrolment into its ongoing clinical trials. The Company also realized significant increases in support services associated with the Company`s move to its new facility and increased costs in logistics, security and IT. Hemosol expects operating expenses to increase significantly over the next six months as enrolment in the ongoing clinical trials accelerate and it continues to advance its manufacturing program. While monthly spending will vary depending on the level of patients treated, the Company expects its expenses will average approximately $5 million per month.
Interest income in the quarter totalled $218,000, down from the $717,000 in the previous year`s first quarter as a result of lower cash and cash-equivalent balances and lower interest rates.
Capital expenditures during the quarter reached approximately $7.6 million, of which $7.2 million related to the new facility, bringing total expenditures to-date on this facility to $63.8 million.
As of March 31, 2002, Hemosol remains well financed with $45.8 million in cash and cash-equivalents and short-term investments excluding the funds raised in the subsequent April financing.
Conference Call Information The Company will host a conference call today at 8:30 a.m. EST. A live audio webcast of the conference call will be available through www.hemosol.com. Please connect to this website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be needed to hear the webcast. A replay of the webcast will be available for 30 days starting on April 26th, at www.hemosol.com and www.financialdisclosure.ca.
A telephone replay of the conference call will also be available from approximately 12:30 p.m. EST on April 25 through May 2, 2002. To access the replay, dial, 416-695-5800 or 1-800-408-3053 and enter reservation number 1132229.
Annual and Special Meeting Hemosol will hold its Annual and Special Meeting of Shareholders on Thursday, May 2, 2002 at 10:00 a.m. EST at the Toronto Stock Exchange Auditorium, 2 First Canadian Place, 130 King Street West, Toronto, Ontario.
About Hemosol Inc. Hemosol is a near-term, commercial-stage biopharmaceutical company focused initially on developing life-sustaining therapies for the treatment of acute anemia resulting from hemoglobin deficiencies. Hemosol has a broad range of products in development, including its flagship product HEMOLINK™ [hemoglobin raffimer], an oxygen therapeutic, that is designed to rapidly and safely improve oxygen delivery to the circulatory system. HEMOLINK is currently being evaluated in late-stage clinical trials. The Company also is developing additional oxygen therapeutics and a hemoglobin-based drug delivery platform to treat diseases such as hepatitis C and cancers of the liver, as well as a cell therapy initially directed to the treatment of cancer through its cell expansion and stem cell research activities.
TORONTO, ON, April 25, 2002 – Hemosol Inc. (NASDAQ: HMSL, TSE: HML, HML.WT) today announced financial results for the first quarter ended March 31, 2002. Unless otherwise stated, all dollar amounts presented herein are Canadian dollars.
For the first quarter ended March 31, 2002, the Company recorded a net loss of $11.7 million or $(0.29) per share compared to a loss of $6.9 million or $(0.20) per share in the corresponding prior year quarter. The prior year’s quarterly loss included an unrealized foreign exchange gain of $2.5 million or $0.07 per share.
“Throughout the first quarter, we made significant progress in our clinical development and manufacturing programs as we continue toward HEMOLINKTM [hemoglobin raffimer] registrations,” said John W. Kennedy, President and Chief Executive Officer of Hemosol. “Results from our ongoing clinical program are expected to strengthen the efficacy and safety database for HEMOLINK. These accomplishments put us in a sound position to respond to the U.K. regulatory authorities later this year, paving the way for them to complete their review of our application by the end of 2002.”
Recent Highlights and Achievements
· The U.S. Food and Drug Administration (FDA) cleared Hemosol to conduct a clinical trial of HEMOLINK in “re-do” coronary artery bypass grafting (CABG) surgery. The Company is running this trial parallel to a very similar study in primary CABG patients that received FDA clearance last November and is currently enrolling patients.
· Subsequent to the end of the quarter, Health Canada cleared Hemosol to add Canadian sites to both ongoing CABG trials.
· The FDA cleared Hemosol to conduct a Phase II clinical trial of HEMOLINK as a treatment for chemotherapy-induced anemia, which could substantially expand the market opportunity beyond surgical anemia. The multi-centre study will be led by investigators at Duke University and is expected to begin enrolling patients in June of 2002.
· Hemosol raised over $22 million to fund ongoing clinical trials and for general working capital purposes.
· The Company entered into an agreement amending its $35 million senior credit facility and plans to begin drawing down funds in May of 2002. The 300,000-unit HEMOLINK production facility is on schedule for completion by the end of the third quarter of 2002 with validation early in 2003.
Financial Results
The Company’s operating expenses in the first quarter totalled $11.6 million, an increase of $1.5 million or 14.6% over the corresponding quarter of the prior year. This increase resulted primarily from costs incurred for medical education events held in conjunction with international conferences and increased market development expenses to correctly position HEMOLINK and to increase the product`s profile within the medical community. In the near-term, the Company believes these expenditures will also enhance patient enrolment into its ongoing clinical trials. The Company also realized significant increases in support services associated with the Company`s move to its new facility and increased costs in logistics, security and IT. Hemosol expects operating expenses to increase significantly over the next six months as enrolment in the ongoing clinical trials accelerate and it continues to advance its manufacturing program. While monthly spending will vary depending on the level of patients treated, the Company expects its expenses will average approximately $5 million per month.
Interest income in the quarter totalled $218,000, down from the $717,000 in the previous year`s first quarter as a result of lower cash and cash-equivalent balances and lower interest rates.
Capital expenditures during the quarter reached approximately $7.6 million, of which $7.2 million related to the new facility, bringing total expenditures to-date on this facility to $63.8 million.
As of March 31, 2002, Hemosol remains well financed with $45.8 million in cash and cash-equivalents and short-term investments excluding the funds raised in the subsequent April financing.
Conference Call Information The Company will host a conference call today at 8:30 a.m. EST. A live audio webcast of the conference call will be available through www.hemosol.com. Please connect to this website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be needed to hear the webcast. A replay of the webcast will be available for 30 days starting on April 26th, at www.hemosol.com and www.financialdisclosure.ca.
A telephone replay of the conference call will also be available from approximately 12:30 p.m. EST on April 25 through May 2, 2002. To access the replay, dial, 416-695-5800 or 1-800-408-3053 and enter reservation number 1132229.
Annual and Special Meeting Hemosol will hold its Annual and Special Meeting of Shareholders on Thursday, May 2, 2002 at 10:00 a.m. EST at the Toronto Stock Exchange Auditorium, 2 First Canadian Place, 130 King Street West, Toronto, Ontario.
About Hemosol Inc. Hemosol is a near-term, commercial-stage biopharmaceutical company focused initially on developing life-sustaining therapies for the treatment of acute anemia resulting from hemoglobin deficiencies. Hemosol has a broad range of products in development, including its flagship product HEMOLINK™ [hemoglobin raffimer], an oxygen therapeutic, that is designed to rapidly and safely improve oxygen delivery to the circulatory system. HEMOLINK is currently being evaluated in late-stage clinical trials. The Company also is developing additional oxygen therapeutics and a hemoglobin-based drug delivery platform to treat diseases such as hepatitis C and cancers of the liver, as well as a cell therapy initially directed to the treatment of cancer through its cell expansion and stem cell research activities.
Fortsetzung:
For more information visit Hemosol’s website at www.hemosol.com.
Hemosol Inc.’s common shares are listed on The NASDAQ Stock Market under the trading symbol “HMSL” and on the Toronto Stock Exchange under the trading symbol “HML”.
HEMOLINK is a registered trademark of Hemosol Inc.
Certain statements concerning Hemosol’s future prospects are “forward-looking statements” under the United States Private Securities Litigation Reform Act of 1995. There can be no assurances that future results will be achieved, and actual results could differ materially from forecasts and estimates. Important factors that could cause actual results to differ materially from forecasts and estimates include, but are not limited to: Hemosol’s ability to obtain regulatory approvals for its products; Hemosol’s ability to successfully complete clinical trials for its products; technical or manufacturing or distribution issues; the competitive environment for Hemosol’s products; the degree of market penetration of Hemosol’s products; and other factors set forth in filings with Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission. These risks and uncertainties, as well as others, are discussed in greater detail in the filings of Hemosol with Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission. Hemosol makes no commitment to revise or update any forward-looking statements in order to reflect events or circumstances after the date any such statement is made.
For more information visit Hemosol’s website at www.hemosol.com.
Hemosol Inc.’s common shares are listed on The NASDAQ Stock Market under the trading symbol “HMSL” and on the Toronto Stock Exchange under the trading symbol “HML”.
HEMOLINK is a registered trademark of Hemosol Inc.
Certain statements concerning Hemosol’s future prospects are “forward-looking statements” under the United States Private Securities Litigation Reform Act of 1995. There can be no assurances that future results will be achieved, and actual results could differ materially from forecasts and estimates. Important factors that could cause actual results to differ materially from forecasts and estimates include, but are not limited to: Hemosol’s ability to obtain regulatory approvals for its products; Hemosol’s ability to successfully complete clinical trials for its products; technical or manufacturing or distribution issues; the competitive environment for Hemosol’s products; the degree of market penetration of Hemosol’s products; and other factors set forth in filings with Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission. These risks and uncertainties, as well as others, are discussed in greater detail in the filings of Hemosol with Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission. Hemosol makes no commitment to revise or update any forward-looking statements in order to reflect events or circumstances after the date any such statement is made.
http://www.corporateinformation.com/cacorp.html
SCHAUT EUCH DIESE SEITE MAL AN UNTER LOAD PROFILE FINDET IHR HEMOSOL MIT ANALYSEN
DANN NOCH EINE SUPER SUCHMASCHINE
http://www.teoma.com
GRUSS
BIG CHARLY
FREUEN WIR UNS AUF JULI_AUGUST DER ZULASSUNG
SCHAUT EUCH DIESE SEITE MAL AN UNTER LOAD PROFILE FINDET IHR HEMOSOL MIT ANALYSEN
DANN NOCH EINE SUPER SUCHMASCHINE
http://www.teoma.com
GRUSS
BIG CHARLY
FREUEN WIR UNS AUF JULI_AUGUST DER ZULASSUNG
Gibt es irgendeinen Grund für die Kursschwankungen gestern/heute???
bei den umsätzen -war doch nichts
down under
Friday June 7, 10:59 am Eastern Time
Reuters Company News
Hemosol says Hemolink trials delayed, stock crashes
(Adds share details paragraphs 2, 11, analyst comment in paragraph 4, details)
By Rajiv Sekhri
TORONTO, June 7 (Reuters) - Hemosol Inc. (Toronto:HML.TO - News; NasdaqNM:HMSL - News) said on Friday two ongoing trials of its Hemolink blood replacement product would be delayed, and added it would cut staff and costs to save at least C$1.5 million ($980,000) in the second quarter.
ADVERTISEMENT
The Canadian biotech firm`s shares fell 38 percent on the Nasdaq and touched 30-month lows on the Toronto Stock Exchange as investors feared the worst for the much-touted trials of Hemolink, an oxygen therapeutic product designed to take the place of donor blood for patients undergoing surgery.
Hemosol said results from one trail would not be available in the third quarter as planned. Results from a second trial are expected in the fourth quarter. The company blamed "administrative complexities" for the delay.
"Delays are common in clinical trial work but certainly not positive. It is a disappointment, but not overwhelming," said Doug Janson, managing director of Sprott Securities` health sciences research.
Janson, whose firm led a C$22 million financing for Hemosol in April, said he rates the company a buy and has a 12-month price target of C$12 a share.
HEMOSOL TO CUT COSTS
Hemosol, which reported a first-quarter loss of C$11.7 million, said it planned to cut operating expenses to C$3 million a month from C$5 million once all its cost-saving measures are in place.
Hemosol said it has decided not to draw down its credit facility until it reports the results of the trials.
"The trials are expected to support both our pending application to commercialize Hemolink in the U.K. and the planned phase III trials in the U.S.," said John Kennedy, president and chief executive.
A company spokesman said Hemosol will delay the opening of its Toronto-based Meadowpine production facility.
He said Hemosol will finish building the C$25 million plant but will delay final approval from health inspectors to cut costs. Inspector approval can take three to six months.
The company`s shares were down C$1.32, or 36 percent, at C$2.38 on the Toronto Stock Exchange on Friday morning. They fell 89 cents on the Nasdaq, or nearly 37 percent, to $1.53.
($1=$1.53 Canadian)
Friday June 7, 10:59 am Eastern Time
Reuters Company News
Hemosol says Hemolink trials delayed, stock crashes
(Adds share details paragraphs 2, 11, analyst comment in paragraph 4, details)
By Rajiv Sekhri
TORONTO, June 7 (Reuters) - Hemosol Inc. (Toronto:HML.TO - News; NasdaqNM:HMSL - News) said on Friday two ongoing trials of its Hemolink blood replacement product would be delayed, and added it would cut staff and costs to save at least C$1.5 million ($980,000) in the second quarter.
ADVERTISEMENT
The Canadian biotech firm`s shares fell 38 percent on the Nasdaq and touched 30-month lows on the Toronto Stock Exchange as investors feared the worst for the much-touted trials of Hemolink, an oxygen therapeutic product designed to take the place of donor blood for patients undergoing surgery.
Hemosol said results from one trail would not be available in the third quarter as planned. Results from a second trial are expected in the fourth quarter. The company blamed "administrative complexities" for the delay.
"Delays are common in clinical trial work but certainly not positive. It is a disappointment, but not overwhelming," said Doug Janson, managing director of Sprott Securities` health sciences research.
Janson, whose firm led a C$22 million financing for Hemosol in April, said he rates the company a buy and has a 12-month price target of C$12 a share.
HEMOSOL TO CUT COSTS
Hemosol, which reported a first-quarter loss of C$11.7 million, said it planned to cut operating expenses to C$3 million a month from C$5 million once all its cost-saving measures are in place.
Hemosol said it has decided not to draw down its credit facility until it reports the results of the trials.
"The trials are expected to support both our pending application to commercialize Hemolink in the U.K. and the planned phase III trials in the U.S.," said John Kennedy, president and chief executive.
A company spokesman said Hemosol will delay the opening of its Toronto-based Meadowpine production facility.
He said Hemosol will finish building the C$25 million plant but will delay final approval from health inspectors to cut costs. Inspector approval can take three to six months.
The company`s shares were down C$1.32, or 36 percent, at C$2.38 on the Toronto Stock Exchange on Friday morning. They fell 89 cents on the Nasdaq, or nearly 37 percent, to $1.53.
($1=$1.53 Canadian)
so, jetzt sind auch die umsätze da:
volles rohr abwärts.
volles rohr abwärts.
Hemosol Verkündet Finanzielle Resultate Des Ersten Viertels 2002
TORONTO AN April 25, 2002 - Hemosol Inc. (Nasdaq: HMSL, TSE: HML, verkündete HML.WT) heute finanzielle Resultate für das erste beendete Viertel März 31, 2002. Wenn nicht anders festgelegt, stellten sich alle Dollarmengen sind hierin kanadische Dollar dar.
Für das erste Viertel, das März 31, 2002 beendet wurde, notierte die Firma einen Reinverlust von $11,7 Million oder $(0.29) pro den Anteil, der mit einem Verlust von $6,9 Million oder $(0.20) pro Anteil am entsprechenden vorherigen Jahrviertel verglichen wurde. Der vorherigen vierteljährliche Verlust des Jahres umfaßte einen unrealized Devisenkursgewinn $2,5 von Million oder von $0,07 pro Anteil.
"während des ersten Viertels, bildeten wir bedeutenden Fortschritt in unseren klinischen Entwicklungs- und Herstellungsprogrammen, während wir in Richtung zu den Ausrichtungen HEMOLINKTM [ Hämoglobinraffimer ] fortfahren," sagten John W. Kennedy, Präsident und Generaldirektor von Hemosol. "Resultate von unserem fortwährenden klinischen Programm werden erwartet, die Wirksamkeit- und Sicherheitsdatenbank für HEMOLINK zu verstärken. Diese Vollendungen setzten uns in eine stichhaltige Position ein, um auf die BRITISCHEN Aufsichtsbehörden später zu reagieren dieses Jahr und pflasterten die Weise, damit sie durchführen ihren Bericht unserer Anwendung Ende 2002.",
Neue Höhepunkte und Ausführungen
·Die STAATNAHRUNG und die Drogeleitung (FDA) gelöschtes Hemosol zum Leiten einen klinischen Versuch von HEMOLINK in "machen" Chirurgie Koronararterieüberbrückungsverpflanzens (CABG) nochmals. Die Firma läßt diesen Versuch laufen, der zu einer sehr ähnlichen Studie bei Primär-CABG-Patienten parallel ist, die FDA-Abstand letzter November empfingen und schreibt z.Z. Patienten ein.
·Folgend dem Ende des Viertels, Gesundheit Kanada löschte Hemosol, um kanadische Aufstellungsorte beiden fortwährenden CABG-Versuchen hinzuzufügen.
·Die FDA löschte Hemosol, um einen klinischen Versuch der Phase II von HEMOLINK als Behandlung für Chemotherapie-verursachte Anämie zu leiten, die die Marktgelegenheit über chirurgischer Anämie hinaus im wesentlichen erweitern könnte. Die multi-centre Studie wird von den Forschern an Duke University geführt und wird erwartet, um Patienten, im Juni von 2002 einzuschreiben anzufangen.
·Hemosol hob über $22 Million an, um fortwährende klinische Versuche zu finanzieren und zu den allgemeinen Arbeitskapitalzwecken.
·Die Firma schloß einen Vertrag, der seine ältere $35 Million Kreditfazilität und Pläne ändert, um hinunter, Kapital im Mai von 2002 zu zeichnen anzufangen. Die Produktionsanlage 300,000-unit HEMOLINK ist auf Zeitplan für Beendigung Ende des dritten Trimesters von 2002 mit Gültigkeitserklärung früh 2003.
Finanzielle Resultate
Die Betriebskosten der Firma im ersten Viertel zählten $11,6 Million, eine Zunahme von Over $1,5 Million oder 14,6% das entsprechende Viertel des vorherigen Jahres zusammen. Diese Zunahme resultierte hauptsächlich aus den Kosten, die für die medizinischen Ausbildungsfälle genommen wurden, die in Verbindung mit internationalen Konferenzen gehalten wurden und erhöhte Markterschließungsunkosten auf richtig in Position bringen HEMOLINK und das Profil des Produktes innerhalb der medizinischen Gemeinschaft zu erhöhen. An das kurzfristige glaubt die Firma, daß diese Aufwendungen auch geduldige Einschreibung in seine fortwährenden klinischen Versuche erhöhen. Die Firma auch verwirklichte bedeutende Zunahmen der Beistandsservices, die mit der Bewegung der Firma zu seinem neuen Service dazugehörig sind und erhöhte Kosten in den Logistik, in der Sicherheit und in IHR. Hemosol erwartet Betriebskosten, um sich über den folgenden sechs Monaten erheblich zu erhöhen, während Einschreibung in den fortwährenden klinischen Versuchen beschleunigen und sie fortfährt, sein Herstellungsprogramm vorzurücken. Während Monats-Ausgabe werden abhängig von dem d Niveau von der behandeln Patient schwanken, erwarten die d Firma daß sein Unkosten werden berechnen ungefähr $5 Million pro Monat.
Interesseneinkommen im Viertel zählte $218.000, unten von den $717.000 im ersten Viertel des vorhergehenden Jahres resultierend aus untererem Bargeld und Bargeld-gleichwertigen Abgleichungs- und niedrigerenzinssätzen zusammen.
Kapitalaufwand während des Viertels erreichte ungefähr $7,6 Million, von denen $7,2 Million bezogen auf dem neuen Service, GesamtaufwendungsZudatum an diesem Service bis $63,8 Million holend.
Ab März 31, 2002, des Remains Hemosol, der gut mit $45,8 Million im Bargeld finanziert wurden und Bargeld-Äquivalente und kurzfristige Investitionen ausschließlich der Kapital hob in die folgende Aprilfinanzierung an.
Konferenzanrufinformationen die Firma bewirten einen Konferenzanruf heute um 8:30 a.m.. Est. Ein Phasenaudiowebcast des Konferenzanrufs ist durch www.hemosol.com vorhanden. Schließen Sie bitte an dieses website mindestens 15 Minuten vor dem Konferenzanruf zum Sicherstellen der ausreichenden Zeit für jedes mögliches Software-Download an, das erforderlich sein kann, das webcast zu hören. Ein Replay des webcast ist für 30 Tage vorhanden, die an April 26., an www.hemosol.com und an www.financialdisclosure.ca beginnen.
Ein Telefon replay vom Konferenzanruf ist auch vorhanden von ungefähr 12:30 P.M. EST an April 25 bis Mai 2, 2002. Den Replay, den Vorwahlknopf, das 416-695-5800 oder das 1-800-408-3053 zugänglich machen und Reservierung Nr. 1132229 eintragen.
Jährliche und Sondersitzung Hemosol hält seine jährliche und spezielle Aktionärsversammlung am Donnerstag, Mai 2, 2002 um 10:00 a.m. ab. Est am Börseauditorium Torontos, 2 erster kanadischer Platz, 130 König Street West, Toronto, Ontario.
Über Hemosol Inc.. Hemosol ist, die biopharmaceutical Firma des Kommerziellstadiums ein kurzfristiges, die zuerst auf sich entwickelnde Leben-unterstützende Therapien für die Behandlung der akuten Anämie gerichtet wird, resultierend aus Hämoglobinmängeln. Hemosol hat eine ausgedehnte Produktpalette in der Entwicklung, einschließlich seines Flaggschiffproduktes HEMOLINK™ [ Hämoglobinraffimer ], in einem therapeutischen Sauerstoff, der zu schnell und verbessern sicher Sauerstoffanlieferung zum zirkulierenden System entworfen wird. HEMOLINK wird z.Z. in klinische Versuche des Spätstadiums ausgewertet. Die Firma auch entwickelt zusätzliche Sauerstofftherapeutik und eine Hämoglobin-gegründete Drogeanlieferungsplattform, um Krankheiten wie Hepatitis C und Krebse der Leber, sowie eine Zellentherapie zu behandeln, die zuerst auf die Behandlung des Krebses durch seine Zellenexpansion und Stammzelleforschungstätigkeiten verwiesen wird.
Für website mehr InformationsbesuchsHemosols an www.hemosol.com.
Allgemeine Anteile Hemosol Inc. werden auf der Börse Nasdaq unter dem handelnden Symbol "HMSL" und auf der Börse Torontos unter dem handelnden Symbol "HML" verzeichnet.
HEMOLINK ist ein eingetragenes eingetragenes Warenzeichen von Hemosol Inc..
Bestimmte Aussagen hinsichtlich sind Hemosols der zukünftigen Aussichten "Vorwärts-schauen Aussagen" unter der Sicherheitsrechtsstreit-Verbesserungtat Vereinigter Staaten privaten von 1995. Es kann keine Versicherungen geben, daß zukünftige Resultate erzielt werden, und tatsächliche Resultate konnten von den Prognosen und von den Schätzungen materiell sich unterscheiden. Wichtige Faktoren, die tatsächliche Resultate veranlassen konnten, sich von den Prognosen materiell zu unterscheiden und Schätzungen umfassen, aber werden nicht begrenzt: Fähigkeit Hemosols, Genehmigungen durch die zuständige Aufsichtsbehörde für seine Produkte zu erreichen; Fähigkeit Hemosols, klinische Versuche für seine Produkte erfolgreich durchzuführen; technisch oder Produktions- oder Verteilungsausgaben; das konkurrierende Klima für Produkte Hemosols; der Grad der Marktdurchdringung der Produkte Hemosols; und andere Faktoren legten in den Archivierungen mit Aufsichtsbehörden der kanadischen Aktien und den STAATAKTIEN und der Austauschkommission fest. Diese Gefahren und Ungewißheiten, sowie andere, werden detaillierter in den Archivierungen von Hemosol mit Aufsichtsbehörden der kanadischen Aktien und den STAATAKTIEN und der Austauschkommission besprochen. Hemosol läßt keine Verpflichtung verbessern, oder irgendwelche Vorwärts-schauenden Aussagen aktualisieren, um Fälle oder Umstände nach dem Datum zu reflektieren, das irgend solche Aussage abgegeben wird.
Das ist eine GOOGLE-Übersetzeung der HEMOSOL.COM Seite.
TORONTO AN April 25, 2002 - Hemosol Inc. (Nasdaq: HMSL, TSE: HML, verkündete HML.WT) heute finanzielle Resultate für das erste beendete Viertel März 31, 2002. Wenn nicht anders festgelegt, stellten sich alle Dollarmengen sind hierin kanadische Dollar dar.
Für das erste Viertel, das März 31, 2002 beendet wurde, notierte die Firma einen Reinverlust von $11,7 Million oder $(0.29) pro den Anteil, der mit einem Verlust von $6,9 Million oder $(0.20) pro Anteil am entsprechenden vorherigen Jahrviertel verglichen wurde. Der vorherigen vierteljährliche Verlust des Jahres umfaßte einen unrealized Devisenkursgewinn $2,5 von Million oder von $0,07 pro Anteil.
"während des ersten Viertels, bildeten wir bedeutenden Fortschritt in unseren klinischen Entwicklungs- und Herstellungsprogrammen, während wir in Richtung zu den Ausrichtungen HEMOLINKTM [ Hämoglobinraffimer ] fortfahren," sagten John W. Kennedy, Präsident und Generaldirektor von Hemosol. "Resultate von unserem fortwährenden klinischen Programm werden erwartet, die Wirksamkeit- und Sicherheitsdatenbank für HEMOLINK zu verstärken. Diese Vollendungen setzten uns in eine stichhaltige Position ein, um auf die BRITISCHEN Aufsichtsbehörden später zu reagieren dieses Jahr und pflasterten die Weise, damit sie durchführen ihren Bericht unserer Anwendung Ende 2002.",
Neue Höhepunkte und Ausführungen
·Die STAATNAHRUNG und die Drogeleitung (FDA) gelöschtes Hemosol zum Leiten einen klinischen Versuch von HEMOLINK in "machen" Chirurgie Koronararterieüberbrückungsverpflanzens (CABG) nochmals. Die Firma läßt diesen Versuch laufen, der zu einer sehr ähnlichen Studie bei Primär-CABG-Patienten parallel ist, die FDA-Abstand letzter November empfingen und schreibt z.Z. Patienten ein.
·Folgend dem Ende des Viertels, Gesundheit Kanada löschte Hemosol, um kanadische Aufstellungsorte beiden fortwährenden CABG-Versuchen hinzuzufügen.
·Die FDA löschte Hemosol, um einen klinischen Versuch der Phase II von HEMOLINK als Behandlung für Chemotherapie-verursachte Anämie zu leiten, die die Marktgelegenheit über chirurgischer Anämie hinaus im wesentlichen erweitern könnte. Die multi-centre Studie wird von den Forschern an Duke University geführt und wird erwartet, um Patienten, im Juni von 2002 einzuschreiben anzufangen.
·Hemosol hob über $22 Million an, um fortwährende klinische Versuche zu finanzieren und zu den allgemeinen Arbeitskapitalzwecken.
·Die Firma schloß einen Vertrag, der seine ältere $35 Million Kreditfazilität und Pläne ändert, um hinunter, Kapital im Mai von 2002 zu zeichnen anzufangen. Die Produktionsanlage 300,000-unit HEMOLINK ist auf Zeitplan für Beendigung Ende des dritten Trimesters von 2002 mit Gültigkeitserklärung früh 2003.
Finanzielle Resultate
Die Betriebskosten der Firma im ersten Viertel zählten $11,6 Million, eine Zunahme von Over $1,5 Million oder 14,6% das entsprechende Viertel des vorherigen Jahres zusammen. Diese Zunahme resultierte hauptsächlich aus den Kosten, die für die medizinischen Ausbildungsfälle genommen wurden, die in Verbindung mit internationalen Konferenzen gehalten wurden und erhöhte Markterschließungsunkosten auf richtig in Position bringen HEMOLINK und das Profil des Produktes innerhalb der medizinischen Gemeinschaft zu erhöhen. An das kurzfristige glaubt die Firma, daß diese Aufwendungen auch geduldige Einschreibung in seine fortwährenden klinischen Versuche erhöhen. Die Firma auch verwirklichte bedeutende Zunahmen der Beistandsservices, die mit der Bewegung der Firma zu seinem neuen Service dazugehörig sind und erhöhte Kosten in den Logistik, in der Sicherheit und in IHR. Hemosol erwartet Betriebskosten, um sich über den folgenden sechs Monaten erheblich zu erhöhen, während Einschreibung in den fortwährenden klinischen Versuchen beschleunigen und sie fortfährt, sein Herstellungsprogramm vorzurücken. Während Monats-Ausgabe werden abhängig von dem d Niveau von der behandeln Patient schwanken, erwarten die d Firma daß sein Unkosten werden berechnen ungefähr $5 Million pro Monat.
Interesseneinkommen im Viertel zählte $218.000, unten von den $717.000 im ersten Viertel des vorhergehenden Jahres resultierend aus untererem Bargeld und Bargeld-gleichwertigen Abgleichungs- und niedrigerenzinssätzen zusammen.
Kapitalaufwand während des Viertels erreichte ungefähr $7,6 Million, von denen $7,2 Million bezogen auf dem neuen Service, GesamtaufwendungsZudatum an diesem Service bis $63,8 Million holend.
Ab März 31, 2002, des Remains Hemosol, der gut mit $45,8 Million im Bargeld finanziert wurden und Bargeld-Äquivalente und kurzfristige Investitionen ausschließlich der Kapital hob in die folgende Aprilfinanzierung an.
Konferenzanrufinformationen die Firma bewirten einen Konferenzanruf heute um 8:30 a.m.. Est. Ein Phasenaudiowebcast des Konferenzanrufs ist durch www.hemosol.com vorhanden. Schließen Sie bitte an dieses website mindestens 15 Minuten vor dem Konferenzanruf zum Sicherstellen der ausreichenden Zeit für jedes mögliches Software-Download an, das erforderlich sein kann, das webcast zu hören. Ein Replay des webcast ist für 30 Tage vorhanden, die an April 26., an www.hemosol.com und an www.financialdisclosure.ca beginnen.
Ein Telefon replay vom Konferenzanruf ist auch vorhanden von ungefähr 12:30 P.M. EST an April 25 bis Mai 2, 2002. Den Replay, den Vorwahlknopf, das 416-695-5800 oder das 1-800-408-3053 zugänglich machen und Reservierung Nr. 1132229 eintragen.
Jährliche und Sondersitzung Hemosol hält seine jährliche und spezielle Aktionärsversammlung am Donnerstag, Mai 2, 2002 um 10:00 a.m. ab. Est am Börseauditorium Torontos, 2 erster kanadischer Platz, 130 König Street West, Toronto, Ontario.
Über Hemosol Inc.. Hemosol ist, die biopharmaceutical Firma des Kommerziellstadiums ein kurzfristiges, die zuerst auf sich entwickelnde Leben-unterstützende Therapien für die Behandlung der akuten Anämie gerichtet wird, resultierend aus Hämoglobinmängeln. Hemosol hat eine ausgedehnte Produktpalette in der Entwicklung, einschließlich seines Flaggschiffproduktes HEMOLINK™ [ Hämoglobinraffimer ], in einem therapeutischen Sauerstoff, der zu schnell und verbessern sicher Sauerstoffanlieferung zum zirkulierenden System entworfen wird. HEMOLINK wird z.Z. in klinische Versuche des Spätstadiums ausgewertet. Die Firma auch entwickelt zusätzliche Sauerstofftherapeutik und eine Hämoglobin-gegründete Drogeanlieferungsplattform, um Krankheiten wie Hepatitis C und Krebse der Leber, sowie eine Zellentherapie zu behandeln, die zuerst auf die Behandlung des Krebses durch seine Zellenexpansion und Stammzelleforschungstätigkeiten verwiesen wird.
Für website mehr InformationsbesuchsHemosols an www.hemosol.com.
Allgemeine Anteile Hemosol Inc. werden auf der Börse Nasdaq unter dem handelnden Symbol "HMSL" und auf der Börse Torontos unter dem handelnden Symbol "HML" verzeichnet.
HEMOLINK ist ein eingetragenes eingetragenes Warenzeichen von Hemosol Inc..
Bestimmte Aussagen hinsichtlich sind Hemosols der zukünftigen Aussichten "Vorwärts-schauen Aussagen" unter der Sicherheitsrechtsstreit-Verbesserungtat Vereinigter Staaten privaten von 1995. Es kann keine Versicherungen geben, daß zukünftige Resultate erzielt werden, und tatsächliche Resultate konnten von den Prognosen und von den Schätzungen materiell sich unterscheiden. Wichtige Faktoren, die tatsächliche Resultate veranlassen konnten, sich von den Prognosen materiell zu unterscheiden und Schätzungen umfassen, aber werden nicht begrenzt: Fähigkeit Hemosols, Genehmigungen durch die zuständige Aufsichtsbehörde für seine Produkte zu erreichen; Fähigkeit Hemosols, klinische Versuche für seine Produkte erfolgreich durchzuführen; technisch oder Produktions- oder Verteilungsausgaben; das konkurrierende Klima für Produkte Hemosols; der Grad der Marktdurchdringung der Produkte Hemosols; und andere Faktoren legten in den Archivierungen mit Aufsichtsbehörden der kanadischen Aktien und den STAATAKTIEN und der Austauschkommission fest. Diese Gefahren und Ungewißheiten, sowie andere, werden detaillierter in den Archivierungen von Hemosol mit Aufsichtsbehörden der kanadischen Aktien und den STAATAKTIEN und der Austauschkommission besprochen. Hemosol läßt keine Verpflichtung verbessern, oder irgendwelche Vorwärts-schauenden Aussagen aktualisieren, um Fälle oder Umstände nach dem Datum zu reflektieren, das irgend solche Aussage abgegeben wird.
Das ist eine GOOGLE-Übersetzeung der HEMOSOL.COM Seite.
Tja,erst kommt der Schmerz,dann das Geld.
hemosol heute + 23% in toronto.
da tut sich was.
da tut sich was.
@all,
da haut´s mich fast aus den Socken. Hemosol bekommt in den USA die Zulassung 28% Kursanstieg, nach dem zwei Wochen zufor fast die Pleitemeldung kam! Und Jetzt, wartet unser lieber Herr Kennedy auf Finanzsprizen, damit er Hemosol Produzieren und Vermarkten kann.
Na dann hoffen wir, dass es jetzt endlich losgeht
CoolMax
da haut´s mich fast aus den Socken. Hemosol bekommt in den USA die Zulassung 28% Kursanstieg, nach dem zwei Wochen zufor fast die Pleitemeldung kam! Und Jetzt, wartet unser lieber Herr Kennedy auf Finanzsprizen, damit er Hemosol Produzieren und Vermarkten kann.
Na dann hoffen wir, dass es jetzt endlich losgeht
CoolMax
Ich fürchte Du hast da was verwechselt.
Die Zulassung kommt nicht vom Patentamt sondern von der FDA.
Der Kurs hätte außerdem sonst explodieren müssen.
Die Zulassung kommt nicht vom Patentamt sondern von der FDA.
Der Kurs hätte außerdem sonst explodieren müssen.
Dem ist wohl so... also ruhig bleiben und jetzt nur noch die Zulassung abwarten... ist doch schon mal ein positives Zeichen so ein Patent...
auf gute Trades
dkF
auf gute Trades
dkF
Es ist aber leider so, daß laut Statistik nur 25% - 30% aller Phase 3 Studien ( bei FDA )erfolgreich abgeschlossen werden und somit zur Vermarktung kommen können.
Also große Chance, daß das Geld verschwindet und kleine Chance, daß es sich vervielfacht.
Zugegeben, das Potential nach der Zulassung wäre enorm.
Also große Chance, daß das Geld verschwindet und kleine Chance, daß es sich vervielfacht.
Zugegeben, das Potential nach der Zulassung wäre enorm.
@upcomer
wo kann man diese Statistik nachlesen?
Danke schon mal für die Info...
dkF
wo kann man diese Statistik nachlesen?
Danke schon mal für die Info...
dkF
Bitte sehr!
www.stocksontheweb.com - dann "The Drug Approval Process" unten links anklicken, zu lesen bei "Phase 3 Clinical Trials"
Ich habe zur Zeit kein Geld mehr, mir die Finger zu verbrennen.
Man bedenke auch, daß sich vor schon langer Zeit Fresenius
zurückgezogen hat, weil das Produkt nicht für hohe Blutersatzvolumina geeignet war ( und ist? ).
Ich war vor längerer Zeit auch investiert, bin aber rechtzeitig ohne großen Verlust raus.
Schon bemerkenswert, in der Spitze an die 20E und jetzt, wo die viel näher an der Zulassung sind 1,50$.
Sehr, sehr heiß und nichts für schwache Nerven.
MfG
www.stocksontheweb.com - dann "The Drug Approval Process" unten links anklicken, zu lesen bei "Phase 3 Clinical Trials"
Ich habe zur Zeit kein Geld mehr, mir die Finger zu verbrennen.
Man bedenke auch, daß sich vor schon langer Zeit Fresenius
zurückgezogen hat, weil das Produkt nicht für hohe Blutersatzvolumina geeignet war ( und ist? ).
Ich war vor längerer Zeit auch investiert, bin aber rechtzeitig ohne großen Verlust raus.
Schon bemerkenswert, in der Spitze an die 20E und jetzt, wo die viel näher an der Zulassung sind 1,50$.
Sehr, sehr heiß und nichts für schwache Nerven.
MfG
Am 27.6.02 Nachtrag
*********************************************************
Zitat aus Boerse Online vom 6.6.02
Schwere Kursverluste verbuchte auch Hemosol. Die Biotechfirma wird Forschungsergebnisse zu dem Blutersatzstoff Hemolink nicht wie geplant im dritten Quartal veröffentlichen. CEO John Kennedy peilt jetzt das vierte Quartal an. Die Aktie brach um 24 Prozent ein und notiert auf dem tiefsten Stand seit zweieinhalb Jahren.
**********************************************************
Heute einsfuffzig!?!? mit 0 Handel in Frankfurt (16:00 Uhr)
*********************************************************
Zitat aus Boerse Online vom 6.6.02
Schwere Kursverluste verbuchte auch Hemosol. Die Biotechfirma wird Forschungsergebnisse zu dem Blutersatzstoff Hemolink nicht wie geplant im dritten Quartal veröffentlichen. CEO John Kennedy peilt jetzt das vierte Quartal an. Die Aktie brach um 24 Prozent ein und notiert auf dem tiefsten Stand seit zweieinhalb Jahren.
**********************************************************
Heute einsfuffzig!?!? mit 0 Handel in Frankfurt (16:00 Uhr)
Endlich ist es raus, lt. neuesten Erkenntnissen und Begutachtung der Fabrikanlage wurde klar, das hier auch in Zukunft kein Blut fließt, denn es handelt sich in Wirklichkeit um die Ausstattung zum Betrieb einer Brauerei. Die FDA wurde unterrichtet. Sämtliche bisher eingereichte Unterlagen waren gefälscht. Der Vorstand sagt es handele sich um ein Mißverständnis.Doch die FDA will kein Bier mit dem Blutfarbstoff HEMOLINK zulassen, deshalb kann das Kursziel lt diverser Analysten nur lauten -1,00 EUR.Vielleicht kann die Anlage ja noch umgebaut werden und in Zukunft H-Milch produzieren, aber die Masse der Anleger will weder Bier noch H-Milch und verkauft deshalb so schnell es geht, natürlich wie immer mit Verlust, so wie es sein soll.PS: Da bleib ich doch besser bei meinem "WARSTEINER"
Der Witz scheint so wirklichkeitsnah, daß ich ihn beinahe ernst genommen hätte.
Ich habe mich daher auf die Suche nach Belegen für diese Aussage gemacht, habe aber keine gefunden.
Wer weiß, ob doch was dran ist? z.B. der Verfasser
noch etwas anderes:
Wenn der Kurs 30 Handelstage unter 1$ ist, kommt die delisting Maschinerie in Gang
und am Ende verschwindet Hemosol vom Nasdaq National Market.
Ich habe mich daher auf die Suche nach Belegen für diese Aussage gemacht, habe aber keine gefunden.
Wer weiß, ob doch was dran ist? z.B. der Verfasser
noch etwas anderes:
Wenn der Kurs 30 Handelstage unter 1$ ist, kommt die delisting Maschinerie in Gang
und am Ende verschwindet Hemosol vom Nasdaq National Market.
Tja, wollen wir hoffen, das es nie zu diesem Szenario kommt.
Ich wünschte ich würde jemanden in Kanada kennen, der dort mal nach dem Rechten schaut. Habe kein Geld für einen Flug übrig, sonst würde ich es selbst machen; kenne
auch niemanden der dort in Nähe Urlaub macht und mal gucken könnte ob die Anlage noch steht und dort noch gearbeitet wird. Glaube aber trotzdem nicht an eine Betrüger-Firma, wie es am „NEUEN MARKT“ so viele gibt, kann aber nirgendwo im Internet einen Hinweis finden warum es zu diesem extremen Kursverfall kommt. Was wissen die in Kanada, was wir hier nicht wissen ? oder verkaufen alle nur wg. dem Chart ?Sollte jemand Verwandschaft in der Nähe von HEMOSOL haben , dann.................ansonsten ist es für mich gesehen eh zu spät zu verkaufen bzw. eher zu verramschen denn ich habe insgesamt 10.000 Stck für etwa 4,30 gekauft, und das hielt ich schon für „Supergünstig.
Trotzdem nichts für Ungut für den kleinen Scherz.
Ich wünschte ich würde jemanden in Kanada kennen, der dort mal nach dem Rechten schaut. Habe kein Geld für einen Flug übrig, sonst würde ich es selbst machen; kenne
auch niemanden der dort in Nähe Urlaub macht und mal gucken könnte ob die Anlage noch steht und dort noch gearbeitet wird. Glaube aber trotzdem nicht an eine Betrüger-Firma, wie es am „NEUEN MARKT“ so viele gibt, kann aber nirgendwo im Internet einen Hinweis finden warum es zu diesem extremen Kursverfall kommt. Was wissen die in Kanada, was wir hier nicht wissen ? oder verkaufen alle nur wg. dem Chart ?Sollte jemand Verwandschaft in der Nähe von HEMOSOL haben , dann.................ansonsten ist es für mich gesehen eh zu spät zu verkaufen bzw. eher zu verramschen denn ich habe insgesamt 10.000 Stck für etwa 4,30 gekauft, und das hielt ich schon für „Supergünstig.
Trotzdem nichts für Ungut für den kleinen Scherz.
- viel Glück, wird schon wieder aufwärtsgehen.
Mit freundlichem Gruß
Alexander Götz
PS:
http://www.stockhouse.ca/bullboards/forum.asp?symbol=HML&tab…
Mit freundlichem Gruß
Alexander Götz
PS:
http://www.stockhouse.ca/bullboards/forum.asp?symbol=HML&tab…
Kann mir mal einer sagen was bei Hemosol los ist? Der Wert fällt ja nur noch.
!
Dieser Beitrag wurde vom System automatisch gesperrt. Bei Fragen wenden Sie sich bitte an feedback@wallstreet-online.de
Je näher das Jahr 2003 heranrückt, desto nervöser werden die Investoren.Schließlich möchte keiner den rechtzeitigen Einstieg verpassen.Jede angekündigte Meldung könnte die "Meldung" schlechthin sein.So sind die meisten rasanten Kursanstiege spekulativ.Man weiß ja nie.
HI,
weis jemand was neues ????????????
Warum knallt´s da jeden Tag
CoolMax
weis jemand was neues ????????????
Warum knallt´s da jeden Tag
CoolMax
http://www.nasdaq.com/asp/quotes_news.asp?mode=&kind=&symbol…
Hallo, schaut euch bitte mal obige News an vom 23.10.hat sich hier MDS eingekauft oder Anteil erhöht??????
Dürfte Erklärung für den Anstieg sein.
Hallo, schaut euch bitte mal obige News an vom 23.10.hat sich hier MDS eingekauft oder Anteil erhöht??????
Dürfte Erklärung für den Anstieg sein.
Gibt es News zu Hemosol????
Bitte schön,
hier die News vom 21.11.2002!
http://www.thestar.com/NASApp/cs/ContentServer?pagename=thes…
hier die News vom 21.11.2002!
http://www.thestar.com/NASApp/cs/ContentServer?pagename=thes…
Danke, Dosto.
Immerhin, es geht weiter.
Immerhin, es geht weiter.
@All,
sorry, aber ich glaube das wars
Hemosol shares close down 65% after trials in key blood product halted
3/14/03
TORONTO, Mar 14, 2003 (The Canadian Press via COMTEX) --
The blood was drained from Hemosol Inc. shares Friday after the company reported safety problems with its key medical product.
The stock plunged as much as 75 per cent during the day after Hemosol said it had stopped clinical trials of Hemolink, a blood substitute, because surgery patients could face heart-related complications. The trial suspension, announced late Thursday, is a terrible blow to the Toronto company, analysts said, because it has pinned much of its hopes on the commercial development of Hemolink.
`The future of the company is very much in doubt,`said Duncan Stewart, portfolio manager of Tera Capital Corp.
But Hemosol disagreed with that gloomy assessment, calling it `too premature`while medical data are studied.
Hemosol`s stock had been halted all day Thursday, pending news. When trading resumed Friday, the stock sank as much as 75 per cent, or $1.54, to an all-time low of 51 cents.
By the bell, it closed at 71 cents, down 65 per cent, or $1.34, on heavy volume of 5.6 million shares - a huge number for the company.
The drop wiped about $62 million off the company`s stock market value, which now stands at about $33 million. The stock`s 52-week high is $6.35 and its 52-week low was 62 cents.
`The vastly probable outcome of this is that these trials will never restart,`Stewart said. `Further, if they don`t, they will not get British or Canadian approval - in which case Hemosol essentially has no assets and will run out of cash.
`But one never knows. It`s always possible that they may recover from this,`he said. But without approval from regulators to sell the Hemolink product commercially, `you`re done. And this is really the only product they have.`
Hemosol said it halted two trials of Hemolink after the company`s safety monitoring board found there was `the potential for an increase in certain cardiac adverse events`- heart problems.
The company didn`t elaborate on those side-effects.
``Cardiac events`are intolerable,`Stewart said, particularly with a product that`s meant to be used instead of blood transfusions - a process that carries some risk but has been used with success for decades.
`The standard for safety is so high that this sort of thing is a real problem.`
Enrolment in Hemosol`s heart-bypass trial in the U.S. was temporarily suspended as the company reviews the data with its safety board and the U.S. Food and Drug Administration. As a precaution, enrolment is also on hold for patients in a new orthopedic surgery trial.
`Until they can conclude that Hemolink is safe . . . they have to suspend the trial,`said David Dean, an analyst with Sprott Securities. `If it turns out that at the end of the day the product is not safe, then there is no Hemosol.`
But Hemosol disagreed with analysts`opinions about its future, saying it was `too premature`to make that kind of assessment.
`This is obviously not something we had expected would happen,`said Jason Hogan, a spokesman for Hemosol.
`It does happen when you`re running any clinical study. We have to wait and review the data.`
Hogan added: `What was announced (Thursday) does not mean the product does not work. It did not relate to efficacy and it does not mean that the product is not safe. The (safety board) has seen some information and they felt it was necessary to make this recommendation in order to further review that data. And we`re going to look at it.`
`We feel that Hemolink is still an exceptional product and that its need is still growing within the marketplace.`
The safety board is made up of independent medical experts. Hogan noted that the company also has the option of creating an outside independent medical board to examine the data.
Suspension of the trials will also hurt the biotechnology company as it tries to raise more cash this year to fund its development.
`They have around four months to restart the trial or they probably won`t have enough money to finish it,`Dean said.
The trial suspension is `not going to help`the company raise funds, Hogan noted.
`We don`t have an active clinical program on right now and clearly this (safety board) ruling is going to raise concerns with respect to safety,`he said. `We need time to assess what exactly this is to be able to have discussions with various parties to determine our course of action.`
The company said it will be looking for more cash this year as it ended 2002 with $17.6 million in cash and is burning about $3 million to $3.5 million a month.
The Toronto-based firm reported Thursday a wider loss for the fourth quarter and all of 2002 as it invested in a new plant and pumped money into the Hemolink trials. For the full year, the company posted a loss of $54.8 million, up 42 per cent from the year earlier.
The online source for news sports entertainment finance and business news in Canada
Copyright (C) 2003 The Canadian Press (CP), All rights reserved
sorry, aber ich glaube das wars
Hemosol shares close down 65% after trials in key blood product halted
3/14/03
TORONTO, Mar 14, 2003 (The Canadian Press via COMTEX) --
The blood was drained from Hemosol Inc. shares Friday after the company reported safety problems with its key medical product.
The stock plunged as much as 75 per cent during the day after Hemosol said it had stopped clinical trials of Hemolink, a blood substitute, because surgery patients could face heart-related complications. The trial suspension, announced late Thursday, is a terrible blow to the Toronto company, analysts said, because it has pinned much of its hopes on the commercial development of Hemolink.
`The future of the company is very much in doubt,`said Duncan Stewart, portfolio manager of Tera Capital Corp.
But Hemosol disagreed with that gloomy assessment, calling it `too premature`while medical data are studied.
Hemosol`s stock had been halted all day Thursday, pending news. When trading resumed Friday, the stock sank as much as 75 per cent, or $1.54, to an all-time low of 51 cents.
By the bell, it closed at 71 cents, down 65 per cent, or $1.34, on heavy volume of 5.6 million shares - a huge number for the company.
The drop wiped about $62 million off the company`s stock market value, which now stands at about $33 million. The stock`s 52-week high is $6.35 and its 52-week low was 62 cents.
`The vastly probable outcome of this is that these trials will never restart,`Stewart said. `Further, if they don`t, they will not get British or Canadian approval - in which case Hemosol essentially has no assets and will run out of cash.
`But one never knows. It`s always possible that they may recover from this,`he said. But without approval from regulators to sell the Hemolink product commercially, `you`re done. And this is really the only product they have.`
Hemosol said it halted two trials of Hemolink after the company`s safety monitoring board found there was `the potential for an increase in certain cardiac adverse events`- heart problems.
The company didn`t elaborate on those side-effects.
``Cardiac events`are intolerable,`Stewart said, particularly with a product that`s meant to be used instead of blood transfusions - a process that carries some risk but has been used with success for decades.
`The standard for safety is so high that this sort of thing is a real problem.`
Enrolment in Hemosol`s heart-bypass trial in the U.S. was temporarily suspended as the company reviews the data with its safety board and the U.S. Food and Drug Administration. As a precaution, enrolment is also on hold for patients in a new orthopedic surgery trial.
`Until they can conclude that Hemolink is safe . . . they have to suspend the trial,`said David Dean, an analyst with Sprott Securities. `If it turns out that at the end of the day the product is not safe, then there is no Hemosol.`
But Hemosol disagreed with analysts`opinions about its future, saying it was `too premature`to make that kind of assessment.
`This is obviously not something we had expected would happen,`said Jason Hogan, a spokesman for Hemosol.
`It does happen when you`re running any clinical study. We have to wait and review the data.`
Hogan added: `What was announced (Thursday) does not mean the product does not work. It did not relate to efficacy and it does not mean that the product is not safe. The (safety board) has seen some information and they felt it was necessary to make this recommendation in order to further review that data. And we`re going to look at it.`
`We feel that Hemolink is still an exceptional product and that its need is still growing within the marketplace.`
The safety board is made up of independent medical experts. Hogan noted that the company also has the option of creating an outside independent medical board to examine the data.
Suspension of the trials will also hurt the biotechnology company as it tries to raise more cash this year to fund its development.
`They have around four months to restart the trial or they probably won`t have enough money to finish it,`Dean said.
The trial suspension is `not going to help`the company raise funds, Hogan noted.
`We don`t have an active clinical program on right now and clearly this (safety board) ruling is going to raise concerns with respect to safety,`he said. `We need time to assess what exactly this is to be able to have discussions with various parties to determine our course of action.`
The company said it will be looking for more cash this year as it ended 2002 with $17.6 million in cash and is burning about $3 million to $3.5 million a month.
The Toronto-based firm reported Thursday a wider loss for the fourth quarter and all of 2002 as it invested in a new plant and pumped money into the Hemolink trials. For the full year, the company posted a loss of $54.8 million, up 42 per cent from the year earlier.
The online source for news sports entertainment finance and business news in Canada
Copyright (C) 2003 The Canadian Press (CP), All rights reserved
na,na,na........so schnell geht`s auch wieder nicht....
Not Asset Value Report March 14, 2003
via CDS
March 20, 2003
Managed by MDS Capital Corp. which targets $1 billion towards building companies In the health and life sciences sector.
Net Asset Value:
As of March 14, 2003 the net asset value (NAV) of The Health Care and Biotechnology Venture Fund (the `Fund`) totals $5.3 million or $1.19 per Trust Unit.
Twenty-five percent of the Fund`s investments, including warrants, are currently held in private companies. All of the Fund`s investments are valued in accordance
with the Fund`s valuation policy, which is fully described in the notes to the audited financial statements included in the Fund`s annual report. As of March 14,
2003 units in the Fund traded on the TSX at $1.10 per unit, which is an 8% discount to the current net asset value.
Total Per Trust (millions) UnitCash $ 1.2 $0.28Investments $ 5.4 $1.21Provision for Performance Fees ($ 1.3) ($0.30)Total Net Assets $ 5.3 $1.19
Existing Investments:
In March 2003, Hemosol Inc. (NASDAQ:HMSL, TSX:HML), announced that at the recommendation of the Company`s Data Safety Monitoring Board (DSMB) it
elected to review safety data prior to continuing enrolment in its cardiac trial (HLK 213/304). This trial involves the use of Hemolink(TM) (hemoglobin raffimer) in
patients undergoing cardiac bypass grafting (CABG) surgery. The DSMB`s recommendation is based on an observation of an imbalance in the incidence of
certain adverse events between the Hemolink and control groups. Although the DSMB had recently cleared the trial to continue following the third and final
interim safety review, their ongoing review of data indicates that there may be the potential for an increase in certain cardiac adverse events in the Hemolink
group.
`Following an in-depth analysis of the data, and with the advice of the regulatory agencies, we will determine how we will proceed,`said John W. Kennedy,
President and CEO of Hemosol. `This observation from the HLK 213 interim data may be due to any number of reasons including variables in the patient
population.`As a precaution the company has also voluntarily suspended enrolment in its Phase II clinical study involving the use of Hemolink in patients
undergoing Orthopedic Surgery (HLK 210). The Fund has invested $3.0 million in Hemosol to date. On March 14, 2003 (before this news was released) the
market value of this investment was $1.0 million.
CONTACT: TEL: (416) 675-6777 ext. 6630 Michael Callaghan, Eric Fredrickson
MDS Capital
Not Asset Value Report March 14, 2003
via CDS
March 20, 2003
Managed by MDS Capital Corp. which targets $1 billion towards building companies In the health and life sciences sector.
Net Asset Value:
As of March 14, 2003 the net asset value (NAV) of The Health Care and Biotechnology Venture Fund (the `Fund`) totals $5.3 million or $1.19 per Trust Unit.
Twenty-five percent of the Fund`s investments, including warrants, are currently held in private companies. All of the Fund`s investments are valued in accordance
with the Fund`s valuation policy, which is fully described in the notes to the audited financial statements included in the Fund`s annual report. As of March 14,
2003 units in the Fund traded on the TSX at $1.10 per unit, which is an 8% discount to the current net asset value.
Total Per Trust (millions) UnitCash $ 1.2 $0.28Investments $ 5.4 $1.21Provision for Performance Fees ($ 1.3) ($0.30)Total Net Assets $ 5.3 $1.19
Existing Investments:
In March 2003, Hemosol Inc. (NASDAQ:HMSL, TSX:HML), announced that at the recommendation of the Company`s Data Safety Monitoring Board (DSMB) it
elected to review safety data prior to continuing enrolment in its cardiac trial (HLK 213/304). This trial involves the use of Hemolink(TM) (hemoglobin raffimer) in
patients undergoing cardiac bypass grafting (CABG) surgery. The DSMB`s recommendation is based on an observation of an imbalance in the incidence of
certain adverse events between the Hemolink and control groups. Although the DSMB had recently cleared the trial to continue following the third and final
interim safety review, their ongoing review of data indicates that there may be the potential for an increase in certain cardiac adverse events in the Hemolink
group.
`Following an in-depth analysis of the data, and with the advice of the regulatory agencies, we will determine how we will proceed,`said John W. Kennedy,
President and CEO of Hemosol. `This observation from the HLK 213 interim data may be due to any number of reasons including variables in the patient
population.`As a precaution the company has also voluntarily suspended enrolment in its Phase II clinical study involving the use of Hemolink in patients
undergoing Orthopedic Surgery (HLK 210). The Fund has invested $3.0 million in Hemosol to date. On March 14, 2003 (before this news was released) the
market value of this investment was $1.0 million.
CONTACT: TEL: (416) 675-6777 ext. 6630 Michael Callaghan, Eric Fredrickson
MDS Capital
This Recent Press Release: April 07, 2003
HEMOSOL PROVIDES CORPORATE UPDATE
Toronto, April 7, 2003 – Hemosol Inc. (NASDAQ: HMSL, TSX: HML) today announced that in order to perform a full safety and efficacy analysis of its cardiac trial (HLK 213/304) for its lead product HEMOLINK™ [hemoglobin raffimer], it will close enrolment at the current level of 152 patients, slightly lower than the originally planned enrolment of 180 patients.
Hemosol suspended enrolment in the HLK 213/304 trial on March 13th following the Company’s Data and Safety Monitoring Board’s (DSMB) observation of an imbalance in the incidence of certain adverse events between the HEMOLINK and control groups. Although limiting enrolment may decrease the planned statistical power of the findings regarding efficacy of the product, it will allow the DSMB’s observations to be fully and promptly investigated and for the Company to assess the benefits of HEMOLINK in this trial. Provided any and all issues are resolved, the remainder of the HEMOLINK clinical development program can be re-initiated as early as possible. The Company expects to conduct the analysis of the data within 60 days and plans to have the final safety database reviewed by an independent group of experts.
“We believe that the analysis will substantiate the safety of HEMOLINK, and will help to address the DSMB’s observations,” said John W. Kennedy, President and Chief Executive Officer of Hemosol. “Our objective is to complete the analysis so that we are in a position to provide information to regulators and the medical community that would lead to the restart of our clinical program.”
In an effort to preserve cash, the Company is also taking proactive steps to manage its burn-rate. This includes giving working notice to substantially all of its employees, effective April 7, 2003 and scaling back all spending not related to the data analysis of HLK 213/304. Hemosol intends to resume its clinical program in the event that the data analysis yields the positive results anticipated by the Company. In these circumstances the Company would expect to maintain the staff required for such purposes.
During this review period, the Company is also continuing a number of strategic initiatives, which include ongoing discussions with potential partners, exploring merger and acquisition opportunities and the possible sale of certain assets. Given current market volatility and the finite cash resources available to the Company, management and the Board of Directors believes these steps to be the most prudent course of action.
About Hemosol Inc.
Hemosol is a biopharmaceutical company focused initially on developing life-sustaining therapies for the treatment of acute anemia. Hemosol has a broad range of products in development, including its flagship product HEMOLINK™ [hemoglobin raffimer], an oxygen therapeutic, that is designed to rapidly and safely improve oxygen delivery via the circulatory system. HEMOLINK is currently being evaluated in late-stage clinical trials. The Company also is developing additional oxygen therapeutics and a hemoglobin-based drug delivery platform to treat diseases such as hepatitis C and cancers of the liver, as well as a cell therapy initially directed to the treatment of cancer through its cell expansion and stem cell research activities.
For more information visit Hemosol’s website at www.hemosol.com.
HEMOLINKTM is a registered trademark of Hemosol Inc.
Hemosol Inc.’s common shares are listed on The Nasdaq Stock Market under the trading symbol “HMSL” and on the Toronto Stock Exchange under the trading symbol “HML”.
Certain statements concerning Hemosol’s future prospects are “forward-looking statements” under the United States Private Securities Litigation Reform Act of 1995. There can be no assurances that future results will be achieved, and actual results could differ materially from forecasts and estimates. Important factors that could cause actual results to differ materially from forecasts and estimates include, but are not limited to: Hemosol’s ability to obtain regulatory approvals for its products; Hemosol’s ability to successfully complete clinical trials for its products; technical or manufacturing or distribution issues; the competitive environment for Hemosol’s products; the degree of market penetration of Hemosol’s products; and other factors set forth in filings with Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission. These risks and uncertainties, as well as others, are discussed in greater detail in the filings of Hemosol with Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission. Hemosol makes no commitment to revise or update any forward-looking statements in order to reflect events or circumstances after the date any such statement is made.
Quelle: www.hemosol.com / Investor Center / News Releases
HEMOSOL PROVIDES CORPORATE UPDATE
Toronto, April 7, 2003 – Hemosol Inc. (NASDAQ: HMSL, TSX: HML) today announced that in order to perform a full safety and efficacy analysis of its cardiac trial (HLK 213/304) for its lead product HEMOLINK™ [hemoglobin raffimer], it will close enrolment at the current level of 152 patients, slightly lower than the originally planned enrolment of 180 patients.
Hemosol suspended enrolment in the HLK 213/304 trial on March 13th following the Company’s Data and Safety Monitoring Board’s (DSMB) observation of an imbalance in the incidence of certain adverse events between the HEMOLINK and control groups. Although limiting enrolment may decrease the planned statistical power of the findings regarding efficacy of the product, it will allow the DSMB’s observations to be fully and promptly investigated and for the Company to assess the benefits of HEMOLINK in this trial. Provided any and all issues are resolved, the remainder of the HEMOLINK clinical development program can be re-initiated as early as possible. The Company expects to conduct the analysis of the data within 60 days and plans to have the final safety database reviewed by an independent group of experts.
“We believe that the analysis will substantiate the safety of HEMOLINK, and will help to address the DSMB’s observations,” said John W. Kennedy, President and Chief Executive Officer of Hemosol. “Our objective is to complete the analysis so that we are in a position to provide information to regulators and the medical community that would lead to the restart of our clinical program.”
In an effort to preserve cash, the Company is also taking proactive steps to manage its burn-rate. This includes giving working notice to substantially all of its employees, effective April 7, 2003 and scaling back all spending not related to the data analysis of HLK 213/304. Hemosol intends to resume its clinical program in the event that the data analysis yields the positive results anticipated by the Company. In these circumstances the Company would expect to maintain the staff required for such purposes.
During this review period, the Company is also continuing a number of strategic initiatives, which include ongoing discussions with potential partners, exploring merger and acquisition opportunities and the possible sale of certain assets. Given current market volatility and the finite cash resources available to the Company, management and the Board of Directors believes these steps to be the most prudent course of action.
About Hemosol Inc.
Hemosol is a biopharmaceutical company focused initially on developing life-sustaining therapies for the treatment of acute anemia. Hemosol has a broad range of products in development, including its flagship product HEMOLINK™ [hemoglobin raffimer], an oxygen therapeutic, that is designed to rapidly and safely improve oxygen delivery via the circulatory system. HEMOLINK is currently being evaluated in late-stage clinical trials. The Company also is developing additional oxygen therapeutics and a hemoglobin-based drug delivery platform to treat diseases such as hepatitis C and cancers of the liver, as well as a cell therapy initially directed to the treatment of cancer through its cell expansion and stem cell research activities.
For more information visit Hemosol’s website at www.hemosol.com.
HEMOLINKTM is a registered trademark of Hemosol Inc.
Hemosol Inc.’s common shares are listed on The Nasdaq Stock Market under the trading symbol “HMSL” and on the Toronto Stock Exchange under the trading symbol “HML”.
Certain statements concerning Hemosol’s future prospects are “forward-looking statements” under the United States Private Securities Litigation Reform Act of 1995. There can be no assurances that future results will be achieved, and actual results could differ materially from forecasts and estimates. Important factors that could cause actual results to differ materially from forecasts and estimates include, but are not limited to: Hemosol’s ability to obtain regulatory approvals for its products; Hemosol’s ability to successfully complete clinical trials for its products; technical or manufacturing or distribution issues; the competitive environment for Hemosol’s products; the degree of market penetration of Hemosol’s products; and other factors set forth in filings with Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission. These risks and uncertainties, as well as others, are discussed in greater detail in the filings of Hemosol with Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission. Hemosol makes no commitment to revise or update any forward-looking statements in order to reflect events or circumstances after the date any such statement is made.
Quelle: www.hemosol.com / Investor Center / News Releases
Und das gleiche noch mal von Goooogle übersetzt!?!?
HEMOSOL LIEFERT KORPORATIVES UPDATE
Toronto, April 7, 2003 - Hemosol Inc. (Nasdaq: HMSL, TSX: HML) heute verkündet daß, um eine volle Sicherheits- und Wirksamkeitanalyse seines Herzversuches (HLK 213/304) durchzuführen für sein Leitungprodukt HEMOLINK™ [ Hämoglobinraffimer ] , schließt es Einschreibung auf dem gegenwärtigen Niveau von 152 Patienten, etwas niedriger als die ursprünglich geplante Einschreibung von 180 Patienten.
Hemosol verschob Einschreibung im Versuch HLK 213/304 auf Th Märzes 13 nach der den Daten und Sicherheit Firma, die überwachen Beobachtung des Brettes (DSMB) von eine Ungleichheit in der Ausdehnung bestimmter nachteiliger Fälle zwischen dem HEMOLINK und den Steuergruppen . Obgleich kann das Begrenzen von Einschreibung die geplante statistische Energie der Entdeckungen betreffend sind Wirksamkeit des Produktes verringern, erlaubt es, daß die Beobachtungen des DSMBs völlig und sofort nachzuforschen und damit die Firma den Nutzen von HEMOLINK in diesem Versuch festsetzt. Vorausgesetzt irgendwelche und alle Ausgaben behoben werden, kann der Rest des klinischen Entwicklungsprogramms HEMOLINK schon in möglichem Re-eingeleitet werden. Die Firma erwartet, die Analyse der Daten innerhalb 60 Tage und Pläne zu zu leiten lassen Sie die abschließende Sicherheitsdatenbank von einer unabhängigen Gruppe Experten wiederholen.
"wir glauben, daß die Analyse die Sicherheit von bestätigt HEMOLINK und hilft, die Beobachtungen des DSMBs zu adressieren, " besagter John W. Kennedy, Präsident und Generaldirektor von Hemosol. "unsere Zielsetzung ist, die Analyse durchzuführen, damit wir in einer Position zum Bereitstellen von Informationen zu den Reglern und zur medizinischen Gemeinschaft sind, die zu den Wiederanlauf unseres klinischen Programms führen würden .",
In einer Bemühung, Bargeld zu konservieren, unternimmt die Firma auch proactive Schritte, um seine Brennenrate zu handhaben. Dieses umfaßt das Geben der Arbeitsnachricht zu im wesentlichen allen seine Angestellten, wirkungsvoller April 7, 2003 und zurück alle Ausgabe einstufen, die nicht auf der Datenanalyse von HLK 213/304 bezogen wird. Hemosol beabsichtigt, sein klinisches Programm wieder aufzunehmen, im Falle daß die Datenanalyse die positiven Resultate erbringt, die von der Firma vorweggenommen werden. Unter diesen Umständen würde die Firma erwarten, den Personal beizubehalten, der für solche Zwecke angefordert wurde.
Während dieser Berichtperiode setzt die Firma auch eine Anzahl von strategischen Initiativen fort, die umfassen fortwährende Diskussionen mit möglichen Partnern, Erforschenfusion- und Erwerbsgelegenheiten und dem möglichen Verkauf bestimmter Werte. Gegebene gegenwärtige Marktflüchtigkeit und begrenzten die Barmittel, die für die Firma, Management und die Direktion vorhanden sind, glauben diesen Schritten, um die besonnenste Vorgehensweise zu sein.
Über Hemosol Inc..
Hemosol ist eine biopharmaceutical Firma, die zuerst auf sich entwickelnde Leben-unterstützende Therapien für die Behandlung der akuten Anämie gerichtet wird. Hemosol hat eine ausgedehnte Produktpalette in der Entwicklung, einschließlich seines Flaggschiffproduktes HEMOLINK™ [ Hämoglobinraffimer ], in einem therapeutischen Sauerstoff, der zu schnell und verbessern sicher Sauerstoffanlieferung über das zirkulierende System entworfen wird. HEMOLINK wird z.Z. in klinische Versuche des Spätstadiums ausgewertet. Die Firma auch entwickelt zusätzliche Sauerstofftherapeutik und eine Hämoglobin-gegründete Drogeanlieferungsplattform, um Krankheiten wie Hepatitis C und Krebse der Leber, sowie eine Zellentherapie zu behandeln, die zuerst auf die Behandlung des Krebses durch seine Zellenexpansion und Stammzelleforschungstätigkeiten verwiesen wird.
Für website mehr InformationsbesuchsHemosols an www.hemosol.com.
HEMOLINK TM ist ein eingetragenes eingetragenes Warenzeichen von Hemosol Inc..
Allgemeine Anteile Hemosol Inc. werden auf der Börse Nasdaq unter dem handelnden Symbol "HMSL" und auf der Börse Torontos unter dem handelnden Symbol "HML" verzeichnet.
Bestimmte Aussagen hinsichtlich sind Hemosols der zukünftigen Aussichten "Vorwärts-schauen Aussagen" unter der Sicherheitsrechtsstreit-Verbesserungtat Vereinigter Staaten privaten von 1995. Es kann keine Versicherungen geben, daß zukünftige Resultate erzielt werden, und tatsächliche Resultate konnten von den Prognosen und von den Schätzungen materiell sich unterscheiden. Wichtige Faktoren, die tatsächliche Resultate veranlassen konnten, sich von den Prognosen materiell zu unterscheiden und Schätzungen umfassen, aber werden nicht begrenzt: Fähigkeit Hemosols, Genehmigungen durch die zuständige Aufsichtsbehörde für seine Produkte zu erreichen; Fähigkeit Hemosols, klinische Versuche für seine Produkte erfolgreich durchzuführen; technisch oder Produktions- oder Verteilungsausgaben; das konkurrierende Klima für Produkte Hemosols; der Grad der Marktdurchdringung der Produkte Hemosols; und andere Faktoren festgelegt in den Archivierungen mit Aufsichtsbehörden der kanadischen Aktien und den STAATAKTIEN und der Austauschkommission. Diese Gefahren und Ungewißheiten, sowie andere, werden detaillierter in den Archivierungen von Hemosol mit Aufsichtsbehörden der kanadischen Aktien und den STAATAKTIEN und der Austauschkommission besprochen. Hemosol läßt keine Verpflichtung verbessern, oder irgendwelche Vorwärts-schauenden Aussagen aktualisieren, um Fälle oder Umstände nach dem Datum zu reflektieren, das irgend solche Aussage abgegeben wird.
HEMOSOL LIEFERT KORPORATIVES UPDATE
Toronto, April 7, 2003 - Hemosol Inc. (Nasdaq: HMSL, TSX: HML) heute verkündet daß, um eine volle Sicherheits- und Wirksamkeitanalyse seines Herzversuches (HLK 213/304) durchzuführen für sein Leitungprodukt HEMOLINK™ [ Hämoglobinraffimer ] , schließt es Einschreibung auf dem gegenwärtigen Niveau von 152 Patienten, etwas niedriger als die ursprünglich geplante Einschreibung von 180 Patienten.
Hemosol verschob Einschreibung im Versuch HLK 213/304 auf Th Märzes 13 nach der den Daten und Sicherheit Firma, die überwachen Beobachtung des Brettes (DSMB) von eine Ungleichheit in der Ausdehnung bestimmter nachteiliger Fälle zwischen dem HEMOLINK und den Steuergruppen . Obgleich kann das Begrenzen von Einschreibung die geplante statistische Energie der Entdeckungen betreffend sind Wirksamkeit des Produktes verringern, erlaubt es, daß die Beobachtungen des DSMBs völlig und sofort nachzuforschen und damit die Firma den Nutzen von HEMOLINK in diesem Versuch festsetzt. Vorausgesetzt irgendwelche und alle Ausgaben behoben werden, kann der Rest des klinischen Entwicklungsprogramms HEMOLINK schon in möglichem Re-eingeleitet werden. Die Firma erwartet, die Analyse der Daten innerhalb 60 Tage und Pläne zu zu leiten lassen Sie die abschließende Sicherheitsdatenbank von einer unabhängigen Gruppe Experten wiederholen.
"wir glauben, daß die Analyse die Sicherheit von bestätigt HEMOLINK und hilft, die Beobachtungen des DSMBs zu adressieren, " besagter John W. Kennedy, Präsident und Generaldirektor von Hemosol. "unsere Zielsetzung ist, die Analyse durchzuführen, damit wir in einer Position zum Bereitstellen von Informationen zu den Reglern und zur medizinischen Gemeinschaft sind, die zu den Wiederanlauf unseres klinischen Programms führen würden .",
In einer Bemühung, Bargeld zu konservieren, unternimmt die Firma auch proactive Schritte, um seine Brennenrate zu handhaben. Dieses umfaßt das Geben der Arbeitsnachricht zu im wesentlichen allen seine Angestellten, wirkungsvoller April 7, 2003 und zurück alle Ausgabe einstufen, die nicht auf der Datenanalyse von HLK 213/304 bezogen wird. Hemosol beabsichtigt, sein klinisches Programm wieder aufzunehmen, im Falle daß die Datenanalyse die positiven Resultate erbringt, die von der Firma vorweggenommen werden. Unter diesen Umständen würde die Firma erwarten, den Personal beizubehalten, der für solche Zwecke angefordert wurde.
Während dieser Berichtperiode setzt die Firma auch eine Anzahl von strategischen Initiativen fort, die umfassen fortwährende Diskussionen mit möglichen Partnern, Erforschenfusion- und Erwerbsgelegenheiten und dem möglichen Verkauf bestimmter Werte. Gegebene gegenwärtige Marktflüchtigkeit und begrenzten die Barmittel, die für die Firma, Management und die Direktion vorhanden sind, glauben diesen Schritten, um die besonnenste Vorgehensweise zu sein.
Über Hemosol Inc..
Hemosol ist eine biopharmaceutical Firma, die zuerst auf sich entwickelnde Leben-unterstützende Therapien für die Behandlung der akuten Anämie gerichtet wird. Hemosol hat eine ausgedehnte Produktpalette in der Entwicklung, einschließlich seines Flaggschiffproduktes HEMOLINK™ [ Hämoglobinraffimer ], in einem therapeutischen Sauerstoff, der zu schnell und verbessern sicher Sauerstoffanlieferung über das zirkulierende System entworfen wird. HEMOLINK wird z.Z. in klinische Versuche des Spätstadiums ausgewertet. Die Firma auch entwickelt zusätzliche Sauerstofftherapeutik und eine Hämoglobin-gegründete Drogeanlieferungsplattform, um Krankheiten wie Hepatitis C und Krebse der Leber, sowie eine Zellentherapie zu behandeln, die zuerst auf die Behandlung des Krebses durch seine Zellenexpansion und Stammzelleforschungstätigkeiten verwiesen wird.
Für website mehr InformationsbesuchsHemosols an www.hemosol.com.
HEMOLINK TM ist ein eingetragenes eingetragenes Warenzeichen von Hemosol Inc..
Allgemeine Anteile Hemosol Inc. werden auf der Börse Nasdaq unter dem handelnden Symbol "HMSL" und auf der Börse Torontos unter dem handelnden Symbol "HML" verzeichnet.
Bestimmte Aussagen hinsichtlich sind Hemosols der zukünftigen Aussichten "Vorwärts-schauen Aussagen" unter der Sicherheitsrechtsstreit-Verbesserungtat Vereinigter Staaten privaten von 1995. Es kann keine Versicherungen geben, daß zukünftige Resultate erzielt werden, und tatsächliche Resultate konnten von den Prognosen und von den Schätzungen materiell sich unterscheiden. Wichtige Faktoren, die tatsächliche Resultate veranlassen konnten, sich von den Prognosen materiell zu unterscheiden und Schätzungen umfassen, aber werden nicht begrenzt: Fähigkeit Hemosols, Genehmigungen durch die zuständige Aufsichtsbehörde für seine Produkte zu erreichen; Fähigkeit Hemosols, klinische Versuche für seine Produkte erfolgreich durchzuführen; technisch oder Produktions- oder Verteilungsausgaben; das konkurrierende Klima für Produkte Hemosols; der Grad der Marktdurchdringung der Produkte Hemosols; und andere Faktoren festgelegt in den Archivierungen mit Aufsichtsbehörden der kanadischen Aktien und den STAATAKTIEN und der Austauschkommission. Diese Gefahren und Ungewißheiten, sowie andere, werden detaillierter in den Archivierungen von Hemosol mit Aufsichtsbehörden der kanadischen Aktien und den STAATAKTIEN und der Austauschkommission besprochen. Hemosol läßt keine Verpflichtung verbessern, oder irgendwelche Vorwärts-schauenden Aussagen aktualisieren, um Fälle oder Umstände nach dem Datum zu reflektieren, das irgend solche Aussage abgegeben wird.
@ Glubsch wie meinst du wird sich der Kurs die nächsten Tage verhalten bei Letzten Jahrestief habe ich knap 100% gemacht obs diesmal klappt ich sage einfach mal wieder bis Freitag min 0,53 bei uns in canada so um 0,68-0,70 was meinst du dazu wen net max .60 Tage abwarten und dann staunen
@ Anderas
Das weiß ich wirklich nicht! Wir in Old Germany merken doch immer nur, wenn die Kurse von Canada ausgehend mal wieder um 45% gefallen sind
Frag mal den Threadauthor.
Das weiß ich wirklich nicht! Wir in Old Germany merken doch immer nur, wenn die Kurse von Canada ausgehend mal wieder um 45% gefallen sind
Frag mal den Threadauthor.
Hemosol gives most staff notice
LEONARD ZEHR 00:00 EDT Tuesday, April 08, 2003
In what could be the beginning of the end, beleaguered drug developer Hemosol Inc. gave 130 of its 140 employees "working notice" yesterday that they face possible layoffs in eight weeks when a review of its blood substitute product is finished.
The announcement, combined with an earlier-than-expected end of a clinical study with its Hemolink product, sent Hemosol`s stock price falling 21.25 per cent to close at 63 cents on the Toronto Stock Exchange.
Volume of 777,200 shares was more than twice the daily average.
In mid-March, Mississauga-based Hemosol temporarily suspended testing of Hemolink, its only product in clinical development, based on the recommendation of an independent Data Safety Monitoring Board, which was overseeing a clinical study with patients undergoing cardiac bypass surgery.
The safety board observed an "imbalance in the incidence of certain adverse [cardiac] events between the Hemolink and control groups" in the first 152 of 180 patients.
In halting the trial, Hemosol said that while 15-per-cent fewer patients "may decrease the planned statistical power of the findings regarding efficacy of the product, it will allow the [safety board`s] observations to be fully and promptly investigated and for the company to assess the benefits of Hemolink in this trial."
Hemolink, an oxygen therapeutic, has been designed to replace donated blood during surgery.
Sources said the early end of the cardiac bypass study was partly influenced by Hemosol`s deteriorating financial condition. The company had $17.6-million of cash at the end of 2002, which is only enough to keep operating until the fall.
Yesterday, Hemosol said it is scaling back all spending that isn`t related to the data analysis
17,6 million cash bei knap 21 million markt cap
LEONARD ZEHR 00:00 EDT Tuesday, April 08, 2003
In what could be the beginning of the end, beleaguered drug developer Hemosol Inc. gave 130 of its 140 employees "working notice" yesterday that they face possible layoffs in eight weeks when a review of its blood substitute product is finished.
The announcement, combined with an earlier-than-expected end of a clinical study with its Hemolink product, sent Hemosol`s stock price falling 21.25 per cent to close at 63 cents on the Toronto Stock Exchange.
Volume of 777,200 shares was more than twice the daily average.
In mid-March, Mississauga-based Hemosol temporarily suspended testing of Hemolink, its only product in clinical development, based on the recommendation of an independent Data Safety Monitoring Board, which was overseeing a clinical study with patients undergoing cardiac bypass surgery.
The safety board observed an "imbalance in the incidence of certain adverse [cardiac] events between the Hemolink and control groups" in the first 152 of 180 patients.
In halting the trial, Hemosol said that while 15-per-cent fewer patients "may decrease the planned statistical power of the findings regarding efficacy of the product, it will allow the [safety board`s] observations to be fully and promptly investigated and for the company to assess the benefits of Hemolink in this trial."
Hemolink, an oxygen therapeutic, has been designed to replace donated blood during surgery.
Sources said the early end of the cardiac bypass study was partly influenced by Hemosol`s deteriorating financial condition. The company had $17.6-million of cash at the end of 2002, which is only enough to keep operating until the fall.
Yesterday, Hemosol said it is scaling back all spending that isn`t related to the data analysis
17,6 million cash bei knap 21 million markt cap
.
.
Chaos bei Hemosol,
...dieses heisse Eisen anfassen?
Mittwoch, April 09, 2003
>>>Maschinelle Übersetzung!
Wachsender Trübsinn über die Zukunft von Hemosol Inc.
Rückschläge des Blut-Ersatzproduktes schickte den Aktienpreis gestern zu einem neuen Allzeittief und setzte seinen freien Fall für einen
zweiten Tag fort.
Minus 27 Prozent gestern 46 Cents (Kanadische Dollar) an der Toronto Börse. Nun hat Hemosol fast die Hälfte seines Wertes allein in dieser Woche verloren.
Es wurde ein ein 52-week Tief von 41 Cents erreicht.
Das Handelsvolumen zu fast 2.2 Million Anteilen
sprang, mehr als achtmal über den tägliche Durchschnitt.
Bevor die Technologieluftblase in frühem 2000 barst, gründeten die
Anteile Hemosols so, die stark wie $26.95, der Firma einen Marktwert
von $600-million fast gebend gehandelt wurden, auf dem Marktpotential
seines Hemolink Wiedereinbaus für Bluttransfusionen während der
Chirurgie.
Aber eine Reihe regelnde und klinische Hindernisse, kulminierend mit
Entscheidung Montages zum Ende, das Hemolink bei Herzüberbrückung
Patienten vor Zeitplan wegen der Sicherheit Interessen prüft, daß
überzogener letzter Monat, Wert Hemosols gehammert haben, der jetzt
an ungefähr $20-million steht.
Finanzanalytiker Dimi Ntantoulis der Nationalbank ließ gestern ihre
Deckung von Hemosol fallen und zitierte "wenig in der Weise der
möglichen Oberseite zu den Investoren" wegen der klinischen
Schwierigkeiten und des Bargeldknirschens der Firma.
Hemosol besagter Montag analysiert es die klinischen
Probeherzresultate während der folgenden 60 Tage, obwohl es nur 152
von ursprünglich geplant 180 Patienten prüfte.
"wir glauben, daß die Analyse die Sicherheit von Hemolink
bestätigt," dem Führen "zu den Wiederanlauf unseres klinischen
Programms," sagte Präsidenten und Generaldirektor John Kennedy.
Aber Ms Ntantoulis sagte in einem neuen Report, daß sie zweifelt,
daß die VEREINIGTE STAATEN Nahrungsmittel-und Droge-Leitung Versuche
Hemosols wieder aufnehmen läßt.
Sie erklärte, daß, da die Herzstudie durch stille nachteilige
Herzfälle gestoppt wurde, "ich skeptisch bin, daß die FDA sie einen
Herzversuch würde wiederbeginnen lassen."
Yorkton Securities Inc. Analytiker David Martin degradierte Hemosol zu
einer "untergewichtigen" Bewertung "vom gleichen Gewicht" gestern.
"obgleich es scheint, daß [ Montages ] Entscheidung nur zusätzlich
mehr Gefahr addiert und dort ist noch eine Wahrscheinlichkeit, welche
die Hemolink Entwicklung fortsetzen könnte, glauben wir, daß die
Vorteile sehr stark gegen Erfolg gestapelt werden," sagte er in einem
neuen Report.
Er reiterierte, daß Hemosol einen geschätzten Buchwert von 40 Cents
pro Anteil hat und drängte Investoren, den Vorrat zu verkaufen, wenn
er über 50 Cents handelt und schrieb einen Wert von 10 Cents pro
Anteil Hemolink zu.
Werte Mississauga-gegründeten Hemosols bestehen hauptsächlich aus
einem neuen $90-million Betrieb, Land und Ausrüstung, die entworfen
sind, um Hemolink herzustellen.
Wenn Hemosol gezwungen wird, um unten zu wickeln, würde das Finden
eines Kunden für den Betrieb das größte single Rückkehr für
Aktionäre erzeugen.
Eine Quelle schlug vor, daß der Betrieb über $45-million zu einem
Kunden wie Biopure Corp. von Cambridge, Mass. sein könnte, das
FDA-Zustimmung dieser Sommer für sein Blutersatzprodukt empfangen
könnte. Hemosol Aktionäre würden eine Rückkehr von $1 pro Anteil
zu einem $45-million Kaufpreis verwirklichen.
"Biopure hat nicht eine Produktionsanlage, alsoIST Betrieb Hemosols
viel mehr zu Biopure als sagen wir jemand wie Pfizer wert," die
addierte Quelle.
Herr besagter Martin sein Wert 40-cent-a-share für Hemosol hängt
groß von den Wicklung-unten Kosten ab und wieviel Bargeld angehoben
werden könnte, indem man den Mississauga Betrieb verkaufte.
Ein Wortführer für Hemosol sagte, daß die Firma keine Diskussionen
mit Biopure gehalten hat, aber besagte Gespräche mit möglichen
Partnern fortfahren, eine mögliche Fusion oder einen Verkauf der
Werte zu erforschen.
"niemand, das wir mit [ letzter Monat ] haben gingen weg sprachen,
aber sicher, möchten einige von ihnen die Phase II Resultate sehen,"
er hinzufügten.
Unterdessen sagte Hemosols größter einzelner Aktionär, MDS Inc. aus Toronto, dass keine Pläne vorliegen, Geld in die Firma einzubringen.
.
Chaos bei Hemosol,
...dieses heisse Eisen anfassen?
Mittwoch, April 09, 2003
>>>Maschinelle Übersetzung!
Wachsender Trübsinn über die Zukunft von Hemosol Inc.
Rückschläge des Blut-Ersatzproduktes schickte den Aktienpreis gestern zu einem neuen Allzeittief und setzte seinen freien Fall für einen
zweiten Tag fort.
Minus 27 Prozent gestern 46 Cents (Kanadische Dollar) an der Toronto Börse. Nun hat Hemosol fast die Hälfte seines Wertes allein in dieser Woche verloren.
Es wurde ein ein 52-week Tief von 41 Cents erreicht.
Das Handelsvolumen zu fast 2.2 Million Anteilen
sprang, mehr als achtmal über den tägliche Durchschnitt.
Bevor die Technologieluftblase in frühem 2000 barst, gründeten die
Anteile Hemosols so, die stark wie $26.95, der Firma einen Marktwert
von $600-million fast gebend gehandelt wurden, auf dem Marktpotential
seines Hemolink Wiedereinbaus für Bluttransfusionen während der
Chirurgie.
Aber eine Reihe regelnde und klinische Hindernisse, kulminierend mit
Entscheidung Montages zum Ende, das Hemolink bei Herzüberbrückung
Patienten vor Zeitplan wegen der Sicherheit Interessen prüft, daß
überzogener letzter Monat, Wert Hemosols gehammert haben, der jetzt
an ungefähr $20-million steht.
Finanzanalytiker Dimi Ntantoulis der Nationalbank ließ gestern ihre
Deckung von Hemosol fallen und zitierte "wenig in der Weise der
möglichen Oberseite zu den Investoren" wegen der klinischen
Schwierigkeiten und des Bargeldknirschens der Firma.
Hemosol besagter Montag analysiert es die klinischen
Probeherzresultate während der folgenden 60 Tage, obwohl es nur 152
von ursprünglich geplant 180 Patienten prüfte.
"wir glauben, daß die Analyse die Sicherheit von Hemolink
bestätigt," dem Führen "zu den Wiederanlauf unseres klinischen
Programms," sagte Präsidenten und Generaldirektor John Kennedy.
Aber Ms Ntantoulis sagte in einem neuen Report, daß sie zweifelt,
daß die VEREINIGTE STAATEN Nahrungsmittel-und Droge-Leitung Versuche
Hemosols wieder aufnehmen läßt.
Sie erklärte, daß, da die Herzstudie durch stille nachteilige
Herzfälle gestoppt wurde, "ich skeptisch bin, daß die FDA sie einen
Herzversuch würde wiederbeginnen lassen."
Yorkton Securities Inc. Analytiker David Martin degradierte Hemosol zu
einer "untergewichtigen" Bewertung "vom gleichen Gewicht" gestern.
"obgleich es scheint, daß [ Montages ] Entscheidung nur zusätzlich
mehr Gefahr addiert und dort ist noch eine Wahrscheinlichkeit, welche
die Hemolink Entwicklung fortsetzen könnte, glauben wir, daß die
Vorteile sehr stark gegen Erfolg gestapelt werden," sagte er in einem
neuen Report.
Er reiterierte, daß Hemosol einen geschätzten Buchwert von 40 Cents
pro Anteil hat und drängte Investoren, den Vorrat zu verkaufen, wenn
er über 50 Cents handelt und schrieb einen Wert von 10 Cents pro
Anteil Hemolink zu.
Werte Mississauga-gegründeten Hemosols bestehen hauptsächlich aus
einem neuen $90-million Betrieb, Land und Ausrüstung, die entworfen
sind, um Hemolink herzustellen.
Wenn Hemosol gezwungen wird, um unten zu wickeln, würde das Finden
eines Kunden für den Betrieb das größte single Rückkehr für
Aktionäre erzeugen.
Eine Quelle schlug vor, daß der Betrieb über $45-million zu einem
Kunden wie Biopure Corp. von Cambridge, Mass. sein könnte, das
FDA-Zustimmung dieser Sommer für sein Blutersatzprodukt empfangen
könnte. Hemosol Aktionäre würden eine Rückkehr von $1 pro Anteil
zu einem $45-million Kaufpreis verwirklichen.
"Biopure hat nicht eine Produktionsanlage, alsoIST Betrieb Hemosols
viel mehr zu Biopure als sagen wir jemand wie Pfizer wert," die
addierte Quelle.
Herr besagter Martin sein Wert 40-cent-a-share für Hemosol hängt
groß von den Wicklung-unten Kosten ab und wieviel Bargeld angehoben
werden könnte, indem man den Mississauga Betrieb verkaufte.
Ein Wortführer für Hemosol sagte, daß die Firma keine Diskussionen
mit Biopure gehalten hat, aber besagte Gespräche mit möglichen
Partnern fortfahren, eine mögliche Fusion oder einen Verkauf der
Werte zu erforschen.
"niemand, das wir mit [ letzter Monat ] haben gingen weg sprachen,
aber sicher, möchten einige von ihnen die Phase II Resultate sehen,"
er hinzufügten.
Unterdessen sagte Hemosols größter einzelner Aktionär, MDS Inc. aus Toronto, dass keine Pläne vorliegen, Geld in die Firma einzubringen.
News from The Globe and Mail
Hemosol shares sink to new low
LEONARD ZEHR 00:00 EDT Wednesday, April 09, 2003
Growing investor gloom about the future of Hemosol Inc.`s blood substitute product sent the drug developer`s stock price to a new low yesterday, continuing its freefall for a second day.
The stock, which tumbled 17 cents or 27 per cent yesterday to 46 cents on the Toronto Stock Exchange, has lost nearly half of its value this week.
It touched a 52-week low of 41 cents earlier in yesterday`s session as trading volume jumped to nearly 2.2 million shares, more than eight times the daily average.
Before the technology bubble burst in early 2000, Hemosol`s shares traded as high as $26.95, giving the company a market value of nearly $600-million, based on the market potential of its Hemolink replacement for blood transfusions during surgery.
But a series of regulatory and clinical setbacks, culminating with Monday`s decision to end testing Hemolink in cardiac bypass patients ahead of schedule because of safety concerns that surfaced last month, have hammered Hemosol`s value, which now stands at about $20-million.
National Bank Financial analyst Dimi Ntantoulis yesterday dropped her coverage of Hemosol, citing "little in the way of potential upside to investors" because of clinical difficulties and the company`s cash crunch.
Hemosol said Monday it will analyze the cardiac clinical trial results during the next 60 days even though it tested only 152 of an originally planned 180 patients.
"We believe that the analysis will substantiate the safety of Hemolink," leading "to the restart of our clinical program," said president and chief executive officer John Kennedy.
But Ms. Ntantoulis said in a new report that she doubts the U.S. Food and Drug Administration will allow Hemosol`s trials to resume.
She explained that since the cardiac study was stopped by undisclosed adverse cardiac events, "I am skeptical that the FDA would let them restart a cardiac trial."
Yorkton Securities Inc. analyst David Martin downgraded Hemosol to an "underweight" rating from "equal weight" yesterday.
"Although it appears that [Monday`s] decision adds only incrementally more risk and there is still a chance the Hemolink development could continue, we believe the odds are stacked very high against success," he said in a new report.
He reiterated that Hemosol has an estimated book value of 40 cents a share and urged investors to sell the stock if it trades above 50 cents, attributing a value of 10 cents a share to Hemolink.
Mississauga-based Hemosol`s assets consist mainly of a new $90-million plant, land and equipment designed to manufacture Hemolink.
If Hemosol is forced to wind down, finding a buyer for the plant would generate the largest single return for shareholders.
One source suggested the plant could be worth about $45-million to a buyer like Biopure Corp. of Cambridge, Mass., which could receive FDA approval this summer for its blood substitute product. Hemosol shareholders would realize a return of $1 a share at a $45-million purchase price.
"Biopure doesn`t have a manufacturing plant, so Hemosol`s plant is worth a lot more to Biopure than, say, somebody like Pfizer," the source added.
Mr. Martin said his 40-cent-a-share value for Hemosol depends largely on winding-down costs and how much cash could be raised by selling the Mississauga plant.
A spokesman for Hemosol said the company has not held any discussions with Biopure but said talks with potential partners are continuing to explore a possible merger or sale of assets.
"Nobody we were talking to [last month] has walked away, but sure, some of them would like to see the Phase II results," he added.
Meanwhile, Hemosol`s largest single shareholder, MDS Inc. of Toronto, with a 16-per-cent stake, said it has no plans to inject any more money into the company.
Hemosol shares sink to new low
LEONARD ZEHR 00:00 EDT Wednesday, April 09, 2003
Growing investor gloom about the future of Hemosol Inc.`s blood substitute product sent the drug developer`s stock price to a new low yesterday, continuing its freefall for a second day.
The stock, which tumbled 17 cents or 27 per cent yesterday to 46 cents on the Toronto Stock Exchange, has lost nearly half of its value this week.
It touched a 52-week low of 41 cents earlier in yesterday`s session as trading volume jumped to nearly 2.2 million shares, more than eight times the daily average.
Before the technology bubble burst in early 2000, Hemosol`s shares traded as high as $26.95, giving the company a market value of nearly $600-million, based on the market potential of its Hemolink replacement for blood transfusions during surgery.
But a series of regulatory and clinical setbacks, culminating with Monday`s decision to end testing Hemolink in cardiac bypass patients ahead of schedule because of safety concerns that surfaced last month, have hammered Hemosol`s value, which now stands at about $20-million.
National Bank Financial analyst Dimi Ntantoulis yesterday dropped her coverage of Hemosol, citing "little in the way of potential upside to investors" because of clinical difficulties and the company`s cash crunch.
Hemosol said Monday it will analyze the cardiac clinical trial results during the next 60 days even though it tested only 152 of an originally planned 180 patients.
"We believe that the analysis will substantiate the safety of Hemolink," leading "to the restart of our clinical program," said president and chief executive officer John Kennedy.
But Ms. Ntantoulis said in a new report that she doubts the U.S. Food and Drug Administration will allow Hemosol`s trials to resume.
She explained that since the cardiac study was stopped by undisclosed adverse cardiac events, "I am skeptical that the FDA would let them restart a cardiac trial."
Yorkton Securities Inc. analyst David Martin downgraded Hemosol to an "underweight" rating from "equal weight" yesterday.
"Although it appears that [Monday`s] decision adds only incrementally more risk and there is still a chance the Hemolink development could continue, we believe the odds are stacked very high against success," he said in a new report.
He reiterated that Hemosol has an estimated book value of 40 cents a share and urged investors to sell the stock if it trades above 50 cents, attributing a value of 10 cents a share to Hemolink.
Mississauga-based Hemosol`s assets consist mainly of a new $90-million plant, land and equipment designed to manufacture Hemolink.
If Hemosol is forced to wind down, finding a buyer for the plant would generate the largest single return for shareholders.
One source suggested the plant could be worth about $45-million to a buyer like Biopure Corp. of Cambridge, Mass., which could receive FDA approval this summer for its blood substitute product. Hemosol shareholders would realize a return of $1 a share at a $45-million purchase price.
"Biopure doesn`t have a manufacturing plant, so Hemosol`s plant is worth a lot more to Biopure than, say, somebody like Pfizer," the source added.
Mr. Martin said his 40-cent-a-share value for Hemosol depends largely on winding-down costs and how much cash could be raised by selling the Mississauga plant.
A spokesman for Hemosol said the company has not held any discussions with Biopure but said talks with potential partners are continuing to explore a possible merger or sale of assets.
"Nobody we were talking to [last month] has walked away, but sure, some of them would like to see the Phase II results," he added.
Meanwhile, Hemosol`s largest single shareholder, MDS Inc. of Toronto, with a 16-per-cent stake, said it has no plans to inject any more money into the company.
@all was geht den hier ab???? USA Kurs 0,43 +10% Cent Germany 0,35 =0% !!!! Will den keiner mehr???
Dabei kam am 17.04 eine nicht mal all zu schlechte Meldung
Hemosol Inc. Quick Quote: T.HML 0.62 (+0.04)
Net Asset Value Report, April 17, 2003
4/22/03
Managed by MDS Capital Corp. which targets $1 billion towards
building companies in the health and life sciences sector.
Net Asset Value:
As of April 17, 2003 the net asset value (NAV) of The Health Care and Biotechnology Venture Fund (the `Fund`) totals $4.6 million or $1.04 per
Trust Unit. Thirty percent of the Fund`s investments, including warrants, are currently held in private companies. All of the Fund`s investments are valued in accordance with the Fund`s valuation policy, which is fully described in the notes to the audited financial statements included in the Fund`s annual report. As of April 17, 2003 units in the Fund traded on the TSX at $0.90 per unit, which is a 13% discount to the current net asset value.
Total Per Trust (millions) Unit Cash $ 1.2 $0.27 Investments $ 4.6 $1.02 Provision for Performance Fees ($ 1.2) ($0.26) Total Net Assets $ 4.6 $1.03
Existing Investments:
In April 2003, GenSci Regeneration Sciences Inc. (TSX:GNS) announced that Osteotech Inc. and GenSci agreed to settle the various disputes between them subject to certain significant conditions. The conditions are that (i) Osteotech receives a letter of credit or other security satisfactory to Osteotech of certain payments over time and (ii) GenSci receives a covenant from Osteotech not to sue GenSci in connection with its newly introduced products. If the above two conditions are satisfactorily resolved, terms of the settlement include payment of $7.5 million by GenSci to Osteotech. GenSci would recognize the validity of the Osteotech patents at issue in the trial completed in December 2001. GenSci would not be permitted to re-introduce products that are the subject of the pending litigation, which have been withdrawn from the market, and all other litigation between the two parties would be dismissed. Finally, the settlement is contingent upon bankruptcy court approval. Terms of the settlement will be incorporated into the terms of a Chapter 11 Plan of Reorganization, which must be confirmed by the bankruptcy court. The Fund invested $500,000 in GenSci in January 1997. On April 17, 2003 (before this news was released) the market value of this investment was $97,000.
In April 2003, Inflazyme Pharmaceuticals Ltd. (TSX:IZP) and GlycoDesign
Inc. (TSX:GD) announced that they entered into a definitive agreement whereby Inflazyme agreed to acquire GlycoDesign. Inflazyme will issue 22 million shares to acquire all outstanding GlycoDesign shares in a deal valued at approximately $12.8 million. The acquisition will expand Inflazyme`s franchise in inflammation and strengthen its product pipeline. The acquisition is subject to approval by GlycoDesign shareholders and regulatory authorities. The Fund has invested $578,000 in GlycoDesign to date. On April 17, 2003 the market value of this investment was $53,000.
In April 2003, Hemosol Inc. (NASDAQ:HMSL, TSX:HML) announced that in order to perform a full safety and efficacy analysis of its cardiac trial (HLK 213/304) for its lead product HEMOLINK(TM) (hemoglobin raffimer), it closed enrolment at the level of 152 patients, slightly lower than the originally planned enrolment of 180 patients. Hemosol had previously suspended enrolment in the HLK 213/304 trial on March 13th following the company`s Data and Safety Monitoring Board`s (DSMB) observation of an imbalance in the incidence of certain adverse events between the HEMOLINK and control groups. In an effort to preserve cash, the company also took proactive steps to manage its burn-rate. This includes giving working notice to substantially all of its employees, effective April 7, 2003 and scaling back all spending not related to the data analysis of HLK 213/304. Hemosol intends to resume its clinical program in the event that the data analysis yields the positive results anticipated by the company. In these circumstances the company would expect to maintain the staff required for such purposes. During this review period, the company is also continuing a number of strategic initiatives which include ongoing discussions with potential partners, exploring merger and acquisition opportunities and the possible sale of certain assets. The Fund has invested $3.1 million in Hemosol to date. On April 17, 2003 the market value of this investment was $220,000.
CONTACT: TEL: (416) 675-6777 Michael Callaghan, Eric Fredrickson
MDS Capital, ext. 6630
EMAIL: info@mdscapital.com
INET : www.mdscapital.com
© 2003 StockHouse.com | Disclaimer
ich persönlich habe wieder aufgestockt
Gruß
CoolMax
Dabei kam am 17.04 eine nicht mal all zu schlechte Meldung
Hemosol Inc. Quick Quote: T.HML 0.62 (+0.04)
Net Asset Value Report, April 17, 2003
4/22/03
Managed by MDS Capital Corp. which targets $1 billion towards
building companies in the health and life sciences sector.
Net Asset Value:
As of April 17, 2003 the net asset value (NAV) of The Health Care and Biotechnology Venture Fund (the `Fund`) totals $4.6 million or $1.04 per
Trust Unit. Thirty percent of the Fund`s investments, including warrants, are currently held in private companies. All of the Fund`s investments are valued in accordance with the Fund`s valuation policy, which is fully described in the notes to the audited financial statements included in the Fund`s annual report. As of April 17, 2003 units in the Fund traded on the TSX at $0.90 per unit, which is a 13% discount to the current net asset value.
Total Per Trust (millions) Unit Cash $ 1.2 $0.27 Investments $ 4.6 $1.02 Provision for Performance Fees ($ 1.2) ($0.26) Total Net Assets $ 4.6 $1.03
Existing Investments:
In April 2003, GenSci Regeneration Sciences Inc. (TSX:GNS) announced that Osteotech Inc. and GenSci agreed to settle the various disputes between them subject to certain significant conditions. The conditions are that (i) Osteotech receives a letter of credit or other security satisfactory to Osteotech of certain payments over time and (ii) GenSci receives a covenant from Osteotech not to sue GenSci in connection with its newly introduced products. If the above two conditions are satisfactorily resolved, terms of the settlement include payment of $7.5 million by GenSci to Osteotech. GenSci would recognize the validity of the Osteotech patents at issue in the trial completed in December 2001. GenSci would not be permitted to re-introduce products that are the subject of the pending litigation, which have been withdrawn from the market, and all other litigation between the two parties would be dismissed. Finally, the settlement is contingent upon bankruptcy court approval. Terms of the settlement will be incorporated into the terms of a Chapter 11 Plan of Reorganization, which must be confirmed by the bankruptcy court. The Fund invested $500,000 in GenSci in January 1997. On April 17, 2003 (before this news was released) the market value of this investment was $97,000.
In April 2003, Inflazyme Pharmaceuticals Ltd. (TSX:IZP) and GlycoDesign
Inc. (TSX:GD) announced that they entered into a definitive agreement whereby Inflazyme agreed to acquire GlycoDesign. Inflazyme will issue 22 million shares to acquire all outstanding GlycoDesign shares in a deal valued at approximately $12.8 million. The acquisition will expand Inflazyme`s franchise in inflammation and strengthen its product pipeline. The acquisition is subject to approval by GlycoDesign shareholders and regulatory authorities. The Fund has invested $578,000 in GlycoDesign to date. On April 17, 2003 the market value of this investment was $53,000.
In April 2003, Hemosol Inc. (NASDAQ:HMSL, TSX:HML) announced that in order to perform a full safety and efficacy analysis of its cardiac trial (HLK 213/304) for its lead product HEMOLINK(TM) (hemoglobin raffimer), it closed enrolment at the level of 152 patients, slightly lower than the originally planned enrolment of 180 patients. Hemosol had previously suspended enrolment in the HLK 213/304 trial on March 13th following the company`s Data and Safety Monitoring Board`s (DSMB) observation of an imbalance in the incidence of certain adverse events between the HEMOLINK and control groups. In an effort to preserve cash, the company also took proactive steps to manage its burn-rate. This includes giving working notice to substantially all of its employees, effective April 7, 2003 and scaling back all spending not related to the data analysis of HLK 213/304. Hemosol intends to resume its clinical program in the event that the data analysis yields the positive results anticipated by the company. In these circumstances the company would expect to maintain the staff required for such purposes. During this review period, the company is also continuing a number of strategic initiatives which include ongoing discussions with potential partners, exploring merger and acquisition opportunities and the possible sale of certain assets. The Fund has invested $3.1 million in Hemosol to date. On April 17, 2003 the market value of this investment was $220,000.
CONTACT: TEL: (416) 675-6777 Michael Callaghan, Eric Fredrickson
MDS Capital, ext. 6630
EMAIL: info@mdscapital.com
INET : www.mdscapital.com
© 2003 StockHouse.com | Disclaimer
ich persönlich habe wieder aufgestockt
Gruß
CoolMax
Hi Leute es giebt wieder NEWS
kurze Zusammenfassung,
Verlust nachwievor Super hoch
Präsident Kennedy hat eine Auszeit genommen, da er Krebs hat.
Cash bis August gesichert
Hemosol loses $10.4 million in Q1, CEO takes leave of absence
5/5/03
TORONTO, May 05, 2003 (The Canadian Press via COMTEX) --
Blood products company Hemosol Inc. narrowed its losses in the first quarter but lost chief executive John Kennedy, who has taken a medical leave of absence to fight cancer.
The company, whose key product was linked with heart problems in clinical trials, announced Monday it lost $10.4 million or 23 cents a share for the three months ended March 31. That compared with a loss of $11.7 million or 29 cents the previous year.
The company did not have product revenues but reported interest income of $32,000, down from $218,000 last year.
Hemosol (TSX:HML) said the lower loss results from a cost cutting program implemented last June that produced lower operating expenses.
Last month, the company gave eight-week layoff noices to almost all its 130 workers and announced it might be sold after it stopped clinical trials of its main Hemolink product because patients could face increased heart problems.
Enrolment in a heart-bypass trial has been temporarily suspended as the company reviews the data with its safety board and the U.S. Food and Drug Administration and decides on its next steps. As a precaution, enrolment is also on hold for patients in an orthopedic surgery trial.
`There were important developments during the first quarter that required management to take decisive action, not the least of which was our voluntary suspension of enrolment in all our clinical trials,`Lee Hartwell, who replaced Kennedy as interim chief executive, said Monday.
`Our entire team is working diligently to resolve all outstanding issues and is looking forward to resuming our development programs.`
Hemolink said it has provided retention compensation packages to a core group of its employees. The program and severances is expected to cost the company between $1.5 million and $2 million. The company also said its strategic initiatives, include `ongoing discussions with potential partners, exploring merger and acquisition opportunities and the possible sale of certain assets.`
Hemosol reported it had $13.7 million of cash and cash equivalents at the end of the quarter and has enough credit to keep operating until the end of August.
Meanwhile, a previously announced $10 million investment into a proposed joint venture involving a Hemosol subsidiary ended without a deal. Cash set aside for the proposed investment has been returned to the company and the joint venture is expected to be dissolved.
In early trading on the Toronto Stock Exchange on Monday, Hemosol shares rose three cents to 59 cents.
The online source for news sports entertainment finance and business news in Canada
Copyright (C) 2003 The Canadian Press (CP), All rights reserved
© 2003 StockHouse.com | Disclaimer
kurze Zusammenfassung,
Verlust nachwievor Super hoch
Präsident Kennedy hat eine Auszeit genommen, da er Krebs hat.
Cash bis August gesichert
Hemosol loses $10.4 million in Q1, CEO takes leave of absence
5/5/03
TORONTO, May 05, 2003 (The Canadian Press via COMTEX) --
Blood products company Hemosol Inc. narrowed its losses in the first quarter but lost chief executive John Kennedy, who has taken a medical leave of absence to fight cancer.
The company, whose key product was linked with heart problems in clinical trials, announced Monday it lost $10.4 million or 23 cents a share for the three months ended March 31. That compared with a loss of $11.7 million or 29 cents the previous year.
The company did not have product revenues but reported interest income of $32,000, down from $218,000 last year.
Hemosol (TSX:HML) said the lower loss results from a cost cutting program implemented last June that produced lower operating expenses.
Last month, the company gave eight-week layoff noices to almost all its 130 workers and announced it might be sold after it stopped clinical trials of its main Hemolink product because patients could face increased heart problems.
Enrolment in a heart-bypass trial has been temporarily suspended as the company reviews the data with its safety board and the U.S. Food and Drug Administration and decides on its next steps. As a precaution, enrolment is also on hold for patients in an orthopedic surgery trial.
`There were important developments during the first quarter that required management to take decisive action, not the least of which was our voluntary suspension of enrolment in all our clinical trials,`Lee Hartwell, who replaced Kennedy as interim chief executive, said Monday.
`Our entire team is working diligently to resolve all outstanding issues and is looking forward to resuming our development programs.`
Hemolink said it has provided retention compensation packages to a core group of its employees. The program and severances is expected to cost the company between $1.5 million and $2 million. The company also said its strategic initiatives, include `ongoing discussions with potential partners, exploring merger and acquisition opportunities and the possible sale of certain assets.`
Hemosol reported it had $13.7 million of cash and cash equivalents at the end of the quarter and has enough credit to keep operating until the end of August.
Meanwhile, a previously announced $10 million investment into a proposed joint venture involving a Hemosol subsidiary ended without a deal. Cash set aside for the proposed investment has been returned to the company and the joint venture is expected to be dissolved.
In early trading on the Toronto Stock Exchange on Monday, Hemosol shares rose three cents to 59 cents.
The online source for news sports entertainment finance and business news in Canada
Copyright (C) 2003 The Canadian Press (CP), All rights reserved
© 2003 StockHouse.com | Disclaimer
WOW
der Laden soll verkauft werden. Jetzt wirds richtig interessant.
Gruß
CoolMax
Hemosol outlook drained by loss of CEO, joint venture, and dwindling cash
5/5/03
TORONTO, May 05, 2003 (The Canadian Press via COMTEX) --
The colour is draining out of the future for Hemosol Inc., as the blood products company discussed Monday plans to try selling the company, the failure of a possible joint venture, the loss of its CEO to a medical leave, and a dwindling cash supply.
All of it happened after the Toronto company halted trials in March on its key Hemolink blood substitute product because heart-bypass patients were at risk of further complications.
`There really is almost no future for the company,`said Duncan Stewart, portfolio manager with Tera Capital, who has followed the Toronto health care company since the early `90s.
On the Toronto Stock Exchange, Hemosol shares (TSX:HML) were up two cents Monday at 57 cents, well off the company`s 52-week high of $4.11.
`They have been so badly hurt, so badly crippled,`Stewart said, adding that Hemolink, the focus of its research, will likely `never get off the ground`and the company has lost precious time in a competitive market.
Currently, there are at least three U.S. companies in various stages of trials will their own blood substitute products including Synthetic Blood International Inc. based in Costa Mesa, Calif., Sanguine Corp. in Pasedena, Calif. and Northfield Laboratories in Evanston, Ill.
`There is almost certainly no future for the (Hemolink) product, or for any of the drugs that Hemosol is developing,`Stewart said.
Hemosol said Monday that it narrowed its first-quarter losses but lost chief executive John Kennedy, who has taken a medical leave of absence to fight cancer.
Enrolment in its heart-bypass trial has been temporarily suspended as the company reviews the data with its safety board and the U.S. Food and Drug Administration and decides on its next steps.
`There is always a slight hope`that an analysis of the trial results could show there is no actual safety problem, the damage is done, Stewart said.
As a precaution, enrolment is also on hold for patients in an orthopedic surgery trial.
`There were important developments during the first quarter that required management to take decisive action, not the least of which was our voluntary suspension of enrolment in all our clinical trials,`said Hemosol`s interim chief executive, Lee Hartwell.
`Our entire team is working diligently to resolve all outstanding issues and is looking forward to resuming our development programs.`
Hemosol didn`t say when any of its trials might restart.
As for Hemosol`s future, the company reiterated that its strategic initiatives include `ongoing discussions with potential partners, exploring merger and acquisition opportunities and the possible sale of certain assets.`
Stewart said there`s `a very high level of probablity`the company will try to sell itself for whatever it can.
`The only real asset actually is the plant,`Stewart said, referring to the $86-million Hemolink manufacturing facility at Hemosol`s headquarters in Mississauga, just west of Toronto.
Among other bad news, Hemosol also revealed that a previously announced $10-million investment into a proposed joint venture involving a Hemosol subsidiary ended without a deal. Cash set aside for the proposed investment has been returned to the company and the joint venture is expected to be dissolved.
That deal involved Hemosol`s pre-clinical drug pipeline, Stewart said.
`That deal fell through, which tells you that there is essentially no interest out there for any product that Hemosol owns.`
It`s also uncertain whether Hemosol has enough cash to keep operating. The company had $13.7 million of cash and cash equivalents at the end of the quarter and has enough credit to keep going until the end of August.
For the three months ended March 31, Hemosol reported that it lost $10.4 million or 23 cents a share, compared with a loss of $11.7 million or 29 cents the previous year.
The company didn`t have product revenues but reported interest income of $32,000, down from $218,000 last year.
Hemosol (TSX:HML) said a cost-cutting program implemented last June reduced expenses. More cost cutting is planned, a month after the company gave eight-week layoff noices to almost all its 130 workers.
The company didn`t say if any of those workers have been officially laid off. Hemosol said it has provided retention compensation packages to a core group of its employees, with the program and severances expected to cost the company between $1.5 million and $2 million.
The online source for news sports entertainment finance and business news in Canada
Copyright (C) 2003 The Canadian Press (CP), All rights reserved
© 2003 StockHouse.com | Disclaimer
der Laden soll verkauft werden. Jetzt wirds richtig interessant.
Gruß
CoolMax
Hemosol outlook drained by loss of CEO, joint venture, and dwindling cash
5/5/03
TORONTO, May 05, 2003 (The Canadian Press via COMTEX) --
The colour is draining out of the future for Hemosol Inc., as the blood products company discussed Monday plans to try selling the company, the failure of a possible joint venture, the loss of its CEO to a medical leave, and a dwindling cash supply.
All of it happened after the Toronto company halted trials in March on its key Hemolink blood substitute product because heart-bypass patients were at risk of further complications.
`There really is almost no future for the company,`said Duncan Stewart, portfolio manager with Tera Capital, who has followed the Toronto health care company since the early `90s.
On the Toronto Stock Exchange, Hemosol shares (TSX:HML) were up two cents Monday at 57 cents, well off the company`s 52-week high of $4.11.
`They have been so badly hurt, so badly crippled,`Stewart said, adding that Hemolink, the focus of its research, will likely `never get off the ground`and the company has lost precious time in a competitive market.
Currently, there are at least three U.S. companies in various stages of trials will their own blood substitute products including Synthetic Blood International Inc. based in Costa Mesa, Calif., Sanguine Corp. in Pasedena, Calif. and Northfield Laboratories in Evanston, Ill.
`There is almost certainly no future for the (Hemolink) product, or for any of the drugs that Hemosol is developing,`Stewart said.
Hemosol said Monday that it narrowed its first-quarter losses but lost chief executive John Kennedy, who has taken a medical leave of absence to fight cancer.
Enrolment in its heart-bypass trial has been temporarily suspended as the company reviews the data with its safety board and the U.S. Food and Drug Administration and decides on its next steps.
`There is always a slight hope`that an analysis of the trial results could show there is no actual safety problem, the damage is done, Stewart said.
As a precaution, enrolment is also on hold for patients in an orthopedic surgery trial.
`There were important developments during the first quarter that required management to take decisive action, not the least of which was our voluntary suspension of enrolment in all our clinical trials,`said Hemosol`s interim chief executive, Lee Hartwell.
`Our entire team is working diligently to resolve all outstanding issues and is looking forward to resuming our development programs.`
Hemosol didn`t say when any of its trials might restart.
As for Hemosol`s future, the company reiterated that its strategic initiatives include `ongoing discussions with potential partners, exploring merger and acquisition opportunities and the possible sale of certain assets.`
Stewart said there`s `a very high level of probablity`the company will try to sell itself for whatever it can.
`The only real asset actually is the plant,`Stewart said, referring to the $86-million Hemolink manufacturing facility at Hemosol`s headquarters in Mississauga, just west of Toronto.
Among other bad news, Hemosol also revealed that a previously announced $10-million investment into a proposed joint venture involving a Hemosol subsidiary ended without a deal. Cash set aside for the proposed investment has been returned to the company and the joint venture is expected to be dissolved.
That deal involved Hemosol`s pre-clinical drug pipeline, Stewart said.
`That deal fell through, which tells you that there is essentially no interest out there for any product that Hemosol owns.`
It`s also uncertain whether Hemosol has enough cash to keep operating. The company had $13.7 million of cash and cash equivalents at the end of the quarter and has enough credit to keep going until the end of August.
For the three months ended March 31, Hemosol reported that it lost $10.4 million or 23 cents a share, compared with a loss of $11.7 million or 29 cents the previous year.
The company didn`t have product revenues but reported interest income of $32,000, down from $218,000 last year.
Hemosol (TSX:HML) said a cost-cutting program implemented last June reduced expenses. More cost cutting is planned, a month after the company gave eight-week layoff noices to almost all its 130 workers.
The company didn`t say if any of those workers have been officially laid off. Hemosol said it has provided retention compensation packages to a core group of its employees, with the program and severances expected to cost the company between $1.5 million and $2 million.
The online source for news sports entertainment finance and business news in Canada
Copyright (C) 2003 The Canadian Press (CP), All rights reserved
© 2003 StockHouse.com | Disclaimer
blablabla...phase3...
...entweder es klappt oder totalverlust, zumindest haben wir in letzter zeit schon genug erlebt von wegen übernahme!
das end vom lied war zu 95% totalverlust, weil irgendwelche ........ es wieder schafften den kram zu verhökern, ohne die aktionäre dran teilhaben zu lassen!
ps.
chance minimal, doch wenns klappt dann geht sie ab!
ich überlege mir vielleich mal 500st. reinzulegen, mehr nicht!
(zumindest nicht bei solch einem chance/risiko verhältnis)
im casino ist bei schwarz/rot die chance wenigstens noch 49/51 hier nicht...
...entweder es klappt oder totalverlust, zumindest haben wir in letzter zeit schon genug erlebt von wegen übernahme!
das end vom lied war zu 95% totalverlust, weil irgendwelche ........ es wieder schafften den kram zu verhökern, ohne die aktionäre dran teilhaben zu lassen!
ps.
chance minimal, doch wenns klappt dann geht sie ab!
ich überlege mir vielleich mal 500st. reinzulegen, mehr nicht!
(zumindest nicht bei solch einem chance/risiko verhältnis)
im casino ist bei schwarz/rot die chance wenigstens noch 49/51 hier nicht...
Biopure - strong buy (aber sehr spekulativ)
Beitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
Wertpapier | Beiträge | |
---|---|---|
240 | ||
98 | ||
81 | ||
78 | ||
75 | ||
53 | ||
41 | ||
38 | ||
36 | ||
33 |
Wertpapier | Beiträge | |
---|---|---|
32 | ||
30 | ||
28 | ||
24 | ||
24 | ||
24 | ||
23 | ||
20 | ||
20 | ||
19 |